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Background: End Stage Renal Disease is an irreversible decline in kidney function and fatal in the 
absence of renal replacement therapy. Resource constraints in the South African public healthcare 
sector limits patients’ access to renal replacement therapy: here 14.8% are on haemodialysis  
compared to 85.2% in private dialysis units. Quality indicators in internationally accepted guidelines 
address complications of End Stage Renal Disease for patients on haemodialysis to reduce mortality 
and morbidity. Monitoring clinical outcomes for patients on haemodialysis is essential for good quality 
of life. 
Aim: To design and validate a record review template for monitoring and describing target and actual 
outcomes for each clinical indicator to assess adherence to established guidelines. 
Methods 
Design: Retrospective chart review. 
Participants: Patient records were accessed from an electronic database in 8 private units between 01 
January and 31 December 2018. 
Data instruments: Data were captured and analysed in SPSS. DAG Stat was used for the Kappa statistic 
for interrater reliability (test-retest). A P-value of <0.05 was taken as significant. 
Results: Of the dialysis population (N=412) for the study period n=243 (58.98%) records were excluded. 
The median age of the convenience sample (169/412, 41.01%) was 60 years (IQR: 21-86), comprising 
100/169 (59.17%) males and 69/169 (40.8%) classified as Coloured. Most patients (55/169, 32.54%) 
had Diabetic Nephropathy. Suboptimal dialysis adequacy (Kt/V levels) was present in 86/133 (64.6%) 
of the patients, similarly 102/166 (62.5%) for serum phosphate. Arterio-venous fistula or graft is 
recommended for vascular access for HD and 112/169 (66.27%) patients had either. While all patients 
should receive erythropoiesis stimulating agents and iron therapy, 110/169 (65.08%) and 104/169 
(61.53%) respectively did. For the required phosphate binders and Vitamin D supplements there were 
recordings for 57/169 (33.72%) and 54/169 (32.72%) patients respectively. 
Conclusion: Adherence to clinical guidelines for 3/5 quality indicators was considered unsatisfactory 
which has implications for patients’ quality of life.  
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AVF – Arteriovenous Fistula 
AVG – Arteriovenous Graft 
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OPERATIONAL DEFINITIONS  
Accuracy (percent correctness) of transcribing - recording parameters on the EuCliD® form accurately 
onto the Record Review Template (Polit & Beck, 2004).  
Anaemia – Anaemia is a common complication of chronic kidney disease (CKD) (Strippoli, Navaneethan, 
& Craig, 2006) 
Clinical guidelines – Guidelines developed internationally for patients on dialysis(Hoy et al., 2007; NKF-
KDOQI, 2002). The guidelines provide benchmarks for improvement of various aspects of the medical 
treatment and care of patients on dialysis who have End Stage Renal Disease (ESRD) (Wikstrom et al., 
2010). 
End stage renal disease (ESRD) – An irreversible decline in kidney function, which is severe enough to 
be fatal in the absence of dialysis or transplantation. ESRD is included under stage 5 of the National 
Kidney Foundation Kidney Disease Outcomes Quality Initiative classification of chronic kidney disease 
(CKD), where it refers to individuals with an estimated glomerular filtration rate of less than 15 ml per 
minute per 1.73 m2 body surface area, or those requiring dialysis irrespective of glomerular filtration 
rate (Abbasi, Chertow, & Hall, 2010).  
Haemodialysis – Blood purification treatment for patients without kidney function (Davids, Marais, & 
Jacobs, 2017) 
Kt/V - is a dimensionless ratio representing fractional clearance where K represents the dialyser 
clearance of urea (expressed in litres per hour), t is time on dialysis (expressed in hours) and V is the 
volume of distributed urea (expressed in litres) (Malekmakan et al., 2010). 
Quality indicators – recommendations of care to improve quality of life and reduce mortality and 
morbidity in patients affected with ESRD (Wikstrom et al., 2010).  
Renal replacement therapy – Renal Replacement Therapy (RRT) is therapy that replaces the normal 
blood filtering function of the kidneys. RRT includes dialysis (haemodialysis or peritoneal dialysis), 
haemofiltration and haemodiafiltration, which are various ways of filtration of blood with or without 
machines(Tamura, Tan, & O'Hare, 2012) 
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CHAPTER ONE   INTRODUCTION 
Chronic kidney disease (CKD), also known as the uremic syndrome (Vanholder, Pletinck, Schepers, 
& Glorieux, 2018), can lead to end stage renal disease (ESRD) (Kalantar-Zadeh, Mehrotra, Fouque, 
& Kopple, 2004). ESRD is an irreversible decline in kidney function, which is severe enough to be 
fatal in the absence of dialysis or transplantation (Allsopp, 2011). ESRD is a worldwide phenomenon 
(Abbasi, Chertow, & Hall, 2010). CKD affects people of all ages but more so the older (>70 years) 
population (Power & Brown, 2013) where the prevalence is almost 50% (Hallan, Coresh, Astor, & 
al., 2006) and the risk of death is high. Treatment is renal replacement therapy (RRT) either by 
peritoneal dialysis (PD) or haemodialysis (HD). The ultimate option is a kidney transplant. RRT and 
kidney transplantation are fraught with ethical implications. 
Do all patients have a right to access PD, HD or a kidney transplant, in other words, a right to life 
(Sidley, 1997)? What if patients cannot afford the costs involved in the provision of RRT? The South 
African Durban High court ruling against the provision of free dialysis treatment for Soobramoney 
was upheld by the Constitutional Court on the grounds that the state would not be able to fulfil its 
other constitutional health obligations (Sidley, 1997). Soobramoney died two days later, reportedly 
from a stroke. This situation raises questions about the ethical principle of justice (fairness). How 
are decisions made about apportioning a limited public sector health budget to primary 
preventative health care activities versus expensive interventions such as HD or kidney 
transplantation for life-threatening illnesses? 
The outcomes of kidney transplantation in human immunodeficiency virus (HIV)-positive patients 
in South Africa have been successful (Muller & Barday, 2018). Peritoneal dialysis may be accessible 
to more patients needing RRT because of the relative ease of access, particularly in resource 
constrained public sector healthcare settings because of the lower costs involved compared to HD 
which is prohibitively expensive and more available in private healthcare settings. Ethical principles 
such as beneficence (doing good) and non-maleficence (doing no harm) may be in conflict 
(Beauchamp & Childress, 2001) particularly when organs become a commodity that can be 
purchased (Bass, 2005; Scheper-Hughes, 2003) albeit illegally. Considerations such as the greatest 
good for the greatest number (utilitarian ethics) by withholding HD or transplantation for patients 
unable to afford this treatment and allocating funds elsewhere, may also be in conflict with 
deontological ethics (strict adherence to a moral code) by considerations of intervention at all costs 
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(Beauchamp & Childress, 2001). Due to the costs involved in RRT particularly kidney transplantation 
and the unavailability of donor kidneys, strict criteria for access to HD are applied in the public 
health sector. When patients meet these criteria and are willing to progress to transplantation, 
they are eligible to enter the HD programme. 
1.1 Background 
CKD has been classified into 5 stages by an international organization, the National Kidney 
Foundation (NKF). ESRD is stage 5 of this classification of CKD where individuals have an estimated 
glomerular filtration rate (GFR) of less than 15 ml per minute per 1.73 m2 body surface area or 
require dialysis irrespective of GFR (Abbasi et al., 2010). Patients in stage 5 present with uremic 
symptoms that are eventually incompatible with life if left untreated. The NKF has developed 
clinical practice guidelines known as NKF-Kidney Disease Outcomes Quality Initiative (NKF-KDOQI) 
guidelines set out as quality indicators that address complications of ESRD.  
In South Africa, the numbers of newly diagnosed patients requiring RRT continues to increase at an 
alarming rate (Davids, Singh, Marais & Jacobs, 2014). From data recorded in the South African Renal 
Register (SARS, 2015), the Western Cape Province has a prevalence rate of 327 per million 
population, with 856 (public sector) and 1172 (private sector) patients on RRT. 
Mortality and morbidity amongst patients with ESRD are very high and providing care comes at a 
great financial cost (Clark, Farrington, & Chilcot, 2014). Because of the marked increase in patients 
requiring HD and the chance of receiving a kidney transplant in South Africa is minimal, patients 
are destined to spend many years on HD (Davids et al., 2014).  
1.1.1 Primary predictors of successful HD outcomes 
HD is one of the treatment modalities of RRT available to patients with ESRD. HD is required at least 
three times a week for sessions that last four hours. Patent vascular access is required in the form 
of an arterio-venous fistula, arteriovenous graft or temporary or permanent central venous 
catheter to access the patient’s blood for distribution from the patient to the dialyser on the dialysis 
machine. The main aim of HD is to eliminate waste products and fluid from the patient in the same 
way that the kidneys normally operate. Patients are prone to anaemia due to heparinisation used 
in the treatment which may cause prolonged bleeding post-dialysis, blood loss due to decreased 
blood clotting and bleeding tendencies due to high levels of urea to mention but a few examples. 
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Permanent and temporary catheters predispose patients to a risk of infection leading to increased 
mortality and morbidity in this patient population (Dutka & Brickel, 2010).  
Dialysis adequacy is closely related to frequency and duration of dialysis, and the quality of the 
access used for the session. Ineffective dialysis leads to complications for example anaemia as 
discussed previously, bone disease that leads to vascular calcifications and malnutrition that causes 
patients with renal disease to have a lowered resistance to infections that are detrimental to 
patients on dialysis. The clinical guidelines referred to previously, address these complications in 
order to deliver quality care and reduce mortality and morbidity. 
Research shows that the primary predictors of successful HD outcomes are: 1) type of HD vascular 
access used, 2) dialysis adequacy, 3) management of anaemia associated with CKD and 
cardiovascular problems, 4) management of bone disease, 5) patients’ nutritional status and 6) HD 
associated infections (Abdelwahab, Shigidi, El-Tohami, & Ibrahim, 2013; NKF-KDOQI, 2002). 
Vascular access management has always been one of the critically important components in the 
care of haemodialysis patients. An arteriovenous fistula therefore is the gold standard of care for 
patients on HD, followed by an arteriovenous graft if patients have vascular problems (NKF-KDOQI, 
2015) for example, patients with diabetic nephropathy. 
1.1.2 Guidelines for patients with End Stage Renal Disease on Haemodialysis 
Since 1997 the National Kidney Foundation has produced evidence-based guidelines such as the 
NKF KDOQI for all stages of CKD and related complications. The guidelines are recognized 
worldwide and have been instrumental in improving the diagnosis and treatment of patients with 
renal disease (NKF-KDOQI, 2002). 
1.1.3 Profile of government versus private health sector renal units in the Western Cape  
In South Africa, where a rationing system in state hospitals is applied in selecting patients for HD, 
socio-demographic factors (excluding race) associated with inadequate housing and sanitation that 
might compromise good clinical outcomes, will limit the chances of a patient receiving dialysis. HD 
requires meticulous care of vascular access sites if the patient is accepted (Moosa & Kidd, 2006). If 
patients are not accepted for the HD programme, PD becomes the next option. The annual per-
patient cost for PD is about 50% of that for HD, without considering the number of HD dialyser 
reuses. However, PD costs less than HD only if the fluids are manufactured and distributed locally 
(Okpechi, Rayner, & Swanepoel, 2012).  
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In Sub-Saharan Africa, CKD affects mainly young adults aged between 20-50 years and is primarily 
due to hypertension and glomerular disease (Jha et al., 2013). Hypertensive renal disease accounts 
for 33.7% of reported causes of ESRD in South Africa (SARS, 2015). 
Monitoring clinical outcomes for patients on HD is essential to ensure a good quality of life. Non-
adherence or non-compliance from a patient perspective is well documented in numerous 
research articles (Clark et al., 2014; Ibrahim, Hossam, & Belal, 2015; Saran et al., 2003). There is, 
however, a paucity of publications on the impact of clinician adherence to clinical guidelines and 
its importance for the provision of quality care. 
The focus of this study is to monitor anonymised patients’ blood results by retrospective record 
review to assess adherence to guidelines for ESRD. Adherence to guidelines should result in a 
patient who has ESRD and is on HD, having achieved blood results for parameters as set out in the 
guidelines. Such a study from a South African perspective has not been located in the published 
literature. The South African Renal Society (SARS) is concerned about quality outcomes following 
HD and it publishes an annual report on HD quality initiatives (SARS, 2015). This study will use the 
NKF-KDOQI (2002) and the NKF-Kidney Disease Improving Global Outcomes (NKF-KDIGO) 
guidelines (2009) to measure outcomes. 
1.2 Problem statement 
Monitoring clinical outcomes for patients on HD is essential for good quality of life. The NKF-KDOQI 
(2002) has established guidelines for improving the management of kidney disease. These 
guidelines have been developed as clinical indicators with parameters to measure patient 
outcomes and serve as a blueprint for all renal units in South Africa and internationally. The SARS 
annual report does not provide specific data that addresses measurement of quality indicators by 
record review to assess adherence to the guidelines and no such South African published study was 
located which is the focus of the present study.  
1.3 Research question 
What proportion of patients with ESRD on chronic haemodialysis in selected private dialysis units 
in the Western Cape Province reached target levels for each clinical indicator outlined in the NKF-
KDOQI (2002) guidelines between 1 January 2018 and 31 December 2018? 
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The aim of the study was to design and validate a record review template to be used for record 
review to describe target and actual outcomes for each clinical indicator to assess adherence to 
established guidelines. 
1.5 Objectives 
The objectives of this study were to: 
1.5.1 design a prototype record review template (Appendix 1); 
1.5.2 validate the prototype record review template by a) ascertaining the index of content 
validity (CVI) and b); to establish accuracy (percent correctness) of the prototype record 
review template by inter-rater reliability testing. 
1.5.3 describe haemodialysed patients’ demographic and clinical characteristics (Appendix 1, 
Section A), prescribed medications (Appendix 1, Section B) and biochemical results 
(Appendix 1, Section C) at the completion of a dialysis session; and 
1.5.4 compare recorded clinical data against the Kidney Disease Quality Outcomes Initiative 
(KDQOI) guidelines and where applicable, the Kidney Disease Improving Global Outcomes 
(KDIGO) guidelines as the gold standard for management of clinical outcomes (Appendix 
1, Section C). 
1.6 Significance of the study 
What is known about the treatment of patients who have ESRD and receive HD is that 
internationally accepted guidelines for improving the management of kidney disease have been 
developed. These guidelines serve as clinical indicators with parameters to measure patient 
outcomes and serve as a blueprint for all renal units in South Africa and internationally. The SARS 
annual report does not provide specific data that addresses measurement of quality indicators by 
record review to assess adherence to the guidelines and no such South African published study was 
located. Nephrology nursing is a scarce skill in South Africa (Moosa, Meyers, Gottlich, & Naicker, 
2016). The University of Cape Town (UCT) Division of Nursing and Midwifery introduced the 
Postgraduate Diploma in Nephrology Nursing in 2010, one of only three Higher Education 
Institutions (HEIs) in South Africa to do so and should provide data for evidence-based practice. 
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This study will add to the existing body of renal knowledge in two ways, by: 1) providing data  on 
adherence to the gold standard for HD practice as set out in the practice guidelines on a validated 
record review form for a sample of adult patients in selected local private HD units to determine 
whether a standardised protocol is fit for purpose for these patients (Saunders, MacLeod, Salyers, 
MacMillan, & Ogborn, 2013); and 2) drawing conclusions about best practice and making 
recommendations for the private healthcare sector in the Western Cape 
1.7 Summary 
In this chapter the outline of this study was described: the background to record review of 
haemodialysis blood results to assess adherence to guidelines for End Stage Renal Disease. The aim 
of the study was to design and validate a record review template to be used to describe target and 
actual outcomes for each clinical indicator to assess adherence to established guidelines which will 
also give an indication of clinicians’ compliance with the guidelines. The study objectives describe 
how the aim of the study will be achieved.  
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CHAPTER TWO   LITERATURE REVIEW 
2.1 Introduction 
This chapter provides a narrative review of published literature on specific aspects of haemodialysis 
(HD) to achieve the aim of the study: adherence to established guidelines and clinical indicators 
relevant to the care of patients with end stage renal disease (ESRD) on HD to reduce morbidity and 
mortality. The literature review is presented to give a fuller understanding of the context in which 
HD is provided and criteria for selection of candidates for RRT and kidney transplantation. Gaps in 
the existing published literature on clinical indicators for good outcomes for patients on HD for 
ESRD and clinician compliance with these indicators are highlighted. In addition, the literature 
review included a search for validation studies referencing Content Validity Index (CVI) and inter-
rater reliability specifically for accuracy of transcription and record review studies.  
2.2 Search strategy 
Multiple bibliographic databases were searched by platform (PubMed, EBSCOHost CINAHL, Africa 
Wide and Medline) and Health Source: Nursing/Academic Edition for relevant publications using 
key words, Boolean operators (AND, OR) and truncations (*) covering the years 2000–2019 and 
filtered for English language publications. MESH terms were searched in PubMed. The search was 
expanded by a manual search for references cited in useful sources. A summary of the search 
strategy is shown in Table 2.1. The full search strategy and results are presented in Appendix 2. 
Published studies were reviewed critically for clinician adherence to best practice international 
renal guidelines and the impact thereof on clinical outcome parameters for patients in ESRD on HD 
and to review factors such as anaemia, bone disease, nutrition, dialysis access and dialysis 
adequacy in these patients.   
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Table 2. 1: Sample of search strategy for keywords  




PubMed  A combination of keywords using Boolean 
operators [AND] [OR] and truncations [*] 
guided the search: 
Kidney Failure-Chronic, Guideline 
Adherence, Treatment Practice 
Guidelines, Treatment Outcome, Anemia, 
Serum Albumin, Chronic Kidney Disease-
Mineral Bone Disorder Arteriovenous 
Fistula and Health Personnel [MESH 
checked (September 2019) 






































TOTAL RESULTS OF THE SEARCH STRATEGY FOR ALL 
DATABASES 
1699 222 80 
 
 
2.3 Hierarchy of evidence and evidence strength rating scale 
Clinical research studies originate from anecdotal findings that may be a catalyst for various types 
of studies. The hierarchy of evidence (Figure 2.1) (Andrade, 2016) represents the types of studies 
on different levels. Meta-analysis and systematic reviews are considered the most robust evidence, 
followed by randomized controlled trials (RCTs), cohort studies, case control and then cross-
sectional studies.  
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Figure 2. 1: Hierarchy of Evidence Retrieved from http://guides.lib.uchicago.edu/nursing 
However, traditional hierarchies of evidence (Figure 2.1) have been challenged in favour of a 
more nuanced typology (Petticrew & Roberts, 2003; Miller & Jones-Harris, 2005). When applied 
to the present study, for example, observational studies (cohort, case control, cross-sectional) 
would have the same level of evidence as RCTs in informing the research question. 
Levels of Clinical Research Evidence 
An explanation of the strength of evidence for nursing practice from levels 1 to 1V and high to 
low from the Johns Hopkins guide are shown in Tables 2.2 and 2.3 respectively. 
Table 2. 2: JHNEBP Evidence Strength Rating Scale 
Strength of Evidence  
Level I Experimental study/randomized controlled trial (RCT) or meta-analysis of RCT 
Level II Level II Quasi-experimental study 
Level III Non-experimental study, qualitative study, or meta-synthesis. 
Level IV Opinion of nationally recognized experts based on research evidence or expert 
consensus panel (systematic review, clinical practice guidelines) 
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Level V Opinion of individual expert based on non-research evidence. (Includes case studies; literature 
review; organizational experience e.g., quality improvement and financial data; clinical 
expertise, or personal experience)   
(Adapted from Poe and White (2010). Johns Hopkins nursing evidence-based practice 
Implementation and translation: Sigma Theta Tau) 
The strength of evidence is explained in detail in Table 2.3. 
Table 2. 3: STRENGTH of the Evidence 
(Adapted from Poe and White (2010). Johns Hopkins nursing evidence-based practice 
Implementation and translation: Sigma Theta Tau) 
The literature that was reviewed was analysed for rigour by hierarchy of evidence (Andrade, 
2016) and level of evidence as shown in Table 2.4. 
 
a. High 
Scientific Consistent results with sufficient sample size, adequate control, and 
definitive conclusions; consistent recommendations based on extensive 
literature review that includes thoughtful reference to scientific evidence. 
Summative 
reviews 
Well-defined, reproducible search strategies; consistent results with 
sufficient numbers of well-defined studies; criteria-based evaluation of 
overall scientific strength and quality of included studies; definitive 
conclusions 
Experiential Expertise is clearly evident 
b. Good 
Scientific Reasonably consistent results, sufficient sample size, some control, with fairly 
definitive conclusions; reasonably consistent recommendations based on 




Reasonably thorough and appropriate search; reasonably consistent results 
with sufficient numbers of well-defined studies; evaluation of strengths and 
limitations of included studies; fairly definitive conclusions. 
Experiential Expertise appears to be credible 
c. Low quality or 
major flaws 
Scientific Little evidence with inconsistent results, insufficient sample size; conclusions 
cannot be drawn. 
Summative 
reviews 
Undefined, poorly defined, or limited search strategies; insufficient evidence 
with inconsistent results; conclusions cannot be drawn. 
Experiential Expertise is not discernible or is dubious 
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Table 2. 4: Analysis of reviewed literature for rigour by hierarchy of evidence (type of study) and level of evidence for five themes that emerged from a literature review 
(vascular access for haemodialysis, assessment of haemodialysis adequacy, nutritional management during haemodialysis, management of anaemia, prevention of bone 
disease during haemodialysis) 
Authors Study Aims/objectives Method and sample size Findings/results Outcome measures/conclusion Level of 
Evidence 
SYSTEMATIC REVIEWS AND META ANALYSES 
Aiyegbusi et al. 
(2017) 
Comprehensive evaluation of 
studies that assessed the 
measurement properties of PROMs 
in adults with CKD. 
Four databases were searched; 
reference list and citation 
searching of included studies 
was also conducted. The 
COnsensus-based Standards for 
the selection of health 
Measurement INstruments 
(COSMIN) checklist was used to 
appraise the methodological 
quality of the included studies 
and to inform a best evidence 
synthesis for each PROM. 
The search strategy retrieved 3,702 
titles/abstracts. After 288 duplicates 
were removed, 3,414 abstracts were 
screened, and 71 full-text articles were 
retrieved for further review. Of these, 
24 full-text articles were excluded as 
they did not meet the eligibility 
criteria. Following reference list and 
citation searching, 19 articles were 
retrieved bringing the total number of 
papers included in the final analysis to 
66. There was strong evidence 
supporting internal consistency and 
moderate evidence supporting 
construct validity for the Kidney 
Disease Quality of Life-36 (KDQOL-36) 
in pre-dialysis patients. In the dialysis 
population, the KDQOL-Short Form 
(KDQOL-SF) had strong evidence for 
internal consistency and structural 
validity and moderate evidence for 
test-retest reliability and construct 
validity while the KDQOL-36 had 
moderate evidence of internal 
consistency, test-retest reliability and 
construct validity. The End Stage Renal 
Disease-Symptom Checklist 
We suggest considering the 
KDQOL-36 for use in pre-dialysis 
patients; the KDQOL-SF or 
KDQOL-36 for dialysis patients 
and the ESRD-SCLTM for use in 
transplant recipients. However, 
further research is required to 
evaluate the measurement 
error, structural validity, 
responsiveness and patient 
acceptability of PROMs used in 
CKD 
IV 
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Authors Study Aims/objectives Method and sample size Findings/results Outcome measures/conclusion Level of 
Evidence 
Transplantation Module (ESRD-SCLTM) 
demonstrated strong evidence for 
internal consistency and moderate 
evidence for test-retest reliability, 
structural and construct validity in 
renal transplant recipients. 
Casey et al, (2008) In this review, the available 
evidence was synthesized to 
determine to what extent 
proactive vascular access 
monitoring affects the incidence of 
AV access thrombosis and 
abandonment compared with 
clinical monitoring. 
Nine studies (1363 patients) 
compared a strategy of 
surveillance vs clinical 
monitoring. A vascular 
intervention to maintain or 
restore patency was provided 
to both groups if needed. 
Surveillance followed by 
intervention led to a 
nonsignificant reduction of the 
risk of access thrombosis (RR, 
0.82; 95% CI, 0.58-1.16; I2 ⴝ 
37%) and access abandonment 
(RR, 0.80; 95% CI, 0.51-1.25; I2 
ⴝ 60%). Three studies (207 
patients) compared the effect 
of vascular interventions vs 
observation in patients with 
abnormal surveillance result. 
Vascular interventions after an 
abnormal AV access 
surveillance led to a significant 
reduction of the risk of access 
thrombosis (RR, 0.53; 95% CI, 
0.36-0.76) and a nonsignificant 
reduction of the risk of access 
Very low quality evidence yielding 
imprecise results suggests a potentially 
beneficial effect of AV access 
surveillance followed by interventions 
to restore patency. This inference, 
however, is weak and will require 
randomized trials of AV access 
surveillance vs clinical monitoring for 
rejection or confirmation. (J Vasc Surg 
2008;48:48S-54S.) 
 IV 
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Authors Study Aims/objectives Method and sample size Findings/results Outcome measures/conclusion Level of 
Evidence 
abandonment (RR, 0.76; 95% CI, 
0.43-1.37) 
Chen, et al. (2016) The focus of the meta-analysis was 
to evaluate the efficacy of nurse-
led disease management programs 
in improving the quality of life for 
patients with chronic kidney 
disease. 
Literature survey was 
performed to identify the 
eligible studies from PubMed, 
Current Nursing and Allied 
Health Literature, and Cochrane 
Central Register of Controlled 
Trials with predefined terms. 
The outcome measured was 
quality of life. This meta-
analysis was conducted in line 
with recommendations from 
the preferred reporting items 
for systematic reviews and 
meta-analyses. 
Eight studies comprising a total of 
1520 patients were included in this 
meta-analysis, with 766 patients 
assigned to the nurse-led disease 
management program. Nurse-led 
disease management improved the 
quality of life in terms of symptoms, 
sleep, staff encouragement, pain, 
general health perception, 
energy/fatigue, overall health and 
mental component summary when 
evaluated 6 weeks after the beginning 
of intervention. When evaluated 12 
weeks later, the quality of life in terms 
of symptoms, sleep, staff 
encouragement, energy/ fatigue, and 
physical component summary was 
improved. Stratified by the modalities 
of dialysis, similar results of pooled 
analyses were observed for patients 
with peritoneal dialysis or 
haemodialysis, compared with the 
overall analyses. The results of 
sensitivity analyses were the same as 
the primary analyses. The symmetric 
funnel plot suggested that the 
possibility of potential publication bias 
was relatively low. 
Nurse-led disease management 
program seems effective to 
improve some parameters of 
quality of life for patients with 
chronic kidney disease. 
However, the seemingly 
promising results should be 
cautiously interpreted and 
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Authors Study Aims/objectives Method and sample size Findings/results Outcome measures/conclusion Level of 
Evidence 
Chironda G., & 
Bhengu B. (2016) 
To highlight the factors 
contributing to nonadherence in 
patients with CKD. 
Six categories of factors 
contributing to nonadherence 
were identified. These were 
patient related, socioeconomic 
factors, psychological factors, 
therapy related factors, 
pathophysiological related 
factors and health care system 
related factors. 
Articles were identified from online 
data bases namely Medline, PubMed, 
Cinahl, Google scholar and Grey 
literature. A comprehensive search 
was done to identify articles which 
highlight the factors contributing to 
non-adherence in patients with CKD. 
The following words were used for this 
search: Adherence & non-adherence, 
factors contributing to non-adherence 
to dialysis, medication, diet and fluid, 
patients with CKD. 96 of them were 
identified. 
Non adherence remains a major 
obstacle in the effective 
management of CKD 
population. There is need for 
collaborative approach to 
devise measures that eliminate 
relevant contributing factors to 
non-adherence in patients with 
CKD. 
IV 
Coronado et al., 
(2015) 
To assess the clinical benefits and 
harms of early versus delayed EPO 
for anaemia in patients with ESKD 
undergoing haemodialysis or 
peritoneal dialysis 
The Cochrane Kidney and 
Transplant Specialised Register 
to 8 July 2015 was searched 
through contact with the Trials’ 
Search Coordinator using 
search terms relevant to this 
review. 
Literature searches yielded 1910 
records, of these 1534 were screened 
after duplicates removed, of which 
1376 were excluded following title and 
abstract assessment. We assessed 158 
full text records and identified 18 
studies (66 records) that were 
potentially eligible for inclusion. 
However, none matched our inclusion 
criteria and were excluded. 
It was planned that two authors 
would independently extract 
data from included studies and 
assess risk of bias using the 
Cochrane risk of bias tool. For 
dichotomous outcomes (all-
cause mortality, cardiovascular 
mortality, overall myocardial 
infarction, overall stroke, 
vascular access thrombosis, 
adverse effects of treatment, 
transfusion), we planned to use 
the risk ratio (RR) with 95% 
confidence intervals (CI). We 
planned to calculate the mean 
difference (MD) and CI 95% for 
continuous data (haemoglobin 
level) and the standardised 
mean difference (SMD) with CI 
IV 
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Authors Study Aims/objectives Method and sample size Findings/results Outcome measures/conclusion Level of 
Evidence 
95% for quality of life if 
different scales had been used. 




To evaluate the effectiveness of 
RRT-related interventions for 
reducing HIRRT in such patients 
across RRT modalities. 
A systematic review of 
publications was undertaken 
using MEDLINE, MEDLINE in 
Process, EMBASE, and 
Cochrane’s Central Registry for 
Randomized Controlled Trials 
(RCTs). Studies that assessed 
any intervention’s effect on 
HIRRT (the primary outcome) in 
critically ill patients with AKI 
were included. HIRRT was 
variably defined according to 
each study’s definition. Two 
reviewers independently 
screened abstracts, identified 
articles for inclusion, extracted 
data, and evaluated study 
quality using validated 
assessment tools. 
Five RCTs and four observational 
studies were included (n = 9; 623 
patients in total). Studies were small, 
and the quality was mostly low. 
Interventions included dialysate 
sodium modeling (n = 3), ultrafiltration 
profiling (n =2), blood volume (n = 2) 
and temperature control (n =3), 
duration of RRT(n =1), and slow blood 
flow rate at initiation (n = 1). Some 
studies applied more than one 
strategy simultaneously (n = 5). 
Interventions shown to reduce HIRRT 
from three studies (two RCTs and one 
observational study) included higher 
dialysate sodium concentration, lower 
dialysate temperature, variable 
ultrafiltration rates, or a combination 
of strategies. Interventions not found 
to have an effect included blood 
volume and temperature control, 
extended duration of intermittent RRT, 
and slower blood flow rates during 
continuous RRT initiation. How HIRRT 
was defined and its frequency of 
occurrence varied widely across 
studies, including those involving the 
same RRT modality. Pooled analysis 
was not possible due to study 
heterogeneity. 
Small clinical studies suggest 
that higher dialysate sodium, 
lower temperature, 
individualized ultrafiltration 
rates, or a combination of these 
strategies may reduce the risk 
of HIRRT. Overall, for all RRT 
modalities, there is a paucity of 
high-quality data regarding 
interventions to reduce the 
occurrence of HIRRT in critically 
ill patients. 
IV 
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Authors Study Aims/objectives Method and sample size Findings/results Outcome measures/conclusion Level of 
Evidence 
Flythe et al (2015) Patients with end-stage renal 
disease (ESRD) receiving dialysis 
have poor health related quality of 
life (HRQoL). Physical symptoms 
are highly prevalent among dialysis 
dependent patients and play 
important roles in HRQoL. A range 
of symptom assessment tools have 
been used in dialysis-dependent 
patients, but there has been no 
previous systematic assessment of 
the existing symptom measures’ 




From 3,148 screened abstracts, 89 full-
text articles were eligible for review. 
After article exclusion and further 
article identification via reference 
reviews, 58 articles on 23 symptom 
assessment instruments with 
documented reliability or validity 
testing were identified. Of the 
assessment instruments, 43.5% were 
generic and 56.5% were ESRD-specific. 
Symptoms most frequently assessed 
were fatigue, shortness of breath, 
insomnia, nausea and vomiting, and 
appetite. The instruments varied 
widely in respondent time burden, 
recall period, and symptom attributes. 
Few instruments considered recall 
periods less than 2 weeks and few 
assessed a range of symptom 
attributes. Psychometric testing was 
completed for congruent validity 
(70%), known group validity (25%), 
responsiveness (30%), internal 
consistency (78%), and test-retest 
reliability (65%). Content validity was 
assessed in dialysis populations in 57% 
of the 23 instruments. 
The number of available 
instruments focused exclusively 
on physical symptoms in 
dialysis patients is limited. Few 
symptom-containing 
instruments have short recall 
periods, assess diverse 
symptom attributes, and have 
undergone comprehensive 
psychometric testing. Improved 
symptom-focused assessment 
tools are needed to improve 
symptom evaluation and 





Castelino R. L., 
Lioufas N. M., 
Peterson G. M., & 
Zaidi S. T. (2015) 
This review summarizes existing 
literature on nonadherence and 
identifies factors associated with 
nonadherence to medication 
A comprehensive search of 
PubMed, Embase, CINAHL, 
PsycInfo, and Cochrane 
Database of Systematic Reviews 
covering the period from 1970 
Of 920 relevant publications, 44 were 
included. The prevalence of 
medication nonadherence varied from 
12.5% to 98.6%, with widespread 
heterogeneity in measures and 
A number of patient-, disease-, 
and medication-related factors 
are associated with medication 
nonadherence in haemodialysis 
patients. Clinicians should be 
IV 
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Authors Study Aims/objectives Method and sample size Findings/results Outcome measures/conclusion Level of 
Evidence 
therapy in patients undergoing 
haemodialysis. 
through November 2014 was 
performed following a 
predefined inclusion and 
exclusion criteria. Reference 
lists from relevant materials 
were reviewed. Data on study 
characteristics, measures of 
nonadherence, prevalence 
rates and factors associated 
with nonadherence were 
collected. The Preferred 
Reporting Items for Systematic 
Reviews and Meta-analyses 
(PRISMA) guidelines was 
followed in conducting this 
systematic review. 
definitions employed. Most common 
patient-related factors significantly 
associated with nonadherence were 
younger age, non-Caucasian ethnicity, 
illness interfering family life, being a 
smoker, and living single and being 
divorced or widowed. Similarly, 
disease-related factors include 
longevity of haemodialysis, recurrent 
hospitalization, depressive symptoms 
and having concomitant illness like 
diabetes and hypertension. 
Medication-related factors such as 
daily tablet count, total pill burden, 
number of phosphate binders 
prescribed, and complexity of 
medication regimen were also 
associated with poor adherence. 
aware of such factors so that 
adherence to medications can 
be optimised in haemodialysis 
patients. Future research 
should be directed towards 
well-designed prospective 
longitudinal studies developing 
standard definitions and 
validating available 
measurement tools, while 
focusing on the role of 
additional factors such as 
psychosocial and behavioural 
factors in predicting 
nonadherence to medications. 
Landreneau K., Lee 
K., & Landreneau 
M. D. (2010) 
The purpose of this review was to 
determine the magnitude of effect 
of renal transplant on quality of life 
measures when compared with 
haemodialysis. 
Sixteen studies were analysed, 
and the summary effect sizes 
were as follows: general quality 
of life was 0.98, physical 
functioning was 0.77, and 
psychosocial functioning was 
0.39. Compared to 
haemodialysis, renal 
transplantation was 
significantly more effective in 
improving all three domains, 
particularly general overall 
quality of life and physical 
functioning. 
a key finding in the study is the lack of 
adequate clinical trials using dialysis 
therapy with that of RT, even when 
methodologies other than randomized 
clinical trials were considered. More 
trials comparing dialysis with RT are 
needed. 
Patients who remain on either 
type of dialysis continue to 
have increased risks as time 
progresses due to the renal 
failure that remains. Although 
RT may not provide quality of 
life equal to what the patient 
had prior to renal failure, 
convergent evidence suggests 
that quality of life benefits are 
distinctly better over that of HD 
after the immediate reduction 
in immunosuppression. Lastly, 
general quality of life and 
IV 
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Authors Study Aims/objectives Method and sample size Findings/results Outcome measures/conclusion Level of 
Evidence 
physical functioning are better 
with RT as the method of renal 
replacement therapy as seen in 
the last several decades of 
ESRD research. 
Muchayi et al. 
(2015) 
The National Kidney Foundation 
Kidney Disease Outcomes Quality 
Initiative recommends the routine 
use of haemodialysis arteriovenous 
(AV) access surveillance to detect 
hemodynamically significant 
stenoses and appropriately correct 
them to reduce the incidence of 
thrombosis and to improve 
accesses patency rates. Access 
blood flow monitoring is 
considered as one of the preferred 
surveillance method for both AV 
fistulas (AVF) and AV grafts (AVG); 
however, published studies have 
reported conflicting results of its 
utility that led healthcare 
professionals to doubt the benefits 
of this surveillance method. 
We performed a meta-analysis 
of the published randomized 
controlled trials (RCTs) of AV 
access surveillance using access 
blood flow monitoring. Our 
hypothesis was that access 
blood flow monitoring lowers 
the risk of AV access thrombosis 
and that the outcome differs 
between AVF and AVG. 
The estimated overall pooled risk ratio 
(RR) of thrombosis was 0.87 (95% 
confidence interval [CI], 0.67 to 1.13) 
favoring access blood flow monitoring. 
The pooled RR of thrombosis were 
0.64 (95% CI, 0.41 to 1.01) and 1.06 
(95% CI, 0.77 to 1.46) in the subgroups 
of only AVF and only AVG, respectively 
Results added to the 
uncertainty of access blood 
flow monitoring as a 
surveillance method of 
haemodialysis accesses 
IV 
Palmer, et al. 
(2017) 
This review evaluated the benefits 
and harms of dietary interventions 
among adults with CKD including 
people with end-stage kidney 
disease (ESKD) treated with dialysis 
or kidney transplantation. 
All studies were combined to 
look at dietary changes for 
people who kidney disease 
including people treated with 
dialysis or who have a kidney 
transplant. 
Included 17 studies involving 1639 
people with CKD. Three studies 
enrolled 341 people treated with 
dialysis, four studies enrolled 168 
kidney transplant recipients, and 10 
studies enrolled 1130 people with CKD 
stages 1 to 5. Eleven studies (900 
people) evaluated dietary counselling 
Dietary interventions have 
uncertain effects on mortality, 
cardiovascular events and ESKD 
among people with CKD as 
these outcomes were rarely 
measured or reported. Dietary 
interventions may increase 
health-related quality of life, 
IV 
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Evidence 
with or without lifestyle advice and six 
evaluated dietary patterns (739 
people), including one study (191 
people) of a carbohydrate-restricted 
low-iron, polyphenol enriched diet, 
two studies (181 people) of increased 
fruit and vegetable intake, two studies 
(355 people) of a Mediterranean diet 
and one study (12 people) of a high 
protein/low carbohydrate diet. Risks of 
bias in the included studies were 
generally high or unclear, lowering 
confidence in the results. Participants 
were followed up for a median of 12 
months (range 1 to 46.8 months). 
eGFR, and serum albumin, and 
lower blood pressure and 
serum cholesterol levels. 
Based on stakeholder 
prioritisation of dietary 
research in the setting of CKD 
and preliminary evidence of 
beneficial effects on risks 
factors for clinical outcomes, 
large-scale pragmatic RCTs to 
test the effects of dietary 
interventions on patient 
outcomes are required 
Yan et al. (2018) This review evaluates the current 
evidence concerning the 
correlation of diabetes and AVF 
failure. 
A search was conducted using 
MEDLINE, SCIENCE DIRECT, 
SPRINGER, WILEYBLACKWELL, 
KARGER, EMbase, CNKI and 
WanFang Data from the 
establishment time of 
databases to January 2016. The 
analysis involved studies that 
contained subgroups of diabetic 
patients and compared their 
outcomes with those of non-
diabetic adults. In total, 23 
articles were retrieved and 
included in the review. 
The meta-analysis revealed a 
statistically significantly higher rate of 
AVF failure in diabetic patients 
compared with non-diabetic patients 
(OR¼1.682; 95% CI, 1.429–1.981, Test 
of OR¼1: z¼6.25, p<.001).  
This review found an increased 
risk of AVF failure in diabetes 
patients. If confirmed by further 
prospective studies, preventive 
measure should be considered 





Nanni E., Cremonini 
To determine whether 
haemodialysis or peritoneal dialysis 
Searched databases: Cinahl, 
Medline, PubMed, Scopus and 
Proquest, including articles 
Only some of the seven articles found 
significant differences between the 
two treatments. One of the studies 
The analysis has not led to a 
unanimous conclusion. 
Quantitative analysis showed 
IV 
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V., & Rubbi I. 
(2017) 
provide a better QoL, a systematic 
meta-analysis was performed. 
published from 2011 until June 
2016; selected articles that 
compared, through KDQOL-SF 
1.3 or 36 questionnaires, QoL 
among patients undergoing 
haemodialysis and peritoneal 
dialysis. The data was collected 
using Excel Office, and t-test 
has been performed on 
independent samples to 
identify significant differences. 
showed a better QoL for peritoneal 
dialysis patients, while, on the 
contrary, two other studies support 
that the best QoL is in patients 
receiving haemodialysis. Another 
article displayed significant difference 
only for satisfaction in relation to care, 
better in patients on peritoneal 
dialysis, and for physical health, better 
in haemodialysis. 
that the only statistically 
significant difference between 
the QoL of patients on 
haemodialysis and peritoneal 
dialysis regards the effect of 
kidney disease, which happens 
to be better in patients 
undergoing peritoneal dialysis. 
Matteson M. L., & 
Russel C. (2010) 
To systematically review 
randomized-controlled trial 
intervention studies designed to 
increase treatment, medication, 
fluid, and diet adherence in adult 
haemodialysis patients 
A search of Cumulative Index of 
Nursing and Allied Health 
Literature (CINAHL) (1982 to 
May 2008), MEDLINE (1950 to 
May 2008), PsycINFO (1806 to 
May 2008), and all Evidence-
Based Medicine (EBM) Reviews 
(Cochran DSR, ACP Journal Club, 
DARE, and CCTR) was 
conducted to identify 
randomized-controlled studies 
that tested the efficacy of 
interventions to improve 
adherence in adult 
haemodialysis patients. 
Eight randomized-controlled trials met 
criteria for inclusion. Six of the 8 
studies found statistically significant 
improvement in adherence with the 
intervention. Of these 6 intervention 
studies, all studies had a cognitive 
component, with 3 studies utilizing 
cognitive/behavioral intervention 
strategies. 
Based on this systematic 
review, interventions utilizing a 
cognitive or 
cognitive/behavioral 
component appear to show the 
most promise for future study. 
IV 
Philipneri et al., 
(2008) 
Clinical practice guidelines for 
management of chronic kidney 
disease (CKD) have been developed 
within the Kidney Disease 
Outcomes Quality Initiative (K/ 
DOQI). Adherence patterns may 
We retrospectively studied 
contemporary CKD care 
patterns within a private health 
system in the United 
States, and systematically 
reviewed literature of reported 
KDOQI-consistent measurements of 
parathyroid hormone (7.1 vs. 0.6%, P = 
0.0002), phosphorus (38.2 vs. 1.9%, 
P\0.0001) and quantified urinary 
protein (23.8 vs. 9.4%, P = 0.008) were 
more common among patients with 
Delivery of CKD care may be 
monitored by administrative 
data. There is opportunity for 
improvement in CKD guideline 
adherence in practice. 
IV 
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identify focus areas for quality 
improvement. 
practices internationally. Five 
hundred and nineteen patients 
with moderate CKD (estimated 
GFR 30–59 ml/ min) using 
healthcare benefits in 2002–
2005 were identified from 
administrative insurance 
records. Thirty-three relevant 
publications in 2000–2006 
describing care in 77,588 
patients with CKD were 
reviewed. Baseline 
demographic traits and 
provider specialty were 
considered as correlates of 
delivered care. Testing 
consistent with K/DOQI 
guidelines and prevalence of 
angiotensin converting enzyme 
inhibitor/ angiotensin receptor 
blocker (ACEi/ARB) medication 
prescriptions were ascertained 
from billing claims. Care 
descriptions in the literature 
sample were based on medical 
charts, electronic records 
and/or claims. 
CKD versus without nephrology 
referral in the administrative data. 
Nephrology referral correlated with 
increased likelihood of testing for 
parathyroid hormone and phosphorus 
after adjustment for baseline patient 
factors. Use of ACEi/ARB medications 
was more common among patients 
with nephrology contact (50.0 vs. 
30.0%; P = 0.008) but appeared largely 
driven by higher comorbidity burden. 
The literature review demonstrated 
similar practice patterns. 
Rao et al. (2016)  The Strengthening the Reporting of 
OBservational studies in 
Epidemiology (STROBE) statement 
was published in October 2007 to 
improve quality of reporting of 
Systematic literature review. 37 papers (11 Pre & 26 Post STROBE) 
were identified from 3621 potential 
articles. Only four of the 22 STROBE 
items and their sub-criteria (objectives 
reporting, choice of quantitative 
This study highlights continuing 
deficiencies in the reporting of 
STROBE items and their sub-
criteria in cohort studies in 
nephrology. There was weak 
IV 
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observational studies. The aim of 
this review was to assess the 
impact of the STROBE statement 
on observational study reporting 
and study design quality in the 
nephrology literature. 
groups and description of and carrying 
out sensitivity analysis) showed 
improvements, with the majority of 
items showing little change between 
the period before and after publication 
of the STROBE statement. Pre- and 
post-period analysis revealed a 
Manuscript STROBE score increase 
(median score 77.8% (Inter-quartile 
range [IQR], 64.7–82.0) vs 83% (IQR, 
78.4–84.9, p = 0.05). There was no 
change in quality of study design with 
identical median scores in the two 
periods for NOS (Manuscript NOS 
score 88.9), SIGN (Manuscript SIGN 
score 83.3) and CASP (Manuscript 
CASP score 91.7) tools. 
evidence of improvement in the 
overall reporting quality, with 
no improvement in 
methodological quality of CKD 
cohort studies between the 
period before and after 
publication of the STROBE 
statement. 
Sinclair P. M., Kable 
A., Levett-Jones T., 
& Booth D. (2016) 
To identify, appraise and synthesise 
the best available evidence for the 
effectiveness of e-learning 
programmes on health care 
professional behaviour and patient 
outcomes. 
A systematic review of 
randomised controlled trials 
was conducted to assess the 
effectiveness of e-learning 
programmes on clinician 
behaviour and patient 
outcomes. Electronic databases 
including CINAHL, Embase, 
ERIC, MEDLINE, Mosby’s Index, 
Scopus and Cochrane – 
CENTRAL were searched in July 
2014 and again in July 2015. 
The results suggest that e-learning was 
at least as effective as traditional 
learning approaches, and superior to 
no instruction at all in improving 
health care professional behaviour. 
There was variation in behavioural 
outcomes depending on the skill being 
taught, and the learning approach 
utilised. No papers were identified that 
reported the effectiveness of an e-
learning programme on patient 
outcomes. 
This review found insufficient 
evidence regarding the 
effectiveness of elearning on 
healthcare professional 
behaviour or patient outcomes, 
consequently further research 
in this area is warranted. Future 
randomised controlled trials 
should adhere to the CONSORT 
reporting guidelines in order to 
improve the quality of 
reporting, to allow evaluation 
of the effectiveness of e-
learning programmes on 
healthcare professional 
IV 
University of Cape Town – Van der Nest, Yolinda. (2020)  





Authors Study Aims/objectives Method and sample size Findings/results Outcome measures/conclusion Level of 
Evidence 
behaviour and patient 
outcomes. 
Strippoli G. F. M., 
Navaneethan S. D., 
Craig J. C., & Palmer 
S. C. (2006) 
To assess the benefits and harms of 
different Hb or HCT targets in 
patients with CKD with CKD 
receiving any treatment for 
anaemia. 
Randomised controlled trials 
(RCTs) and quasi-RCTs 
comparing different Hb/HCT 
targets in patients with the 
anaemia of CKD. Two reviewers 
independently assessed trial 
quality and extracted data. 
Statistical analyses were 
performed using the random 
effects model and results 
expressed as risk ratio (RR) for 
dichotomous outcomes and 
mean difference (MD) for 
continuous outcomes, with 95% 
confidence intervals (CI). 
Twenty-two trials (3707 patients) were 
included. Hb ≥ 133 g/L was not 
associated with a reduction in the risk 
of all-cause mortality compared with 
120 g/L in dialysis and pre-dialysis 
patients. In pre-dialysis patients, there 
was a significantly lower end of 
treatment creatinine clearance with 
Hb < 120 g/L compared to > 130 g/L 
(MD -4.17, 95% CI -6.33 to -2.02) but 
no significant difference in the risk of 
end-stage kidney disease (ESKD) (RR 
1.05, 95% CI 0.50 to 2.22). Lower Hb 
targets resulted in an increased risk for 
seizures (RR 5.25, 95% CI 1.13 to 
24.34) and a reduced risk of 
hypertensive episodes (RR 0.50, 95% CI 
0.33 to 0.76). There were no 
significant differences in the risk of 
vascular access thrombosis. 
There was no significant 
difference in the risk of death 
for low (< 120 g/L) versus 
higher Hb targets (>133 g/L). 
Lower Hb targets were 
significantly associated with an 
increased risk for seizures but a 
reduced risk of hypertension. In 
general study quality was poor. 
There is a need for more 
adequately powered, well-
designed and reported trials. 
Trials should be pragmatic, 
focusing on hard endpoints 
(mortality, ESKD, major side 
effects) or outcomes which 
were previously not studied 
adequately (e.g. seizures, 
quality of life). 
IV 
van der Veer et al 
(2011) 
Recent studies showed wide 
variation in the extent to which 
guidelines and other types of best 
practice have been implemented as 
part of routine health care. This is 
also true for the delivery of renal 
replacement therapy (RRT) for 
ESRD patients. Increasing uptake of 
best practice within such complex 
care systems requires an 
Systematic review of over 5000 
titles published since 1990 
including papers describing 
planned attempts to accelerate 
uptake of best RRT practice into 
daily care. 
Results tend to support previous 
findings that multifaceted strategies 
are more effective than single 
strategies. Improving our 
understanding of how to successfully 
implement best practice can inform 
system-level change and is the only 
way to close the gap between 
knowledge on what works and the 
actual care delivered to ESRD patients. 
Research into implementation, 
using specific QI techniques, 
should therefore be given 
priority in future. 
IV 
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understanding of implementation 
strategies and specific quality 
improvement (QI) techniques. 
Research into implementation, using 
specific QI techniques, should 
therefore be given priority in future. 
Wyczesany B., & 
Steefel L. (2015) 
The objective of this project was to 
provide an education module to 
increase the knowledge of care of 
patients with ESRD on dialysis 
regarding albumin as a quality 
indicator among team members in 
an outpatient, private 
haemodialysis clinic. 
Methods: A convenience 
sample of team members 
(n=24) in an outpatient 
haemodialysis unit participated 
in an education program of four 
25-minute sessions for four 
days. A10-question pre-test 
initiated the program, followed 
by a PowerPoint presentation 
and a 10-question post-test. 
The test questions, which were 
analysed using a paired sample t-test, 
showed a significant increase in 
nephrology team members’ 
knowledge from pre-test to post-test 
(p= .000). 
The education program was 
successful in improving team 
members’ knowledge regarding 
albumin as a quality indicator, 
which can result in improved 
patient care. 
IV 
Yong K., & Kairaitis 
L. (2010) 
This manuscript describes the 
effect of implementing proactive 
protocol-driven adjustments for 
iron and ESA in maintenance 
haemodialysis patients. 
This was a cohort study of 46 
satellite haemodialysis patients 
examined from 2004 to 2006 
with protocol implementation 
in 2005. Baseline haemoglobin, 
transferrin saturations (TSAT), 
ferritin values and ESA 
administration were obtained 
during 2004. Follow-up data 
was collected in 2006 and 
compared to baseline values in 
reference to specified targets in 
the 2004 Caring for 
Australasians with Renal 
Impairment (CARI) guidelines. 
Fifty-four percent of patients achieved 
haemoglobin targets during follow up 
versus 43% patients during baseline. 
Seventy-nine percent of patients 
achieved TSAT targets during follow up 
versus 67% patients during baseline. 
Ninety percent of patients achieved 
ferritin targets during follow up versus 
75% patients during baseline. Odds 
ratios for values falling within target 
ranges during follow up compared to 
baseline were 1.63 (Hb: P = 0.037; 95% 
confidence interval (CI), 1.03–2.57), 
1.90 (TSAT: P = 0.006; 95% CI, 1.20– 
3.01) and 3.72 (ferritin: P = 0.003; 95% 
CI, 1.57–8.83). There was a trend 
toward lower average ESA dose (P = 
0.07) 
This study demonstrates the 
successful implementation and 
efficacy of a proactive protocol 
for iron and ESA treatment in 
haemodialysis patients. 
Benefits include increased 
concordance with historical 
guideline targets and decreased 
haemoglobin variability. 
Improved iron status and 
optimizing ESA response allows 
for lower ESA doses, limiting 
both potential side-effects of 
ESA (hypertension) and the 
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RANDOMISED CLINICAL TRIALS 
Coiera E., Choong 
M. K., Tsafnat G., 
Hibbert P., & 
Runciman W. B. 
(2017) 
This study tests a novel method for 
automatically linking indicators to 
clinical trial registrations. 
A set of 522 quality of care 
indicators for 22 common 
conditions drawn from the 
CareTrack study were 
automatically mapped to 
outcome measures reported in 
13 971 trials from 
ClinicalTrials.gov. Intervention: 
Text mining methods extracted 
phrases mentioning indicators 
and outcome phrases, and 
these were compared using the 
Levenshtein edit distance ratio 
to measure similarity. Main 
Outcome Measure: Number of 
care indicators that mapped to 
outcome measures in clinical 
trials. 
While only 13% of the 522 CareTrack 
indicators were thought to have Level I 
or II evidence behind them, 353 (68%) 
could be directly linked to randomized 
controlled trials. Within these 522, 50 
of 70 (71%) Level I and II evidence-
based indicators, and 268 of 370 (72%) 
Level V (consensus-based) indicators 
could be linked to evidence. Of the 
indicators known to have evidence 
behind them, only 5.7% (4 of 70) were 
mentioned in the trial reports but 
were missed by our method. 
Number of care indicators that 
mapped to outcome measures 
in clinical trials were 
automatically linked indicators 
to clinical trial registrations with 
high precision. Whilst the 
majority of quality indicators 
studied could be directly linked 
to research evidence, a small 
portion could not and these 
require closer scrutiny. It is 
feasible to support the process 
of indicator development using 
automated methods to identify 
research evidence. 
1 
Shi Y. X., Fan X. Y., 
Han H. J., Wu Q. X., 
Di H. J., Hou Y. H., & 
Zhao Y. (2013) 
To prospectively evaluate the 
effects of a nurse-led educational 
intervention on the management 
of hyperphosphataemia as well as 
knowledge of phosphate among 
patients with end-stage renal 
disease. 
This prospective randomised 
controlled trial was conducted 
during the period from June 
2009–March 2011 at the HD 
units of two hospitals in Tianjin, 
China. Methods. A total of 80 
participants were randomly 
assigned to experimental group 
(n = 40) and control group (n = 
40). Participants in the 
There were statistically significant 
differences between the study groups 
in decline in serum phosphorus and 
calcium– phosphorus product levels 
and improvement in patients’ general 
knowledge three months 
postintervention, and these 
differences sustained until the end of 
the study. Increased serum calcium 
level was observed both in the 
Nurse-led intensive educational 
programme plays an important 
role in the control of 
hyperphosphataemia among 
patients with end-stage renal 
disease.  
 
Relevance to clinical practice. 
Chronic kidney failure patients 
with hyperphosphataemia are 
1 
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experimental group received 
the nurse-led intensive 
educational programme, 
including individualised 
education and educational 
session about diet and medicine 
regimes, etc., while participants 
in the control group received 
the routine guidance. 
experimental group and in the control 
group, but there was no significant 
difference between groups. No 
statistical significance was found 
regarding serum albumin level 
between the groups. No significant 
difference in the serum parathyroid 
hormone level was found between the 
groups by month 6. 
more likely to benefit from 
nurse-led intensive educational 
programmes. 
Williams A., Manias 
E., Walker R., & 
Gorelik A. (2012) 
The aim of this study was to test 
the feasibility and impact of an 
intervention consisting of self-
monitored blood pressure, 
medicine review, a Digital Versatile 
Disc, and motivational interviewing 
telephone calls to help people with 
diabetes and kidney disease 
improve their blood pressure 
control and adherence to 
prescribed medications. 
Patients aged ‡18 years with 
diabetes, chronic kidney 
disease and systolic 
hypertension were recruited 
from nephrology and diabetes 
outpatients’ clinics of an 
Australian metropolitan 
hospital between 2008–2009. 
Participants were randomly 
allocated on a 1:1 basis to one 
of two groups in a randomized 
controlled trial: the 
intervention delivered over 3 
months (n = 39) and usual care 
(n = 41), with follow up at 3, 6 
and 9 months postintervention. 
People collecting data and 
assessing outcomes were 
blinded to group assignment. 
Seventy-five participants completed 
the study. The intervention was 
acceptable and feasible for this cohort. 
There were no statistically significant 
differences between groups, although 
the mean systolic blood pressure 
reduction in the intervention group (n 
= 36) was 6Æ9 mmHg 95% CI (13Æ8, 
0Æ02) at 9 months postintervention. 
The study was feasible and 
statistically significant 
differences may be 
determinable in a larger sample 
to overcome the variability 
between groups, paying 
attention to recommendations 
for further research. 
1 
OBSERVATIONAL STUDIES 
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Cicolini G., Palma 
E., Simonetta C., & 
Di Nicola M. (2012) 
To determine the influence of a 
family carer on haemodialyzed 
patients’ ‘adherence’. 
A total of 72 subjects with end-
stage renal disease participated 
in the study. The subjects 
assisted by a family carer were 
identified as cases (n = 36), 
whereas those who did not 
have a family carer, as controls 
(n = 36). All subjects were 
followed up (4 months) and 
checked up regarding 
interdialytic weight gain, and 
serum levels of potassium and 
phosphate. Important 
differences in potassium and 
phosphate serum level and 
interdialytic weight gain 
between the two groups were 
evaluated separately using a 
repeated measures ANOVAOVA 
test. 
Participants in the case group showed 
significantly lower phosphate and 
potassium serum levels and a lower 
interdialytic weight gain during follow-
up when compared to controls 
The presence of a family carer 
improves patients’ adherence, 
particularly as far as phosphate 
levels are concerned, since 
phosphate intake plays a 
fundamental role in avoiding 
long-term complications in end-
stage renal disease patients. 
3 
Ogawa C., Tsuchiya 
K., Tomosugi N., 
Kanda F., Maeda K., 
& Maeda T. (2017) 
To Investigate the relationship 
between hemoglobin (Hb) level 
and iron status in hemodialysis 
patients to identify the optimal 
iron levels for patients undergoing 
hemodialysis. 
A total of 208 outpatients on 
maintenance hemodialysis 
were followed up between July 
2006 and June 2007. Men 
accounted for 64.9% cases 
[mean age, 59.3 ± 13.1 years 
and median dialysis history, 7.7 
(3.6–13.2) years], and diabetic 
nephropathy accounted for 
25.0% cases. Hemoglobin level 
was measured twice a month 
and serum ferritin, serum iron, 
By receiver operating characteristic 
curve, the cutoff point of serum 
ferritin and transferrin saturation 
levels with a hemoglobin 10 g/dL 
showed <90 ng/mL (sensitivity: 69.1%, 
specificity: 72.1%, p < 0.001) and 20% 
(sensitivity: 77.6%, specificity: 48.8%, p 
= 0.302). Upon logistic regression 
model analysis with a hemoglobin 10 
g/dL as the endpoint, 
the analysis of odds ratios relative to a 
group with serum ferritin 90 ng/mL 
In this study, the iron status of 
serum ferritin <90 ng/mL and 
transferrin saturation 20% was 
optimal in hemodialysis 
patients receiving recombinant 
human erythropoietin for 
anemia therapy. This result 
indicates that the threshold 
values for the optimal iron 
status may be lower than those 
currently recommended in iron-
level management guideline. 
3 
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and total iron-binding capacity 
were measured once a month. 
The doses of recombinant 
human erythropoietin and low-
dose iron supplement were 
adjusted to maintain a 
hemoglobin level of 10–11 g/dL, 
according to the guidelines of 
the Japanese Society for 
Dialysis Therapy. Hepcidin was 
measured at baseline. Using the 
mean values for 1-year period, 
the relationships among 
hemoglobin, serum ferritin 
levels, and transferrin 
saturation levels were 
investigated based on a 
receiver operating 
characteristic curve and a 
logistic regression model. In 
addition, the correlations 
among serum ferritin, 
transferrin saturation, and 
hepcidin levels were analyzed 
by Pearson product—moment 
correlation coefficient and 
linear regression model. 
and transferrin saturation <20% 
revealed that the group with serum 
ferritin <90 ng/mL and transferrin 
saturation 20% had the highest ratio: 
46.75 (95% confidence interval: 10.89–
200.70, p < 0.001). In Pearson 
product—moment correlation 
coefficient, hepcidin showed a strong 
positive correlation with serum ferritin 
[r = 0.78 (95% confidence interval: 
0.72–0.83, p < 0.001)] and a weak 
positive correlation with transferrin 
saturation [r = 0.18 (95% confidence 
interval: 0.04–0.31, p = 0.010)]. In the 
multivariable analyses of the linear 
regression model, a positive 
relationship was shown between 
hepcidin and serum ferritin 
[βcoefficient of 0.30 (95% confidence 
interval: 0.27–0.34, p < 0.001)]; 
however, no relationship was shown 
with transferrin saturation [β-
coefficient of 0.09 (95% confidence 
interval: −0.31–0.49, p = 0.660)]. 
Pronai et al. (2017) This study was conducted to 
identify treatment combinations 
used in clinical practice in Austria 
and Switzerland and the potential 
to control this disorder. 
A total of 333 adult 
hemodialysis and peritoneal 
dialysis patients were analysed. 
All patients received 
conventional care prior to 
Overall, the mean intact parathyroid 
hormone (iPTH) increased from 64.2 
pmol/l to 79.6 pmol/l under 
conventional therapy and decreased 
after cinacalcet initiation to 44.0 
In conclusion, cinacalcet 
appears to be a necessary 
treatment component to 
achieve recommended targets. 
The detailed composition of the 
3 
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initiation of a cinacalcet-based 
regimen. During the study, 
treatment components, e.g. 
cinacalcet, active vitamin D 
analogues and phosphate 
binders, were adapted to 
individual patient requirements 
and treatment dynamics were 
documented. 
pmol/l after 12 months (mean 
decrease between baseline and 12 
months –45%). Calcium remained 
within the normal range throughout 
the study and phosphorus ranged 
around the upper limit of normal. The 
Kidney Disease: Improving Global 
Outcomes (KDIGO) target achievement 
for iPTH increased from 44.5% of 
patients at baseline to 65.7% at 12 
months, corrected calcium from 58.9% 
to 51.9% and phosphorus from 18.4% 
to 24.4%. On average, approximately 
30% of patients adapted their regimen 
from one observation period to the 
next. The reasons for changing a given 
regimen were to attain or maintain 
any of the bone mineral markers 
within recommended targets and to 
avoid developments to extreme 
values. Some regional differences in 
practice patterns were identified. No 
new safety signals emerged. 
treatment mix should be 
adapted to patient 
requirements and reassessed 
on a regular basis. 
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2.4 Introduction and main themes 
Implementation and achievement of the clinical indicators in patients with ESRD have improved 
patient outcomes and decreased hospitalisations (Plantinga et al., 2007). Patient outcomes are also 
determined by adherence to the guidelines. Patient adherence to renal guidelines is well described 
in the literature, for example clinical studies from Europe on hyperphosphatemia in patients with 
ESRD (Covic & Rastogi, 2013). Diet and fluid non-adherence are described in a study undertaken in 
Belgium (Vlaminck, Maes, Jacobs, Reyntjens, & Evers, 2001), and the prevalence and psychological 
determinants of non-adherence in dialysis patients in the United Kingdom (Clark et al., 2014). 
The (NKF-KDOQI, 2002) has established guidelines for improvement in the process of kidney 
disease care from pre-dialysis and dialysis (haemodialysis and peritoneal dialysis) to 
transplantation. The guidelines were further developed into clinical indicators with parameters to 
measure patient outcomes. Moosa (SARS, 2015, p. 2) reports that “Extensive use was made of the 
European Best Practice Guidelines (EBPG) and the Kidney Disease Outcomes Quality Initiative 
(K/DOQI) guidelines in drawing up” the SARS Guidelines.  
KDIGO (2012) guidelines focus on topics related to the prevention of complications and 
management of individuals with kidney disease. Adherence to guidelines to achieve recommended 
outcomes assists in decision-making that contributes to the total care of patients on RRT. The 
desired outcomes that underpin adherence to best practice guidelines seek to reduce disease-
related morbidity in patients. Previous studies relating to adherence to the guidelines report 
improved quality of life and decreased morbidity and mortality in patients presenting with ESRD 
(Leggat, 2005; Miranda et al., 2016). Compliance with the guidelines largely depends on adherence 
by both clinicians and patients (Djukanovic et al., 2015; Plantinga et al., 2007). The focus in this 
study is not on patient compliance (that is, adherence to dietary or fluid restrictions for example) 
but on compliance in achieving the recommended blood result parameters as set out in the 
guidelines, which implies clinician compliance with the guidelines. The implementation of the 
clinical practice guidelines seeks to improve the results of haemodialysis treatment and outcomes 
of patients with ESRD. 
In addition to five relevant topics related to adherence to clinical guidelines in haemodialysis for 
patients in ESRD (presented in Table 2.4), the decision to provide HD is based on set criteria as 
outlined in this table (Okpechi et al., 2012).   
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Table 2. 5: Renal assessment tool for the provision of renal replacement therapy (Okpechi et al., 2012). 
Category 1 
• Patients must be 
accepted 
Category 2 
• Patients will be accepted 
depending on availability of space 
on the program and number of 
factors in this category 
Category 3 
• Patients will be excluded 
• Age: <50 years 
• Body mass index: <30 
kg/m2 
• Gainfully employed 
• HIV negative 
• Hepatitis B negative 
• South African Citizen 
• Age: 50 – 60 years  
• Body mass index: 30 – 35 kg/m2 
• Hypertension with target organ 
damage 
• Diabetes Mellitus 
• Smoking 
• Hepatitis B or Hepatitis C (no 
cirrhosis) 
• HIV positive (CD4 count >200, 
undetectable viral load, on 
HAART) 
• Late presentation needing urgent 
dialysis 
• Co-morbid disease 
• Previous renal transplant 
• Poor home circumstances 
• Convicted criminal for serious 
offence 
• Not gainfully employed 
• Poor social network/support 
• No proximity to dialysis unit 
 
• Age: >50 years 






• HIV infection other than 
described in Category 2 
• Active substance abuse 
• Hepatitis B positive with 
cirrhosis 
• Diabetes Mellitus and Age 
>50 years 
• Active uncontrolled 
malignancy with short life 
expectancy 
• Non-South African citizen 
• Advanced irreversible 
progressive vital organ 
disease 
• Mental Illness resulting in 
diminished capacity to 
take responsibility for 
actions 
• Habitual non- adherence 
with any medical 
treatment 
 
As patients from category 1 undergo transplantation, space is opened for other ESRD patients to 
be accepted for HD. If, however, the program is full, patients with ESRD needing HD cannot be 
accepted. South Africa, a middle-income developing country, has limited resources and the 
government healthcare sector does not provide equal access to all patients with ESRD. Only 
patients who can pay privately or who have medical aid are offered dialysis in private clinics (Davids 
et al., 2014). Space for dialysis in the private sector is therefore unlimited; anyone who can pay is 
accommodated (Okpechi et al., 2012). 
The five main themes related to adherence to clinical guidelines in haemodialysis for patients in 
ESRD and presented in Table 2.3 are: 
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• Vascular access for haemodialysis 
• Assessment of haemodialysis adequacy  
• Nutritional management during haemodialysis 
• Management of anaemia 
• Prevention of bone disease during haemodialysis 
Each theme and the relevant literature are discussed next. 
2.4.1 Vascular access for haemodialysis 
The National Kidney Foundation (NKF) has published the Dialysis Outcomes Quality Initiative 
(KDOQI) clinical practice guidelines for vascular access with regular updates (NKF-KDOQI, 2002). 
The guidelines provide clinicians the framework to optimize vascular access care of haemodialysis 
patients. The guidelines are based on available data from published literature and the opinion of 
the leaders in the vascular access field. Vascular access issues impose a major financial burden to 
health care and can be associated with increased hospitalisations among haemodialysis patients 
and the rise in morbidity and mortality (Jackson & Litchfield, 2006). The rope-ladder cannulation 
technique involves the cannulation of the vein/graft that moves progressively up the vein/graft in 
a systematic manner at each cannulation, to ensure uniform use of the vein/graft (Levey, 2012). 
This should be used for to prevent complications such as aneurysm, stenosis and infections (Deaver, 
2010). For dialysis dose management, frequent and long dialysis sessions are recommended. This 
improves quality of life, controls hyperphosphatemia and reduces hypertension (Locatelli & 
Canaud, 2012). 
Vascular access is referred to as the Achilles heel of dialysis treatment. A patent vascular access 
yielding a good blood flow is of fundamental importance to ensure adequate dialysis.  Access refers 
to a surgically created Arterio-Venous Fistula (AVF) for the specific use of dialysis recommended in 
the KDOQI Guidelines as the first choice of access for patients receiving HD. The preferred vascular 
access type for patients on HD is indicated as an AVF. A synthetic arteriovenous graft (AVG) would 
be an alternative option for patients with diabetic nephropathy or problematic vasculature (SARS, 
2015). There is evidence that clinical outcomes play a crucial role in regulating the overall treatment 
plan for patients afflicted with ESRD. Allsopp (2011) suggests that staff in an emergency 
department should know how to take care of a dialysis access point when such patients present 
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themselves to emergency departments. For example, no blood samples should be taken from a 
fistula or blood pressure measurements taken on that arm. 
Other forms of vascular access include placement of a central venous catheter or a permanent 
catheter. Catheters pose numerous potential complications for example such as infections and 
stenosis of vessels. Appropriate placement of vascular access (for example AVF or graft) at an early 
stage, ensures that patients do not succumb to the potential complications of emergency insertion 
of any catheter. Furthermore, patients in ESRD are uremic and prone to infections (Dinwiddie & 
Bhola, 2010).  
Frequency and duration of HD sessions should be 4 to 5 hours, three times a week (Leggat, 2005). 
Clinical studies have shown that the use of AV fistulas results in lower rates of infection, thrombosis, 
and hospitalizations (Jackson & Litchfield, 2006) compared to the use of grafts and catheters (Dutka 
& Brickel, 2010).  
2.4.2 Assessment of haemodialysis adequacy 
Adequacy of dialysis refers to the amount of dialysis needed for a patient to remain asymptomatic. 
Adequacy of haemodialysis improves patient survival, quality of life and biochemical outcomes and 
minimizes disease complications and hospitalisation (Adas, Al-Ramahi, Jaradat, & Badran, 2014). 
Dialysis adequacy is therefore an important determinant of patient outcome and thus an important 
clinical performance indicator. Dialysis adequacy refers to how well a patient is dialysed after 
measurement of urea clearance, expressed as Kt/V. Kt/V refers to a value (for example 1.2) used in 
medicine to quantify haemodialysis treatment adequacy: K, dialyzer clearance of urea; t, dialysis 
time divided by V, volume of distribution of urea, approximately equal to a patient's total body 
water. The guidelines recommend a Dialysis Adequacy of Kt/V of 1.2 for patients receiving dialysis 
three times a week and 1.6 for patients being dialyzed twice a week (Malekmakan et al., 2010; NKF-
KDOQI, 2015). 
Dialysis adequacy relies on removal of accumulated solutes achieved during the HD with the 
ultimate objective of each dialysis session being to restore the patient’s homeostasis and realizing 
a zero sodium and water balance. ‘Dialysis dose’, defined as the net product of ‘solute clearance’ 
(K) and ‘treatment time’ (t), is a useful index for assessing treatment delivery (Locatelli & Canaud, 
2012). Inadequate dialysis increases mortality and morbidity among dialysis patients therefore 
evaluation of HD adequacy using various biochemical tests is recommended (Sehgal, 2002). 
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According to NKF-KDOQI guidelines, to achieve adequate HD, the urea reduction ratio must be 
above 65%, with a target Kt/V of 1.4 and a minimum of 1.2 (NKF-KDOQI, 2015). Every 0.1 fall in Kt/V 
leads to a 7% increase in relative risk of death and an 11% rise in annual hospitalization levels 
(Sehgal, 2002). 
2.4.3 Nutritional Management during haemodialysis 
Nutritional management in ESRD is important to assess patient’s nutritional status by evaluating 
serum albumin and body weight. A pre dialysis albumin level of ≥-4.0 g/dl is the outcome goal, and 
patients with serum albumin levels lower than 3.5 g/dl should be evaluated for protein-energy 
malnutrition (Combe et al., 2004).  
Nutrition is an important factor in maintaining good health of patients on HD, affecting their 
morbidity and mortality (Al-Ali et al., 2016). Albumin is one of the many nutritional indicators to 
evaluate nutritional status in patients on HD that correlates with morbidity and mortality. Protein-
energy wasting, sodium and water retention, vitamin D deficiency, and phosphate retention are 
some of the nutritional abnormalities commonly encountered in patients with CKD (Ameh, Cilliers, 
& Okpechi, 2016). Taking measures to ensure good nutrition (or lack thereof) perhaps represents 
the strongest predictors of clinical outcomes in patients in ESRD (Ibrahim, Hossam, & Belal, 2015; 
Kovesdy, 2016).  
Poverty is a problem in South Africa and yet patients are expected to follow strict treatment and 
dietary regimes. This often results in non-adherence to treatment leading to poor outcomes but 
there is a paucity of published research on the association between patient outcomes and patient 
adherence to dietary regimes. 
Nutritional management is important to ensure that patients have an adequate level of serum 
albumin to create a physiologically desirable blood oncotic pressure (‘pull’ of interstitial fluid into 
the vessel) to prevent hypoalbuminaemia. Furthermore, a low serum albumin level would result is 
low production of immunoglobulins and increase the risk of infection. The guidelines recommend 
a serum Albumin of >35 mmol as a nutritional marker. 
Serum plasma albumin, an important measurement for ESRD, predicts quality outcomes. Clinicians 
need to be aware of deviations in albumin levels and acceptable nutritional goals in order to ensure 
patients are as healthy as possible. Team members’ knowledge of the ill-effects of 
hypoalbuminemia is essential for the provision of quality care (Wyczesany & Steefel, 2015a). 
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In ESRD, chronic inflammation is independently associated with malnutrition and anaemia, leading 
to accelerated atherosclerosis, cardiovascular complications and death (Kalantar-Zadeh et al., 
2005). Other causes of infection and/or inflammation are, for example, related to the dialysis 
treatment itself such as microbial dialysate contamination or oxidative stress and uraemia in CKD 
(Vanholder et al., 2018).  
2.4.4 Management of anaemia 
In ESRD anaemia refers to a HB level of <10 g/dL. The management of anaemia during HD includes 
measurement of parameters such as serum HB, Transferrin Saturation and Ferritin. The burden of 
anaemia in patients with ESRD is substantial, resulting in considerable morbidity that dramatically 
reduces their quality of life (Locatelli et al., 2008).  
Anaemia can be defined as having a lower-than-normal number of red blood cells or quantity of HB 
and in ESRD anaemia refers to an HB level of <10 g/dL. Anaemia is caused by: 1) an inability of the 
kidneys to produce the hormone erythropoietin to stimulate bone marrow to produce red blood 
cells which contain Hb; 2) blood loss; and 3) high rates of red blood cell destruction during the 
haemodialysis process.  
The management of anaemia during haemodialysis includes measurement of parameters such as 
serum HB, Transferrin Saturation and Ferritin. The guidelines recommend maintaining the levels 
for these parameters at 10 – 12 g/dL for serum HB, 20% for Transferrin Saturation (TSAT) and 200 
ng/L for Ferritin. Transferrin saturation (TSAT) and ferritin are measures of iron status, used to 
detect abnormalities relating to iron status for diagnosing iron deficiency and to guide therapy 
(Besarab & Szczech, 2014). Transferrin levels are measured as total iron building capacity (TIBC). 
Ibrahim (2010) found that the KDOQI target of 11 to 12 g/dL for Hb after the administration of 
erythropoietin to prevent anaemia was achievable only in 18% of prevalent dialysis cases in Egypt. 
The mean value of Hb in this study (9.23 ± 7.18 g/dL) is lower than that reported by the Dialysis 
Outcomes and Practice Patterns Study (Locatelli et al., 2004).  
The burden of anaemia in patients with ESRD is substantial, resulting in considerable morbidity that 
dramatically reduces their quality of life (Locatelli et al., 2004). The inability of the bone marrow to 
form red blood cells due to decreased levels of erythropoietin, the shorter than normal lifespan of 
red blood cells and blood loss during HD are some of the factors that may influence the 
maintenance of Hb levels in the target range of 11 – 12g/dl (NKF-KDOQI, 2007).  
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Current Kidney Disease Improving Global Outcomes (KDIGO) guidelines recommend iron 
supplementation to maintain TSAT >20% in patients with CKD to compensate for the reduced TIBC 
and the reduction in metabolic cycling of iron (KDIGO, 2012). A ferritin >200 ng/ml is recommended 
in ESRD patients, but irrespective of TSAT, an upper ferritin limit of 500 ng/ml is also recommended 
(KDIGO, 2012).  
Individualised treatment of anemia requires the use of erythropoiesis-stimulating agents (ESAs) 
(Messana, 2006), the parenteral administration of iron (Besarab & Szczech, 2014) and frequent 
monitoring of Hb levels. It has been well documented that patients at the start of dialysis present 
with low HB/haematocrit levels, malnourishment, elevated parathyroid hormone levels, elevated 
phosphorus levels, low calcium levels, acidosis, elevated blood pressure, and congestive heart 
failure (Levin et al., 2008). 
The KDIGO Clinical practice guideline (CPG) (2012) for the management of anaemia in chronic 
kidney disease (CKD) is based upon systematic literature searches last conducted in October 2010, 
supplemented with additional evidence up to March 2012. It is designed to provide information 
and assist decision making. CPGs can improve the quality of clinical decisions. Evidence-based 
guidelines support interventions that are of proven benefit while documenting the quality of the 
supporting data (Drüeke & Parfrey, 2012). Complications of anaemia in ESRD result in left 
ventricular hypertrophy and or dilatation, decreased exercise capability, increased intradialytic 
hypotension, decreased quality of life, decreased cognitive function and increased sexual 
dysfunction (Weisbord et al., 2004).  
The kidney produces approximately 90% of circulating erythropoietin in the body, therefore the 
level of anaemia that develops is directly related to the amount of residual renal function present. 
As the kidney disease progresses, the iron carrying capacity of the Hb is limited as a result of 
decreased erythropoiesis as transferrin, a carrier protein that transports absorbed and stored 
iron, is also decreased (Kanbay, Perazella, Kasapoglu, Koroglu, & Covic, 2010).  
The KDOQI Clinical Practice Guidelines and Clinical Practice Recommendations for Anaemia in 
Chronic Kidney Disease define iron deficiency as a serum ferritin concentration of <200 ng/ml in 
haemodialysis patients. A transferrin saturation of <20% indicates iron deficiency in patients with 
CKD and may be corrected with intravenous iron which will decrease the need for blood 
transfusions in the presence of anaemia. The KDIGO guidelines, released in 2012, recommend that 
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intravenous iron should be routinely administered to patients on haemodialysis. Erythropoietin 
Stimulating Agents (ESA) are routinely prescribed for the production of red blood cells.  
Anaemia management is the first of the evidence based quality of care indicators: Hb levels of 
patients on HD should be maintained at between 10 and 12 g/dl, transferrin saturation (TSAT) at 
≥20% and ferritin at ≥200 ng/dl (NKF-KDOQI, 2007). ESA therapy should be initiated when Hb levels 
are ≤9 g/dl, and iron supplement therapy should be commenced if TSAT is ≤20% and ferritin is ≤200 
ng/dl (KDIGO, 2012).  
2.4.5 Prevention of bone disease during haemodialysis 
Monitoring of phosphate, calcium and parathyroid hormone (PTH) is important for the prevention 
of bone disease, vascular calcification and uncontrollable increased levels of PTH (Bazydlo, 
Needham, & Harris, 2014). Progressive loss of kidney function in CKD leads to reduced production 
of 1.25-(OH)2vitamin-D3 (1,25-dihydroxyvitamin D; calcitriol) and abnormal mineral homeostasis 
reflected mainly by an imbalance in both serum calcium (Ca) and phosphorus (P) levels, as well as 
increasing levels of parathyroid hormone (PTH) (KDIGO, 2009) Phosphate Binders are routinely 
prescribed to treat hyperphosphatemia. Calcium levels are regulated by the dialysate used in the 
process of dialysis. Abnormal serum calcium levels are regulated by prescribed calcium 
supplements. Clinicians need to have an awareness and understanding of desirable serum calcium 
and serum phosphate levels following dialysis. Adequate dietary advice needs to be given to 
patients to maintain acceptable levels of calcium and phosphate. 
Bone disease management ensures that patients’ calcium and phosphate levels remain within 
acceptable limits to prevent bone disease and an overactive parathyroid. The four parathyroid 
glands are situated on the thyroid gland, one at the upper pole and another at the lower pole of 
each of the two lobes of the thyroid gland. The parathyroid glands secrete parathyroid hormone to 
regulate serum calcium and phosphate. 
The secretory function of the kidney cannot be substituted by the dialysis process therefore, the 
patient will have to receive erythropoietin as a subcutaneous injection for the stimulation of bone 
marrow to form red blood cells. One Alpha is a tablet administered orally as a vitamin D supplement 
essential to maintain bone formation and prevent osteoporosis (Levy, Morgan, & Brown, 2004). A 
Calcium x Phosphate (Calcium-Phosphate Product) of >4 indicates that bone is demineralising, and 
the patient is at risk of developing osteoporosis. Bone disease management is where the calcium 
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(Ca) and phosphate (Phos) product will be considered as the indicator for bone disease, the target 
of Ca x Phos product of less than 4 (Hoy et al., 2007). 
Abnormalities in calcium and phosphorus metabolism are common among patients regularly 
treated with dialysis, and observational studies suggest that elevated serum calcium and 
phosphorus levels are associated with increases in all-cause and cardiovascular mortality (Hoy et 
al., 2007; KDIGO, 2009b). The KDOQI Clinical Practice Guidelines for Bone Metabolism and Disease 
in Chronic Kidney Disease provide recommendations for the frequency of biochemical testing to 
determine plasma parathormone (PTH) levels and the serum levels of calcium (Ca) and phosphorus 
(P) and also includes calculated values for the calcium-phosphorus ion product in serum (Ca × P). 
Acceptable target ranges for these biochemical parameters also are delineated. In previous studies 
hyperphosphatemia has emerged as an important clinical issue in dialysis patients because higher 
levels of serum phosphorus (P) and calcium–phosphorus (Ca x P) product have now been associated 
with increased vascular calcification and cardiovascular mortality (Block et al., 2004; Hoy et al., 
2007; Uribarri, 2004b; Wei et al., 2006). 
In summary, target outcomes for clinical indicators (dialysis access, anaemia management, dialysis 
adequacy, mineral bone disease and nutritional management) are well documented (AlYousef et 
al., 2016; Kimata et al., 2014; Miranda et al., 2016; Uribarri, 2004b; Wyczesany & Steefel, 2015b). 
Increased morbidity and mortality are associated with inadequate dialysis, poor dietary protein 
intake, hyperphosphatemia, low Hb levels and co-morbid conditions (NKF-KDOQI, 2002) in dialysed 
patients. 
2.5 Validation studies 
Validation studies are referred to as works consisting of research using processes by which the 
reliability and relevance of a procedure for a specific purpose are established (Kimberlin & 
Winterstein, 2008). Confirmation of the validity and reliability of tools are a prerequisite for 
assuring the integrity of study findings (DeVon et al., 2007). For rigorous research, instruments 
and profiles should be psychometrically sound, valid and reliable (DeVon et al., 2007). 
The process of developing and validating an instrument is in large part focused on reducing error 
in the measurement process ((Kimberlin & Winterstein, 2008). Validity is the extent to which the 
interpretations of the results of a test are warranted, which depends on the particular use the 
test is intended to serve (Rodrigues, Adachi, Beattie, & MacDermid, 2017). The responsiveness of 
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the measure to change is of interest in many of the applications in health care where 
improvement in outcomes as a result of treatment is a primary goal of research (Kimberlin & 
Winterstein, 2008). 
2.5.1 Content Validity Index and face validity 
Content validity (CV) has become one of the most important validation processes in instrument 
development due to confusion with face validity and unavailability of standardised ways of 
conducting validation (Lynn, 1986). Lynn (1986), therefore proposed the quantification of content 
development in two stages: 1) the development stage that consists of activities such as domain 
identification, item generation and instrument formation and 2) the judgment stage which includes 
the quantification of CV items (Lynn, 1986). Measuring content validity of research instruments is 
important (Yaghmaie, 2003). According to Rusticus (2014) validity refers to the degree to which an 
instrument measures what it is designed to measure, while content validation provides evidence 
about the validity of the instrument and how well it measures the targeted construct to make 
meaningful and appropriate inferences. Content validity is a subjective judgement of experts about 
the degree of relevant construct in an assessment instrument (Yaghmaie, 2003). Content validity 
can be quantified by using an index of validity, referred to as the content validity index (CVI) (Lynn, 
1986; Waltz & Bausell, 1983). In addition to assessing experts’ judgement of the relevance of each 
item in a research instrument (Lynn, 1986), Yaghmaie (2003) added clarity, simplicity and 
ambiguity. The concepts clarity, simplicity and ambiguity were implied in the assessment of face 
validity of Kyriacos’ (2011) research instrument. Assessment of face validity is a subjective form of 
validation (Yaghmaie, 2003). 
2.5.2 Accuracy 
Reliability estimates the stability of measures, internal consistency of measurement instruments 
and interrater reliability of instrument scores (Burns, 2014). Internal consistency is a measure of 
how consistently each item measures the same underlying construct by correlating performance 
on each item with overall performance across participants which can be represented by Cronbach’s 
alpha reliability coefficient. Interrater reliability refers to the degree of agreement determined by 
having two or more observers watching the same event and independently recording the variables 
according to a predetermined coding system represented as a percentage of agreement or Cohens 
Kappa (Wagner, Healy & Johnson, 1999).  
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Several issues may affect the accuracy of data collected, such as those related to self-report and 
secondary data sources (Atkinson, 2012). Self-report of patients or subjects is required for many of 
the measurements conducted in health care, but self-reports of behaviour are particularly subject 
to problems with social desirability biases (Kimberlin & Winterstein, 2008). Interrater reliability is 
the agreement of the same data obtained by different raters, using the same scale, classification, 
instrument, or procedure, when assessing the same subjects or objects (Kottner et al., 2011). Inter-
rater reliability testing for accuracy of transcription amongst raters was appropriate for this study. 
2.6 Record review 
According to Vassar and Holzman (2013), the most common strategy for Record Chart Reviews 
(RCR) was convenience sampling because researcher could use medical data that was available. 
While this method presents limitations with respect to the generalizability of results, it proved to 
be a practical method and particularly useful when dealing with small sample sizes, as observed in 
this study. 
2.7 Summary 
The available published literature on search terms from databases between 2000 and 2019 yielded 
major subject areas, particularly relating to adherence from the point of view of patients. 
Numerous studies have been published relating to the different quality indicators this was used to 
inform the foundation and background of the different quality indicators however, this study was 
specifically aimed at the adherence of clinicians to quality indicators.  
The National Kidney Foundation (NKF) has published the Dialysis Outcomes Quality Initiative (DOQI) 
clinical practice guidelines based on numerous Randomised Controlled Trials. These guidelines are 
further divided into clinical quality indicators that acts as a framework in delivering care to the 
patient with ESRD on haemodialysis for the purpose of this study. Guidelines recommend that  
• AVF/AVG should be the first choice of access to deliver haemodialysis to patients in ESRD 
and it is referred to as the gold standard. 
• Anaemia profile Hb 10 -12g/dl, TSAT above 20% and Ferritin 200 – 500ng/dl 
• Adequacy reflected in a Kt/V 1.2 – 1.4  
• Bone disease management Calcium Phosphate product of < 4 
• Nutritional Albumin > 35mmol/l 
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Literature reveals patients have invasive catheters in place for the purpose of dialysis which 
predisposes them to blood stream infections (Dutka & Brickel, 2010). There is also a difficulty in 
limiting anaemia and bone management profiles in patients with ESRD. Furthermore, adequacy and 
nutritional aspects also pose problems for these patients. Numerous studies on patients and non-
compliance have been published while it is not known how well clinicians adhere to guidelines due 
to the paucity in research. Literature reveals the greater percentage of patients that reach each of 
these targets results in a decrease in morbidity and mortality in patients with ESRD and thereby 
improving the quality of life of these patients. 
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CHAPTER THREE   METHODS 
3.1 Introduction 
In this chapter the methods employed to answer the research question are described. The research 
question was “What proportion of patients with ESRD on chronic haemodialysis (HD) in selected 
private dialysis units in the Western Cape reached target levels for each clinical indicator outlined 
in the NKF-KDOQI (2002) guidelines between 1 January 2018 and 31 December 2018?”. The primary 
aim of this multi-phase study was to design (Phase 1) and validate a prototype record review 
template to ensure that the results of the study are valid (Phase 2) and reliable (Phase 3) (DeVon 
et al., 2007; Lynn, 1986; van Melle et al., 2018). Construction of the template was based on the 
Quality Indicators outlined in the KDOQI/KDIGO Guidelines for patients on HD. This was followed 
by record review (Phase 4) using the validated record review template to describe target and actual 
levels outcomes for each clinical indicator to assess adherence to established guidelines (KDIGO, 
2009a, 2012; NKF-KDOQI, 2002, 2007; Uribarri, 2004a). 
3.2 Research design 
Retrospective record review using a multi-phase descriptive design was employed to achieve the 
aim of the study. The advantages of conducting chart review include the following: it is inexpensive, 
existing records are used and it allows for the study of rare occurrences (Gearing, Mian, Barber, & 
Ickowicz, 2006; Vassar & Holzmann, 2013). However, the limitations of this design are that it relies 
on accuracy and recall of individuals, important data may not be available and records might not 
be accessible (Hess, 2004). An outline of the 4-phase study design is presented in Figure 3. 1. 
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Phase 4: Commence study 
Gain access to institutions & EuCliD®  N=176 patient records for review (n=22 from each 
cluster of 8 HD units) 
Figure 3. 1: Diagram of the four research phases 
3.3 Research sites 
The head nurse of the national Fresenius Medical Care (FMC) company allocated eight of 11 HD 
units within the Western Cape Province, South Africa which used the European Clinical Database 
(EuCliD®) for patient records, as research sites for this study. The eight HD units in the private 
healthcare sector where patients received Renal Replacement Therapy (RRT) were situated in 
various geographical areas within Cape Town. The clinical records of patients who received RRT 
Phase 3: Establish accuracy (percent correctness) of transcription
Transcription of data from EuCliD patient 
database onto validated record review template
Information Sheet & Consent Form (Appendix 4)
4 fictitious datasets for 22 patients on 1 EuCliD 
form (Appendix 5) for transcribing onto record 
review template
Phase 2: Validation of Record Review Template
Content Validity Index (CVI) + face validity
Information Sheet & Consent Form (Appendix 2)
CVI & face validity checklist (Appendix 3)
Phase 1: Design
Construction of Record Review Template 
(Appendix 1)
Guided by literature review + existing renal 
practice guidelines
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between 1 January 2018 and 31 December 2018 were considered for review. Patients in the public 
healthcare sector do not comply with all the inclusion criteria, therefore the study was conducted 
in the private healthcare sector where older patients needing HD who can afford the treatment are 
accepted onto the programme. In public sector units younger patients have a better chance of 
accessing HD. In addition, more patients are on HD in private units (85.2%) than in public sector 
units (14.8%). Patients in public sector renal units reportedly receive predominantly peritoneal 
dialysis (PD) (South African Renal Registry Report, 2016). It was anticipated that a larger sample 
would therefore be available in the private sector. 
3.4 Phase 1: Construction of Prototype Record Review Template 
The first objective of the study was to design a prototype record review template for data 
extraction to describe target and actual levels for each identified clinical indicator to assess 
adherence to established guidelines. The variables in the prototype were constructed using the 
KDOQI/KDIGO guidelines for biochemical targets as the gold standard. A 3-part prototype record 
review template comprising 58 variables (Appendix 1) was constructed in a Statistical Package for 
the Social Sciences (SPSS) version 26 (IBM, 2013) data file.  
The FMC EuCliD® contains clinical data of large numbers of patients in various international dialysis 
units including South Africa. Gregory and Radovinsky (2012) report that the organisation and 
structure of the data collection tool are important and ideally, the tool should correspond to the 
data as these appear in the patient’s record. Grouping the relevant data facilitates reliable data 
collection and ease of use by the data abstractor (Gregory & Radovinsky, 2012). 
Demographic data such as gender and age and clinical characteristics are entered into the EuCliD® 
and maintained by FMC staff on an ongoing basis to ensure quality outcomes. Demographic data 
such as marital status and ethnicity are located in other parts of the EuCliD® not easily accessible 
to renal nurse practitioners. The 3-part prototype record review template (Sections A, B and C, each 
with sub-divisions) (Appendix 1) comprised of: 
• Demographic data: gender, age, ethnicity (for disease-linked patterns), marital status (to 
assess social support systems) and clinical data such as diagnosis (Section A1-5); 
• medications taken (Section B1-4); 
• selected laboratory results: Hb, Transferrin Saturation (TSAT) and Ferritin (quality indicator 
of anaemia) (Section C1-3); 
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• type of access (Section C4); 
• Kt/V which indicates adequacy of dialysis (Section C5); 
• serum phosphorus (Section C6); 
• serum calcium (Section C7); 
• Calcium and Phosphate (including Ca x Phos product) (for bone disease management) 
(Section C8); and 
• Albumin (quality indicator of nutritional status) (Section C9). 
An excerpt from the SPSS data record review template (data extraction form) (Appendix 1) is 
presented in Table 3.1. 
Table 3. 1: Excerpt from the Prototype Record Review Template (Appendix 1) 
 
The organisation and structure of the record review template corresponded with the actual patient 
data recorded on the EuCliD®. According to Gearing et al. (2006), logical organisation of data and a 
user-friendly structure is a good strategy for optimal data collection. Each variable was allocated a 
numerical code. Internal validity and reproducibility of any retrospective study is significantly 
enhanced by the standardisation of data (Gregory & Radovinsky, 2012). 
To achieve coherence, the validation processes (Phases 2 and 3) for the record review template are 
described separately as a whole in this chapter: study population (inclusion and exclusion criteria 
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for participants), research activities and followed by the results. For Phase 4 (record review), the 
study population and estimation of sample size, data collection procedure including gaining access 
to the research sites are described but the results are presented in Chapter 4 . 
3.5 Phase 2: Instrument Validation 
The second objective of the study was to validate the prototype record review template (Appendix 
1) by ascertaining the content validity index (CVI) (Phase 2) and to establish accuracy (percent 
correctness) of transcription of the prototype record review template by inter-rater reliability 
(Phase 3). Although the CVI was conducted, validation was actually an assessment of renal 
healthcare professionals’ perceptions of the relevance of the quality indicators on the EuCliD® 
reflected on the prototype record review template. Therefore, even if not considered content valid 
at the conclusion of the validation process, the items could not be changed before the actual clinical 
record review (Phase 4 of the study). 
3.5.1 Validation of the record review template 
It must be kept in mind that this validation process was actually an assessment of renal healthcare 
professionals’ perceptions of the relevance of the items on the prototype record review template 
that reflect the quality indicators on the EuCliD®. Although content and face validity of the template 
were measured, the items, even if not content valid at the conclusion of the validation process, 
could not be removed before the actual clinical record review (Phase 4 of the study). 
3.5.1 Validation of the CVI and face validity checklist for the record review template 
An Information Sheet and Consent form (Appendix 3) and a checklist (Appendix 4) for determining 
the CVI and face validity of the prototype Record Review Template (Appendix 1) were designed. 
The organisation and structure of the CVI/face validity checklist corresponded with the variables 
on the record review template (Appendix 1) in SPSS and therefore with the actual patient data 
recorded in the same order on the EuCliD® (except for Section A which is explained later). The 
checklist (Appendix 4) comprised Section A – Demographic and clinical characteristics with 18 
variables, Section B – Treatment details with 16 variables and Section C – Quality Indicator 
Outcomes with 24 variables (total n=58 variables), as indicated in Tables 3.1 and 3.3. However, 8 
items not appearing on the EuCliD® and relating to demographic characteristics were added. 
Ratings on the CVI checklist (Appendix 4) were indicated as 1 = not relevant, 2 = somewhat relevant, 
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3 = relevant or 4 very relevant. A separate column for comments was available. An excerpt of the 
CVI checklist is shown in Table 3.2. 
Table 3. 2: Excerpt from the Index of Content Validity checklist for the record review template 













 Section A – Demographic Details 
A1 Gender 
A1.1 Male      
A1.2 Female      
A2 Age 
       
A panel of experts was purposively sampled and invited to validate the tool.  
3.5.1.1 Participants for CVI and face validity 
It has been established that a minimum of five experts can produce a sufficient level of control for 
chance agreement (Lynn, 1986:383). 
Inclusion criteria for five experts purposively selected for index of content validity (CVI) and 
numerical face validity of the research instrument: 
• 1 Nephrologist in Private Practice 
• 1 nurse lecturer with a Postgraduate Diploma in Nephrology Nursing at a University in 
South Africa 
• 1 clinical facilitator with a Postgraduate Diploma in Nephrology Nursing in a private renal 
unit 
• 2 qualified nephrology nurse practitioners working in two different private renal units. 
Exclusion criteria: 
• Students in training. 
3.5.1.2 Data management and analysis for CVI and face validity 
The CVI for each item (ratings at 1 = not relevant, 2 = somewhat relevant; 3 = relevant or 4 = very 
relevant) was determined by the proportion of experts who rated it as content valid (a rating of 3 
or 4) (Yaghmaie, 2003; (Lynn, 1986). As Likert score values are ordinal level data, a median was 
calculated (Jamieson, 2004)(Jamieson, 2004) for each item. The items that had CVI of 0.80 (4/5 
experts rating 1 item) amongst raters of a rating of 3 or were regarded as valid whereas Yaghmaie’s 
(2003) study reported content validity of 0.75 and Gutmann, Hunter-Schaedle and Shannon, (2006) 
regarded a preset >70% agreement as acceptable. The CVI for the entire instrument was the 
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proportion of total items judged content valid (Lynn, 1986) for example for 77/80 items deemed 
content valid, the CVI would be .96 (DeVon, 2007). For a count of the total scores for each of the 
ratings (1, 2, 3, 4) a median and interquartile range (IQR) and mean and standard deviation (SD) 
were calculated. The intended method of data analysis is shown in Table 3.3.  
Table 3. 3: Intended method of analysis of data for CVI of the record review template (n=5 experts) 











Section A – Demographic Details 
A1 Gender       
A1.1 Male       
A1.2 Female       
A2 Age       
       
Total numbers of this score 
amongst 290 ratings of 58 
items 
    
Median (IQR) of items with 
this score 
    
Mean (SD) of items with this 
score 
    




The intended method of data analysis for face validity of the record review template (adapted from 
Kyriacos, 2011) is shown in an excerpt from the template in Table 3.4. 
Table 3. 4: Intended method of analysis of data for face validity of the record review template (n=5 
experts) 












Layout     
Format     
Length of the record review template     
Total number of items with this score amongst 5 raters 
of 58 items  
    
Median (IQR) of items with this score     
Mean (SD) of items with this score     
Total numbers with this score     
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3.5.1.3 Data collection for CVI and face validity process 
The researcher met with potential participants individually in the units during day working hours 
(there are no night shifts although there are late shifts up until 21h00). Potential participants 
were purposively selected and considered as a result of their knowledge and competency in the 
renal field, they were also active mentors in the clinical setting, training nephrology students or 
skilful in research aspects of evidence practice within the renal field respectively. Each expert was 
given a printed Information Sheet and Consent Form (Appendix 3). After indicating their 
understanding by questioning and clarifying aspects of the contents of the study, they signed the 
consent form (Appendix 3) to participate voluntarily in the study.  
A printed copy of the content and face validity checklist (Appendix 4) was given to each expert on 
which to rate the relevance of each item on the prototype record review template (Appendix 1) in 
SPSS on the researcher’s laptop not yet populated for fictitious patient data (needed for Phase 4). 
Participants were requested to scroll across the SPSS file in ‘data view’ to see all the variables that 
were on the checklist. The experts rated the relevance of each item on a 4-point Likert scale on the 
checklist (Appendix 4) that corresponded with variables on the template in the SPSS file. The 
researcher was sitting at a distance from the participants and therefore available for answering any 
questions that might have arisen. 
3.5.1.4 Results for CVI and face validity 
Results for the CVI from the checklist are shown in Table 3.5. 
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Section A – Demographic Details 
A1 Gender 
A1.1 Male 0 1 (20%) 1(20%) 3 (60%) 4 (80%) 2 None 
A1.2 Female 0 1 (20%) 1 (20%) 3 (60%) 4 (80%) 2 None 
A2.1 Age 0 0 2 (40%) 3 (60%) 5 (100%) 2,5 None 
A3 *Ethnicity:  
A3.1 Asian 0 1 (20%) 3 (60%) 1 (20%) 4 (80%) 2,5 None 
A3.2 Black 0 1 (20%) 2 (40%) 2 (40%) 4 (80%) 2 None 
A3.3 Coloured 0 1 (20%) 2 (40%) 2 (40%) 4 (80%) 2 None 
A3.4 White 0 1 (20%) 3 (60%) 1 (20%) 4 (80%) 2 None 
A4 *Marital Status 
A4.1 Single 1 (20%) 1 (20%) 3 (60%) 0 3 (60%) 1,5 None 
A4.2 Married 1 (20%) 1 (20%) 2 (40%) 1 (20%) 3 (60%) 1,5 None 
A4.3 Separated 1 (20%) 1 (20%) 2 (40%) 1 (20%) 3 (60%) 1,5 None 
A4.4 Divorced 1 (20%) 1 (20%) 3 (60%) 0 3 (60%) 1,5 None 
A5 Diagnosis 
A5.1 Hypertension 0 1 (20%) 0 4 (80%) 4 (80%) 2 None 
A5.2 Diabetes 0 1 (20%) 0 4 (80%) 4 (80%) 2 None 
A5.3 Glomerulonephritis 0 1 (20%) 0 4 (80%) 4 (80%) 2 None 
A5.4 Systemic Lupus 
Erythematosus 
0 1 (20%) 0 4 (80%) 4 (80%) 
2 
None 
A5.5 Polycystic Kidney 
Disease 
0 1 (20%) 0 4 (80%) 4 (80%) 
2 
None 
A5.6 Other 0 1 (20%) 1 (20%) 3 (60%) 4 (80%) 2 None 
A5.7 Unknown 0 1 (20%) 1 (20%) 3 (60%) 4 (80%) 2 None 
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Section B – Treatment Details 
B1 Erythropoietin Stimulating Agent (ESA) 
















B1.5 Not prescribed 0 0 0 5 (100%) 5 (100%) 2,5 None 
B1.6 Treatment on hold 0 0 0 5 (100%) 5 (100%) 2,5 None 
B2 Iron Therapy 








B2.3 Other 0 2 (40%) 1 (20%) 2 (40%) 3 (60%) 1,5 None 
B2.4 Not prescribed 0 0 0 5 (100%) 5 (100%) 2,5 None 
B3 Phosphate binders 












B3.4 Not prescribed 0 0 1 (20%) 4 (80%) 5 (100%) 2,5 None 
B4 Vitamin D supplements 
B4.1 One Alpha 0 0 0 5 (100%) 5 (100%) 2,5 None 
B4.2 Not prescribed 0 0 0 5 (100%) 5 (100%) 2,5 None 
        1-ADD: 
Calcimemetics 
 Section C Quality Indicator Outcomes 
C1 Haemoglobin, g/dl 
C1.1 <10 0 0 0 5 (100%) 5 (100%) 2,5 None 
C1.2 10 – 12 0 0 1 (20%) 4 (80%) 5 (100%) 2,5 None 
C1.3 >12.1 0 0 1 (20%) 4 (80%) 5 (100%) 2,5 None 
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Total numbers (%) of this 
score amongst 290 ratings 
of 58 items 
5 (1.72) 27 (9.32) 55 
(18.96) 
203 (70.0) 258 
(88.96) 
Median (IQR) of items with 
this score 
0 (0) 0 (1) 1 (1) 4 (1) 5 (1) 
Mean (SD) of items with 
this score 
.09 (.283) .47 (.599) .95 (.867) 3.50 (1.274) 4.45 
(.705) 
Count: scores of 3 and 4 of 58 items 37/58 (63.79%) 
Note to table: A total of five raters each scored 58 items. 
*Items are not on the EuCliD® form but were added for the purpose of this study. 
 
As described in Section 3.5.2.2, a rating of 3 or 4 was accepted as valid. For 51/58 (87.93%) items 
there was between 80-100% agreement by the experts for a rating of these items at 3 (relevant) or 
4 (very relevant) which exceeded the predetermined CVI of 0.80 (4/5 experts rating 1 item) for this 
study. The CVI for the entire instrument was the proportion of total items judged content valid 
























C2 Transferrin Saturation, % 
C2.1 <20 0 0 0 5 (100%) 5 (100%) 2,5 None 
C2.2 >20 0 0 1 (20%) 4 (80%) 5 (100%) 2,5 None 
C3 Ferritin, ng/dl 
C3.1 <200 0 0 0 5 (100%) 5 (100%) 2,5 None 
C3.2 200 – 500 0 0 1 (20%) 4 (80%) 5 (100%) 2,5 None 
C3.3 >501 0 0 1 (20%) 4 (80%) 5 (100%) 2,5 None 
C4 Dialysis Access 
 
C4.1 
Temporary Catheter 0 0 1 (20%) 4 (80%) 5 (100%) 2,5 None 
 
C4.2 
Permanent Catheter 0 0 1 (20%) 4 (80%) 5 (100%) 2,5 None 
C4.3 AVF 0 0 1 (20%) 4 (80%) 5 (100%) 2,5 None 
C4.4 AVG 0 0 1 (20%) 4 (80%) 5 (100%) 2,5 None 
C5 Single pool Kt/V 
C5.1 <1.2 0 0 0 5 (100%) 5 (100%) 2,5 None 
C5.2 1.2 – 1.4 0 0 1 (20%) 4 (80%) 5 (100%) 2,5 None 
C5.3 >1.4 0 0 2 (40%) 3 (60%) 5 (100%) 2,5 None 
C6 Serum Phosphorus, mmol/L 
C6.1 <0.8 0 0 0 5 (100%) 5 (100%) 2,5 None 
C6.2 0.8 – 1.4 0 0 1 (20%) 4 (80%) 5 (100%) 2,5 None 
C6.3 >1.41 0 0 1 (20%) 4 (80%) 5 (100%) 2,5 None 
C7 Serum Calcium, mmol/L 
C7.1 <2.15 0 0 0 5 (100%) 5 (100%) 2,5 None 
C7.2 2.15 – 2.5 0 0 1 (20%) 4 (80%) 5 (100%) 2,5 None 
C7.3 >2.51 0 0 1 (20%) 4 (80%) 5 (100%) 2,5 None 
C8 Serum Calcium x Phosphorus, mmol²/L² 
C8.1 >4.4 1 (20%) 0 1 (20%) 3 (60%) 4 (80%) 2 None 
C9 Serum Albumin, mmol/L 
C9.1 <35 0 0 0 5 (100%) 5 (100%) 2,5 None 
C9.2 >35 0 0 1 (20%) 4 (80%) 5 (100%) 2,5 None 
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Results from the validation processes would have warranted changes to the items in the prototype 
Record Review Template (Appendix 1) that did not achieve CVI in preparation for the main study. 
However, as the CVI was an assessment of clinician’s perceptions of the relevance of the EuCliD® 
form these changes could not be effected. 
Results for face validity and shown in Table 3.6. 
Table 3. 6: Results for face validity of the record review template from the checklist (n=5 participants) 
















Layout 3 (60%) 2 (40%) 0 0 
Format 3 (60%) 2 (40%) 0 0 
Quality of printing 3 (60%) 2 (40%) 0 0 
Length of the questionnaire 3 (60%) 2 (40%) 0 0 
If visually easy to read 4 (80%) 1 (20%) 0 0 
If visually easy to comprehend 3 (60%) 2 (40%) 0 0 
If instructions at the beginning of the questionnaire are 
clear and easy to understand 
4 (80%) 1 (20%) 0 0 
Total number of items with this score amongst 5 raters of 
58 items  
23 12 0 0 
Median (IQR) of items with this score 3 (1) 2 (1)   
Mean (SD) of items with this score 3.29 (.488) 1.71 (.488)   
 
Results for face validity indicated that all the experts rated the prototype record review template 
as either very skillful (23/35, 65.7%) or satisfactory (12/35, 34.2%) and no improvements were 
required. 
Results for the CVI of the prototype record review template show that of the n=8 items not on the 
current EuCliD®, 4 /58 (6.89%) and 8/58 (13.79%) of the variables were rated as not relevant (1) 
and somewhat relevant (2) respectively and refer to ethnicity and marital status that might be 
useful for further research. For example, ethnicity might be linked to disease patterns and marital 
status might be useful to assess social support systems.  
Results from the CVI showed that the items on the record review template (Appendix 1) were 
content valid (63.79%, 37/58). The prototype template was used unchanged for Phase 3: inter-rater 
reliability testing for accuracy of transcription. 
3.6 Phase 3: Inter-rater reliability testing for accuracy of transcription 
Inter-rater reliability testing for accuracy of transcription was conducted to measure agreement 
amongst raters. In this study reliability refers to the accuracy (percent correctness) of transcribing 
data from the EuCliD® form onto the Record Review Template. Protocols (KDOQI/KDIGO guidelines) 
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with explicit criteria (NKF-KDOQI, 2002) should increase inter-rater reliability of data extraction and 
transcription as these guidelines are used for each HD session. An instrument cannot be valid unless 
it is reliable, yet the reliability of an instrument does not depend on its validity (Takavol & Dennick, 
2011) and needs to be measured independently. Construct validity for internal consistency of a 
research instrument should be assessed for example by using the Cronbach alpha coefficient 
(Takavol & Dennick, 2011), but in this study, record review template constructs were taken from 
clinical records and from established guidelines and therefore not assessed. 
3.6.1 Participants for Inter-rater Reliability testing for accuracy of transcription 
There are a number of statistics that have been used to measure interrater and intrarater reliability. 
Two of the most common measures includes percent agreement (agreement amongst raters) and 
Cohen’s kappa specifically for two raters, Cohen specifically discussed two raters in his papers 
(McHugh, 2012). The best advice for researchers is to calculate both percent agreement and kappa. 
Cohen's Kappa is the most used agreement statistic in literature (Zec, Soriani, Comoretto, & Baldi, 
2017). The greater the expected chance agreement, the lower the resulting value of the kappa. 
Inclusion criteria for record review 
• 1 nurse lecturer with a Postgraduate Diploma in Nephrology Nursing at a University in 
South Africa. 
• 1 qualified nephrology nurse practitioner in a private renal unit. 
Exclusion criteria for record review 
• Participants for the Index of content validity process 
• Students in training. 
3.6.2 Process for establishing accuracy (percent correctness) of transcription 
Two expert renal health practitioners who did not participate in the CVI validation process were 
purposively selected and invited to participate in the interrater reliability testing of the validated 
record review template (Appendix 1).  Each expert was given an Information Sheet and Consent 
Form (Appendix 5). After indicating their understanding of the contents of the study and willingness 
to participate voluntarily in the study, they signed the consent form (Appendix 5). When consent 
had been obtained, a prototype Record Review Template populated with 22 study subject code 
numbers and one EuCliD® form populated with 22 sets of fictitious patient data (Appendix 6) was 
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given to each expert. An excerpt of the EuCliD® form populated with 22 sets of fictitious patient 
data is shown in Table 3.7. 
 
Table 3. 7: Excerpt from one EuCliD® form populated with 22 sets of fictitious patient 
data (Appendix 6)  
 
Research participants transcribed data directly from the paper EuCliD® (Marcelli et al., 2001) form 
populated with 4 fictitious datasets for Month 1, 2, 3, 4 for each of 22 fictitious patients (Appendix 
6) onto a blank Record Review Template (Appendix 1) to estimate accuracy (percent correctness) 
of transcriptions. After giving each expert Appendices 1 and 6 on days at their convenience, they 
were also given one paper SPSS code guide in Word (Appendix 7) as a guide for transcribing the 
fictitious data onto the SPSS template on the researcher’s password protected laptop. During the 
transcription the researcher was available to clarify question participants may have had. The 
transcription process took approximately 2 hours as indicated on the consent form.  
Testing the degree of inter-rater reliability (IRR), in this context, relates to an estimation of 
consistency and accuracy in transcribing fictitious clinical data onto the prototype record review 
template. The Cohen’s kappa statistical test which measures interrater reliability (sometimes called 
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interobserver agreement) was conducted using Dag Stat and a 95% level of accuracy between the 
two raters was accepted for reliability. Interrater reliability, or precision, refers to the two raters 
giving the same score for the same data item (Gearing et al., 2006). 
Sim and Wright’s (2005) classification of Cohen’s kappa was employed as shown in Table 3.8. 
Table 3. 8: Classification of Cohen’s kappa 
0 Agreement equivalent to chance 
0.1 – 0.20 Slight agreement 
0.21-0.40 Fair agreement 
0.41-0.60 Moderate agreement 
0.61-0.80 Substantial agreement 
0.81-0.99 Near perfect agreement 
1.0 Perfect agreement 
This should be sufficient to detect Cohen’s kappa of 0.61-0.80 (substantial agreement or better) 
(Sim & Wright, 2005:264).  
3.6.3 IRR results 
There was perfect agreement (100% accuracy of transcription) between the two raters for 42 items. 
Only results where there is a difference are presented in Table 3.9. 
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Correct = 1/ 


















0.955 0.045 0.867-1.043 
40.17 
<0.003 



















































































































Rater 2  
correct   
21 1 
Rater 2  
Incorrect    
0 22 
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Rater 2  
correct  
20 2 
Rater 2  
Incorrect   
0 22 












Rater 2  
correct   
22 0 
Rater 2  
Incorrect   
1 21 








Kt/V 2 (n=22) Rater 2  
correct   
21 1 
Rater 2  
Incorrect   
0 22 











Rater 2  
correct   
21 1 
Rater 2  
Incorrect   
0 22 











Rater 2  
correct   
21 1 
Rater 2  
Incorrect   
1 21 











Rater 2  
correct   
22 0 
Rater 2  
Incorrect   
7 15 











Rater 2  
correct   
22 0 
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Rater 2  
correct   




Rater 2  
Incorrect  
0 22 
     
 
The P-value for the difference between correct and incorrect transcriptions for all 16 items 
achieved statistical significance (<0.003). Data in Table 3.11 show IRR agreement results in terms 
of Sim and Wrights’s (2005) classification. 
 
Table 3. 10: Agreement for IRR results  
Item statement 
0 Agreement equivalent to chance 0 
0.1 – 0.20 Slight agreement 0 
0.21-0.40 Fair agreement 0 
0.41-0.60 Moderate agreement 0 
0.61-0.80 Substantial agreement ESA Month 3, Calcium Month 3 (2 items) 
0.81-0.99 Near perfect agreement Gender, ESA Month 1 & Month 4, Phosphate 
Binder Month 4, Vitamin D Supplement Month 
2&Month 4, Hb Month 4, Ferritin Month 4, 
Vascular Access Month 3, Kt/V Month 2, Serum 
Phosphate Month 2 & Month 4, Albumin 
Month 2 & Month 3 (14 items) 
1.0 Perfect agreement 42 items not included in Table 3.9 
(Sim & Wright, 2005) 
There were no ratings for slight, fair or moderate agreement. There was substantial agreement 
(0.61-0.80) for 2 items (ESA Month 3, Calcium Month 3); near perfect agreement (0.81-0.99) for 
14 items (Gender, ESA Month 1 & 4, Phosphate Binder Month 4, Vitamin D Supplement Month 2 
& 4, Hb Month 4, Ferritin Month 4, Vascular Access Month 3, Kt/V Month 2, Serum Phosphate 
Month 2 & 4, Albumin Month 2 & 3) and perfect agreement (1.0) (100% accuracy) for 42 items 
which could not be computed. 
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Validation processes yielded the results above regarding the record review prototype. It is evident 
that the validated record review instrument was reliable. The measurement scale therefore had 
stability. All items on the template were content valid (Polit & Beck, 2012) and retained for data 
collection for record review for Phase 4.  
3.7 Phase 4: Record review 
Vassar and Holzman (2013) posit that the most common strategy for record chart review (RCR) is 
convenience sampling because researchers can use medical records that are available. While 
convenience sampling limits external validity of study results and therefore the generalizability of 
results, it is practical and particularly useful when dealing with small sample sizes. Methodology 
guidelines (Gearing et al., 2006) enhance the planning and process of the record review process 
and adherence to these guidelines adds rigour to a study (Vassar & Holzmann, 2013). The record 
review process for the present study was carefully planned. 
3.7.1 Study Population 
The clinical records of patients who received RRT between 1 January 2018 and 31 December 2018 
in the eight HD units in the Western Cape Province that had been allocated for the purpose of this 
study were considered for review. 
3.7.7.1 Sampling method and estimation of sample size 
It was estimated that for eight HD units at the research sites approximately N=370 patient records 
will be required for record review. The sample size was estimated as follows using Stat Calc (Epi 
info7, CDC): 
• Population of N=370 records (based on 2015 data); 
• 95% confidence interval (CI); 
• 5% confidence limit; 
• 8 clusters (dialysis units); and 
• In the absence of published data on all the parameters to be measured in this study, an 
expected frequency of 30% adherence to the guidelines for clinical indicators (acceptable 
blood results) was taken, therefore a sample size of n=22 per cluster will be required; a 
total sample size of n=176. 
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At the commencement of Phase 4 simple random sampling of anonymised records for the study 
period was done for each of the eight units using the Randbetween function in Microsoft Excel 
(2013). 
3.7.1.2 Eligibility criteria 
Inclusion criteria 
• Patients must be 18 years and older 
• Have End Stage Renal Disease  
• Receive haemodialysis three times a week for four hours per session 
• 4 available datasets from each patients’ records for record review. 
Exclusion criteria 
• Acutely ill patients  
• Haemodialysis units in the public sector as patient records are not on the EuCliD®. 
3.7.1.3 Recruitment for participation 
At the commencement of the planning stage for this study (2018), 8 units within the Western Cape 
region assigned to the researcher used the EuCliD® Database System; other units only started using 
the database at a later stage. Records of all patients over 18 years who received haemodialysis 
during the period under review (01 January 2018 to 31 December 2018) were selected and 
screened to ascertain whether records met the inclusion criteria: patients who had had HD three 
times a week for four hours; and assessment of clinical parameters Hb, Ferritin, SATS, Albumin, 
Calcium, Phosphate and Kt/V every three months (therefore for the 12-month period under review 
each record would have four available datasets for record review).  
Of the total eligible population of records (N=412) (Figure 3.2) the estimated sample size of 176 
records (22 for each of 8 clusters) was not achieved because the return rate was 169 (94.0%), 
therefore no datasets with missing data were excluded and all n=169 records were included in the 
review for eligibility. There were few records in some units and records reviewed from the 8 
participating units ranged from n=9 (5.3%) to n=51 (30.2%). Reasons for excluding records are 
illustrated in Figure 3.2, a diagrammatic representation of the record selection process. 
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Figure 3. 2: Diagrammatic representation of the record selection process for Phase 4 
Simple random sampling for 22 records per unit could not be realised for this study as all the units 
had different numbers of patients on dialysis. Furthermore, only a few patients in small units 
fulfilled the inclusion criteria. This resulted in a final sample size of n=169. 
3.8 Data collection procedure 
The rigour of the data collection method correlates with the reliability of the data and, ultimately, 
the analytical outcome of the study (Gregory & Radovinsky, 2012). 
3.8.1 Gaining access 
Formal permission-seeking letters were written to the FMC Research Committee (Appendix 8a and 
8b), national Head Nurse of the private dialysis provider and the unit managers and the Appendix 
9 requesting permission to access patient data and invite selected personnel to participate 
voluntarily in the validation processes (CVI and IRR). The letters (Appendices 8 and 9) outlined the 
Patient records for the period  
01 January 2018 – 31 December 2018  






• Records with no signed 
consent (n=75) 
• Acute patients on dialysis 
<3months at 
commencement of the 
study(n=78)  
• Patients on dialysis 2x/week, 
dialysed <4hrs/session and 
<4 blood datasets(n=90) 
 
Records reviewed (n=169) 
• Patients with 4 blood datasets  
• ≥18 years of age 
• Dialysed 3 times a week for 
4hours/session 
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study purpose, ethical principles to be upheld, the University of Cape Town (UCT) Faculty of Health 
Sciences Human Research Ethics Committee approval and ethics clearance number (Appendix 10), 
details of the researcher and supervisor, the process for data collection and the timeframe for 
returning the completed questionnaires. Upon receiving ethics clearance and written permission 
from the relevant authorising bodies, the researcher made telephonic contact with the Unit 
Managers to arrange a face to face meeting, to provide them with copies of the ethics clearance 
and the permission letters that allowed the researcher access to the dialysis centres to retrieve 
data from EuCliD® (Appendix 11). 
The data collection process was discussed in the office of each unit manager and they had an 
opportunity to deal with any uncertainty. The unit managers identified a physical space for the 
researcher to occupy during working hours for the data collection process. This meeting was also 
used to request the unit managers to identify, approach and recruit experts in the unit to 
participate in the validation processes at a later stage of the study. 
Written patient consent is obtained by Fresenius Medical Care staff from all haemodialysed 
patients upon commencement of treatment which allows all patient data to be placed on the 
Fresenius EuCliD® (Appendix 12). A signed consent form confirms that all patients have been 
informed that their results will be placed on the database anonymously and that the data may be 
used for research purposes. This however was not the case therefore, many records needed to be 
excluded from the study. Entered patient data receive an automatic pin code, which is only 
identifiable by dialysis centre. To ensure patient privacy rights, information on the system is 
password protected and only accessible to a designated unit manager and is sent to the Clinical 
Management Europe (CME) part of the Fresenius Medical Care organisation. The researcher was 
given the same access for record review during Phase 4 of the study as the national Head Nurse of 
the private dialysis provider. 
3.9 Data management and analysis 
Patient data from the EuCliD® system for the actual study were entered into the validated template 
file in SPSS (version 25) on a password protected personal computer, cleaned and analysed using 
SPSS software. Anonymised data for the 1-year period were analysed using KDOQI /KDIGO 
guidelines as the gold standard. Statistical tests used for analysis of data on the Record Review 
Template (Appendix 1) are presented in Table 3. Data will be stored securely for 5 years on a 
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password protected encrypted flash drive to which only the researcher has access and then deleted 
permanently. 
3.9.1 Data analysis  
The 3-part prototype record review template (Appendix 1) comprised 58 variables. Descriptive and 
inferential statistics will be used as outlined in Table 3.13 to compare data against international 
guidelines for number, proportion and percentage as the gold standard.  
To enhance the rigour of the study and transparency in reporting, an extension of the Strengthening 
the Reporting of Observational Studies in Epidemiology (STROBE) checklist, the REporting of studies 
Conducted using Observational Routinely collected health Data (RECORD) Statement (RECORD) 
(Benchimol et al., 2015) was used (Appendix 14). 
Table 3. 11: Data analysis and statistical tests 
Socio-demographic Parameters 
Variables Indicator Variables Data Statistical Analysis 
Gender F     (= 0) 
M      (= 1) 
Categorical Number, Proportion, percentage  
Age Actual Age  Categorical If data are normally distributed: Mean, min -max, Standard 
Deviation  
Median if data are not normally distributed 
Ethnicity Asian     (= 0) 
Black     (= 1) 
Coloured (= 2) 
White    (= 3) 
Not specified   (=4) 
Categorical Number, Proportion, percentage 
Marital Status Single      (= 0) 
Married     (= 1) 
Separated, Divorced or Widowed  (= 2) 
Categorical Number, Proportion, percentage 
Diagnosis Hypertension  (= 0) 
Diabetes          (= 1) 
Glomerulonephritis   (= 2) 
SLE          (= 3) 
Polycystic Kidney   (= 4) 
Other           (= 5) 
Unknown      (= 6) 





Binary  Yes = 0    No =1 
Binary  Yes = 0    No = 1 
Binary  Yes = 0    No = 1 
Binary  Yes = 0    No = 1 
Number, Proportion, percentage 
Physiological Parameters 
Physiological Variables Indicator Variables Data Statistical Analysis 
Dialysis Access Temporary Catheter  (= 0) 
Permanent Catheter  (= 1) 
Arteriovenous Fistula (= 2) 
Arteriovenous Graft   (= 3) 
Numerical Number, Proportion, percentage 
Single Pool Kt/V <1.2          (=0) 
1.2 - 1.4     (=1) 
>1.4           (=2) 
Numerical Number, Proportion, percentage 
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<10g/dl         (= 0) 
10 - 12g/dl     (= 1) 
>12g/dl          (=2) 
<20%            (= 0) 
>20%            (= 1) 
>200ng/l        (= 0) 
200 - 500ng/l  (= 1) 










Number, Proportion, percentage, Mean 
 
 
Number, Proportion, percentage, Mean 
Number, Proportion, percentage, Mean 







Serum Calcium x Phosphate 
(Ca x P) Product 
 
0 = < 1.1 
1 = 1.2 – 1.79 
2 = > 1.8 
0 = < 2.10 
1 = 2.11 – 2.39 
2 = > 2.4 
0 = < 5.49 










Number, Proportion, percentage, Mean 
 
Number, Proportion, percentage, Mean 
 




0 = < 35 




Number, Proportion, percentage, Mean 
Note to table: Gold standards for relevant parameters are in italics. 
3.10 Ethical considerations 
The study received ethical clearance in June 2019 HREC Ref 306/2019 from the University of Cape 
Town, Faculty of Health Sciences’ Human Research Ethics Committee (Appendix 10).  
3.10.1 General Principles 
According to the Declaration of Helsinki (2013) the principles of autonomy, beneficence and non-
maleficence were considered and privacy and confidentiality were adhered to (World Medical 
Association, 2013), including the protection of personal information.  
The nature of the study was a retrospective record review therefore the researcher had no personal 
contact with any of the patients represented by anonymised data in clinical records. There was no 
risk of personal or psychological harm. Although the researcher is an employee at FMC all efforts 
were made to ensure that there was no conflict of interest: code numbers were allocated to 
participants for the validation processes of the prototype record review sheet and fictitious data 
were used for inter-rater reliability processes. In addition, the final dataset for the actual study 
were anonymised by the FMC country head nurse before the researcher was issued with a 
username and password to access to the data. The study was partially funded by my supervisor, 
A/Prof U Kyriacos (R10,000 from NRF CSUR Grant No. 90295). 
University of Cape Town – Van der Nest, Yolinda. (2020)  






3.10.2 Risks, Burdens and Benefits 
The risk-benefit ratio of the study was carefully considered (Lott, 2005). There was no risk or burden 
to patients in the actual study as a result of the record review design. Participants might have 
experienced the process of assessing content validity and inter-rater reliability potentially 
burdensome. However, the benefits of this retrospective study outweigh the risks by a great margin 
as it provided data that can reduce morbidity and mortality of patients receiving haemodialysis. 
Data about guideline adherence will have the potential to raise the level of awareness amongst 
renal healthcare practitioners and this should improve patient outcomes. The principles of privacy, 
confidentiality, anonymity, autonomy and justice were upheld before, during and after the study. 
3.10.3 Vulnerable Groups and Individuals 
The patients are a vulnerable group having been diagnosed with a chronic life-threatening disease 
and their rights and dignity would be respected. Patients’ physical, psychological or social 
wellbeing will not be affected in any way as no information will be linked to them to change their 
treatment regime in any way (Richter, Groft, & Prinsloo, 2007). This retrospective record review 
seeks to improve practice where possible to improve patients’ quality of life and decrease 
morbidity and mortality. 
3.10.4 Privacy and Confidentiality 
The Fresenius Medical Care database EuCliD® (European Clinical Database) stores patient data 
and replaces patient names with a code number that ensured their anonymity (Appendix 12 - 
EuCliD® consent form). A researcher confidentiality and non-disclosure agreement (Appendix 13) 
is enclosed. Precautions was taken to protect the privacy of participants and the confidentiality 
of their personal information by using code numbers. No personal, identifiable data were 
recorded. Responses were not of a personal nature. 
3.10.5 Informed Consent 
The process of informed consent involved information provision to and understanding of the 
information by renal health professionals invited to validate the record review template (Appendix 
1). It also involves verification of whether the subject understands the information at his level of 
education, an overall ability to reason with the information, and the expression of choice about 
participation in the validation process. Participants who voluntarily agreed to assist with the 
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content validation (Appendix 3) and inter-rater reliability testing (Appendix 5) were informed of 
the aims, methods, sources of funding, institutional affiliations of the researcher as well as 
anticipated benefits and possible burdens of the study. Participants were informed of their right 
to refuse to participate in the study or to withdraw consent to participate at any time without 
reprisal after which all voluntarily gave written informed consent for inter-rater reliability testing 
(Appendix 5). Participants returning a completed CVI provided implicit informed consent to 
participate in the study in addition to the written consent. 
3.11 Summary 
The primary aim of this multi-phase study was achieved. In Phase 1 a prototype record review 
template was designed and validated. Construction of the template was based on the Quality 
Indicators outlined in the KDOQI/KDIGO Guidelines for patients on HD. The template was content 
valid following Phase 2: for 51/58 (87.93%) items there was between 80-100% agreement by the 
experts for a rating of these items at 3 (relevant) or 4 (very relevant) which exceeded the 
predetermined CVI of 0.80 (4/5 experts rating 1 item) for this study. Results for face validity 
indicated that all the experts rated the prototype record review template as either very skillful 
(23/35, 65.7%) or satisfactory (12/35, 34.2%) and no improvements were required. The template 
was reliable as there were no ratings for slight, fair or moderate agreement and substantial 
agreement (0.61-0.80) for 2 items; near perfect agreement (0.81-0.99) for 14 items3) and perfect 
agreement (1.0) (100% accuracy of transcription) for 42 items. The next chapter describes results 
for the record review (Phase 4) using the validated template to describe target and actual levels 
outcomes for each clinical indicator to assess adherence to established guidelines. 
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CHAPTER FOUR    RESULTS 
4.1 Introduction 
This chapter presents the results of Phase 4 of the study guided by the research question, aim and 
objectives 1.5.3 and 1.5.4 (Chapter 1): to describe target and actual outcomes for each clinical 
indicator to assess adherence to established guidelines (KDIGO, 2009a, 2012; NKF-KDOQI, 2002, 
2007; Uribarri, 2004a) for patients receiving haemodialysis (HD). The head nurse for the national 
Fresenius company allocated eight HD units within the Western Cape Province as research sites for 
this study because they used the EuCliD® for patient records.  
The research question investigated the proportion of patients with ESRD on chronic haemodialysis 
in selected private dialysis units in the Western Cape Province that reached target levels for each 
clinical indicator outlined in the NKF-KDOQI (2002) guidelines between 1 January 2018 and 31 
December 2018 
4.2 Objectives for Phase 4 
The objective of the final phase of the study was to undertake record review to: 
• describe haemodialysed patients’ demographic and clinical characteristics, prescribed 
medications and biochemical results at the completion of a dialysis session; and 
• compare recorded clinical data against the Kidney Disease Quality Outcomes Initiative (KDQOI) 
guidelines and where applicable, the Kidney Disease Improving Global Outcomes (KDIGO) 
guidelines as the gold standard for management of clinical outcomes. 
4.3 Response rate 
As outlined in section 3.9.2 and summarized in Table 4.1, the estimated sample size was 176 
records and the return rate were 169 (96.02 %). 
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<3 months) NO CONSENT 
EXCLUSION CRITERIA 
(x2/week, <4 
hrs/session and <4 
datasets 
INCLUSION 
CRITERIA MET % 
1 65 13 7 15 30 46.15 
2 25 2 2 10 11 44 
3 18 1 4 4 9 50 
4 111 20 20 20 51 45.94 
5 60 8 16 10 16 26.66 
6 27 4 10 3 10 37.03 
7 31 8 6 7 10 32.25 
8 85 22 10 21 32 37.64 
(n) 412 78 75 90 169  
 
4.4 Description of Demographic and Clinical Characteristics 
Patients’ age, gender, ethnicity, marital status and diagnosis are summarised in Table 4.2. 
Table 4. 2: Demographic and clinical characteristics (n=169 patient records) 
Demographic characteristics Number  Percent 
Age in years 
21 – 35 10 5.91 
36-52 32 18.93 
53 – 70 99 58.57 
71 + 28 16.56 
Gender 
Females  69 40.82 
Males 100 59.17 
Ethnicity (South African classification) (n=113; missing data n=56) 
Asian 0 0 
Black 22 13.00 
Coloured 69 40.80 
White  22 13.00 
Marital Status (n=119; missing data n=50) 
Single 29 24.37 
Married 81 68.07 
Separated 7 5.89 
Divorced  2 1.68 
Widowed  0 0 
Diagnosis 
Hypertension 42 24.85 
Diabetic Nephropathy 55 32.54 
Glomerulonephritis 16 9.46 
Systemic Lupus Erythematosus 3 1.77 
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Polycystic Kidney Disease  9 5.32 
Other 13 7.76 
Unknown (not recorded) 31 18.34 
Missing data were recoded -1 in the SPSS database for analysis. Data for age in years (range: 
minimum 21 – 86 maximum) were not normally distributed (Shapiro-Wilk P=0.055) although only 
marginally so therefore the median (60.0) and interquartile range (IQR) 17 were accepted. The data 
for age in Table 4.2 are categorised for grouping purposes comprising mostly those between 53-70 
years 99/169 (58.57%) with the least number of patients in the youngest age category 10/169 
(5.91%). The largest proportion of the cohort was male 100/169 (59.17%), classified as Coloured 
69/169 (40.8%) missing data for ethnicity 56/169 (33.1%), married 81/169 (47.93%) and had a 
diagnosis of diabetic nephropathy 55/169 (32.54%). The other causes noted were Hypertension 
42/169 (24.85%), Glomerulonephritis 16/169 (9.46%), unknown 31/169 (18.3%), Systemic Lupus 
Erythematosus 3/169 (1.8%) and Polycystic Kidney Disease 9/169 (5.3%).  
4.5 Results for Medications as prescribed  
The secretion of Erythropoietin (EPO) stimulates the bone marrow to form red blood cells (RBC). 
The failing kidneys are unable to secrete EPO and therefore Erythropoietin Stimulating Agents (ESA) 
are prescribed for the majority of patients in ESRD. Iron Therapy is prescribed in conjunction with 
EPO to assist in the formation of haemoglobin (Hb) so that oxygenated blood can be distributed 
throughout the body and to compensate for blood loss during dialysis sessions resulting in a low 
Hb level. 
Patients diagnosed with ESRD experience loss of bone minerals in the form of Calcium and 
Phosphorus which can also combine and form calcification of vessels. An imbalance of these two 
elements can cause complications such as mineral bone disease by stimulating the secretion of 
parathyroid hormone (PTH) and creating a negative feedback system leading to bone disease. 
Active Vitamin D is therefore prescribed to control the balance of calcium, phosphorus and PTH. 
Phosphate binders are prescribed to reduce the amount of phosphate in the blood that increases 
due to failing kidney function and the bound phosphate is then excreted by the bowel. Some of the 
phosphate will be removed by dialysis depending on the properties of the dialyser clearance and 
time on dialysis. Phosphorus is difficult to control as it is contained in the patients’ dietary intake. 
Data in Table 4.3 represent the number and percentage of patients on various prescribed medicines 
and the mean recordings for four HD sessions. 
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Table 4. 3: Prescribed medication for 4 HD sessions 
  Month 1 Month 2 Month 3 Month 4 Mean for the 4 periods 
No. of patients 169 169 169 169 169 
      
Medication 
ESA n=, (%) 103 (61) 110 (65) 115 (68) 110 (65) 110 (65.08) 
Iron Therapy n=, (%) 102 (60) 104 (62) 107 (63) 107 (63) 104 (61.53) 
Phosphate Binders n=, (%) 41 (24) 60 (36) 67 (40) 60 (36) 57 (33.72) 
Vit D Supplements n=, (%) 56 (33) 56 (33) 54 (32) 52 (31) 54 (31.95) 
 
Data in Table 4.3 show the mean number of recordings for each of the prescribed medicines for 
the four HD sessions: 110/169 (65.08%) for ESA, 104/169 (61.53%) for Iron Therapy, 57/169 
(33.72%) for Phosphate Binders and 54/169 (31.95%) for Vitamin D supplementation. 
4.6 Results for Quality Indicators 
Results for the quality indicators are presented in the order outlined in the literature review 
Chapter 2: dialysis access, dialysis adequacy, management of nutrition, management of anaemia 
and management of bone disease. 
4.6.1 Results for Dialysis Access 
Well-functioning vascular access (VA) sites, recommended in the guidelines as quality indicators, 
are essential for efficient dialysis therapy. Access refers to a surgically created Arterio-Venous 
Fistula (AVF) for the specific use of dialysis recommended in the KDOQI Guidelines as the first 
choice of access for patients receiving HD. A synthetic arteriovenous graft (AVG) is an alternative 
option for patients with diabetic nephropathy or problematic vasculature (SARS, 2015). Results for 
VA from the record review for the four HD sessions showing levels of adherence to the guidelines 
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Table 4. 4: Quality indicator: dialysis vascular access for HD 4 sessions (mean values and levels of 
adherence) 
Note to table: TC = Temporary Catheter, PC = Permanent Catheter AVF/AVG = Arteriovenous Catheter/Arteriovenous Graft;  
Data in Table 4.4 show that overall, recordings of dialysis access attained a mean level of 112/169 
(66.27%) with no missing data for the four HD sessions. AVF and AVG were used the most frequently 
as recommended and collectively yielded a mean number of 112/169 (62.27%) recordings. 
Temporary catheters were used the least 5/169 (2.95%) and the mean number of recordings for 
the use of permanent catheters was 52/169 (30.76%).  This means that 57/169 (33.72%) of the 
patient recordings indicated that dialysis access did not meet targets set in the guidelines. 
4.6.2 Results for Dialysis Adequacy  
Adequacy of dialysis refers to the amount of dialysis needed for a patient to remain asymptomatic 
and improves patient survival, quality of life and biochemical outcomes and minimizes disease 
complications and hospitalisation (Adas, Al-Ramahi, Jaradat, & Badran, 2014). Dialysis adequacy is 
therefore an important determinant of patient outcome and thus an important clinical 
performance indicator. Dialysis adequacy refers to how well a patient is dialysed after 
measurement of urea clearance, expressed as Kt/V: a value (for example 1.2) used in medicine to 
quantify haemodialysis treatment adequacy: K, dialyzer clearance of urea; t, dialysis time divided 
by V, volume of distribution of urea, approximately equal to a patient's total body water. The 
guidelines recommend a Dialysis Adequacy of Kt/V of 1.2 for patients receiving dialysis three times 
a week and 1.6 for patients being dialyzed twice a week (Malekmakan et al., 2010; NKF-KDOQI, 
2015). Data in Table 4.5 show recordings for dialysis adequacy (Single Pool Kt/V of 1.2 – 1.4) for the 
four HD sessions for the study period under review. 
  Month 1 Month 2 Month 3 Month 4 
Mean for the 4 
periods 
Dialysis Access 
No. of patients n=, (%) 169 (100) 169 (100) 169 (100) 169 (100) 169 (100) 
TC n=, (%) 6 (3.55) 3 (1.77) 3 (1.77) 6 (3.55) 5 (2.95) 
PC n=, (%) 56 (33.13) 56 (33.13) 51 (30.17) 48 (28.40) 52 (30.76) 
AVF/AVG n=, (%) 
107 
(63.31) 110 (65.08) 115 (68.04) 115 (68.04) 112 (66.27) 
Dialysis Access  
Dialysis Access:  
Target not Attained  




Dialysis Access:  
Target Attained n=, (%) 
107 
(63.31) 110 (65.08) 115 (68.04) 115 (68.04) 
 
112 (66.27) 
University of Cape Town – Van der Nest, Yolinda. (2020)  







Table 4. 5: Quality indicator: dialysis adequacy for 4 HD sessions (mean values and levels of adherence) 
 Month 1 Month 2 Month 3 Month 4 
Mean for the 4 
periods 
Single Pool Kt/V  
No. of patients 
n=, (%) 134 (79.28) 139 (82.24) 143 (84.6) 114 (67.45) 
 
133 (78.69) 
<1.2 n=, (%) 51 (38.05) 48(34.53) 41 (28.67) 35 (30.70) 44 (33.08) 
*1.2 – 1.4 n=, (%) 47 (35.07) 40 (28.77) 55 (34.46) 45 (39.47) 47 (35.33) 
>1.4 n=, (%) 36 (26.86) 51.(36.69) 47 (32.86) 34 (29.82) 42 (31.57) 
 
Single Pool Kt/V  
Target not Attained 
n=, (%) 71.(52.98) 80 (57.55) 74 (51.74) 47.(41.22 86 (64.66) 
Single Pool Kt/V  
Target Attained n=, 
(%) 47 (35.07) 40 (29.86) 55 (38.46) 45 (39.47) 47 (35.33) 
Note to table: * Target for dialysis adequacy 
Data in Table 4.5 show that a mean of 47/169 (35.33%) of the recordings for dialysis adequacy 
(Single Pool Kt/V of 1.2 – 1.4) for the four HD sessions attained the target level stipulated in the 
guideline. The mean number of recordings for dialysis adequacy was 133/169 (78.69%) of which 
missing data accounted for 36/169 (21.30%) of the recordings, results below the target (<1.2) were 
found in 44/169 (33.08%) of the recordings and recordings above the target (> 1.4) accounted for 
42/169 (31.57%) of the recordings. This means that 86/169 (64.66%) of the patient records 
indicated that target levels for dialysis adequacy were not attained. 
4.6.3 Results for Management of Nutrition  
Assessing patients’ nutritional status in ESRD is important by evaluating serum albumin and body 
weight. A pre-dialysis albumin level of ≥4.0 g/dl is the outcome goal, and patients with serum 
albumin levels lower than 3.5 g/dl should be evaluated for protein-energy malnutrition (Combe et 
al., 2004). Data in Table 4.6 show mean values for recordings of the management of nutrition for 
four HD sessions. 
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Table 4. 6: Quality indicator: Management of nutrition for 4 HD sessions (mean values and levels of 
adherence) 
  Month 1 Month 2 Month 3 Month 4 
Mean for the 4 
periods 
Serum Albumin in mmol/L (N) 
No. of patients n=, (%) 167 (98.8) 169 (100) 167 (98.8) 169 (100) 168 (99.40) 
<35mmol/L n=, (%) 49 (29.34) 49 (28.99) 26 (15.56) 26 (15.38) 
 
38 (22.61) 
>35mmol/L n=, (%) 118 (70.65) 120 (71.00) 141 (84.43) 143 (84.61) 
 
130 (77.38) 
Serum Albumin in mmol/L 




Serum Albumin in mmol/L 





For Nutritional Management a mean of 130/168 (77.38%) records attained the guidelines, while 
38/168 (22.61) records failed to meet the prescribed guidelines and missing data accounted for a 
mean of 1/169 (0.6%) of the study data for this parameter. 
4.6.4 Results for Management of Anaemia 
In ESRD anaemia refers to a HB level of <10 g/dL. The management of anaemia during HD includes 
measurement of parameters such as serum HB, Transferrin Saturation and Ferritin. The guidelines 
recommend maintaining the levels for these parameters at 10 – 12 g/dL for serum HB, 20% for 
Transferrin Saturation (TSAT) and 200 ng/L for Ferritin. Data in Table 4.6 show mean values for 
recordings for the management of nutrition for four HD sessions. Anaemia levels lower or higher 
than the targets as set out in the guidelines as indicated below can lead to adverse effects that can 
negatively affect quality of life. Data in Table 4.7 show mean values and levels of adherence for 
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Table 4. 7: Quality Indicator: Management of anaemia (mean values and levels of adherence) for 4 HD 
sessions 
  Month 1 Month 2 Month 3 Month 4 
Mean for the 
4 periods 
Hb in g/dl      
No. of patients n=, 




<10 g/dl n=, (%) 47 (29.01) 23 (13.60) 25 (14.88) 36 (21.30) 33 (19.76) 
10 – 12g/dl n=, (%) 80 (49.38) 106 (62.72) 101 (60.11) 88 (52.07) 93 (55.68) 
>12g/dl n=, (%) 35 (21.60) 40 (23.66) 42 (25.0) 45 (26.62) 41 (24.55) 
Transferrin Saturation in% 
No. of patients n=, 
(%) 163 (96.4) 162 (95.8) 159 (94.0) 160 (94.6) 
 
161 (95.2) 
<20 % n=, (%) 58 (35.58) 59 (36.41) 49 (30.81) 46 (28.75) 53 (32.91) 
>20 % n=, (%) 105 (64.41) 103 (63.58) 110 (69.18) 114 (71.25) 108 (67.08) 
Ferritin in ng/dl     
 
 
No. of patients n=, 
(%) 163 (96.4) 164 (97) 162 (95.8) 163 (96.4) 
 
163 (96.4) 
<200 ng/dl n=, (%) 41 (25.15) 39 (23.78) 28 (17.28) 28 (17.17) 34 (20.85) 
200 – 500 ng/dL n=, 
(%) 50 (30.67) 50 (30.48) 54 (33.33) 52 (31.9) 
 
52(31.90) 
>500 ng/dL n=, (%) 72 (44.17) 75.(44.4) 80 (49.38) 83 (50.92) 77 (47.23) 
Hb in g/dl 
Target not Attained 
n=, (%) 82 (50.61) 63 (37.27) 67 (39.88) 81(47.92) 
 
74 (44.31) 
Target Attained n=, 
(%) 80 (49.38) 106 (62.72) 101 (60.11) 88 (52.07) 
 
93 (55.68) 
Transferrin Saturation in % 
Target not Attained 
n=, (%) 58 (35.58) 59 (36.41) 49 (30.81) 46 (28.75) 
 
53 (32.91) 
Target Attained n=, 
(%) 105 (64.41) 103 (63.58) 110 (69.18) 114 (71.25) 
 
108 (67.08) 
Ferritin in ng/dl 
Target not Attained 
n=, (%) 113 (69.32) 114 (69.51) 108 (66.66) 111 (68.09) 
 
111 (68.09) 
Target Attained n=, 
(%) 50 (30.67) 50 (30.48) 54 (33.33) 52 (31.90) 
 
52 (31.90) 
Note to table: Hb = Haemoglobin; g/dL Ferritin; ng/dL SATS=Transferrin Saturation % 
Data in Table 4.7 show that 93/167 (55.68%) recordings for management of anaemia revealed an 
Hb of 10 – 12g/dl, therefore that the mean target level had been attained. Records that yielded a 
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result Hb <10 g/dl was 33/167 (19.76%) and Hb >12g/dl was 41/167 (24.55%), therefore 74/167 
(44.31%) failed to meet the required guidelines for Hb. Suboptimal Hb levels were present in 
44.31% of the patient recordings. For Transferrin Saturation a mean of 108/161 (67.08%) 
recordings attained the prescribed target and 53/161 (32.91%) failed to reach the desired 
outcomes. For ferritin levels 34/163 (20.8%) reported levels below the desired target level, while, 
77/163 (47.2%) represented levels above the desired target level. Collectively 111/163 (68.09%) of 
the records failed to attain target levels. Furthermore, 52/163 (31.09%) of the records attained the 
desired targets for Ferritin as required by the guidelines.  
4.6.5 Results for Management of Bone Disease 
Bone disease management in patients with ESRD requires careful monitoring of serum Calcium 
and serum phosphate levels to maintain these within target levels. Limiting dietary intake of 
phosphates and adequate dialysis can keep the levels within required limits. Data in Table 4.8 
show mean values and levels of adherence for the quality indicator, management of bone 
disease. 
Table 4. 8: Quality Indicator: Management of Bone Disease (mean values and levels of adherence) for 4 
HD sessions 




Serum Phosphorus in mmol/L (N) 
No. of patients n=, (%) 
163 168 167 166 
 
166 
< 0.8mmol/L n=, (%) 8 (4.90) 5 (2.97) 5 (2.99) 7 (4.21) 6 (3.61) 
0.8 – 1.4mmol/L n=, (%) 61 (37.42) 60 (35.71) 72 (43.11) 64 (38.55) 64 (38.55) 
>1.4mmol/L n=, (%) 94 (57.66) 103 (61.30) 90 (53.89) 95 (57.22) 96 (57.83) 
Serum Calcium in mmol/L (N) 
No. of patients n=, (%) 
165 133 162 132 
 
148 
< 2.1mmol/L n=, (%) 49 (29.69) 33 (24.81) 44 (27.16) 46 (34.84.) 43(29.05) 
2.1 – 2.5mmol/L n=, (%) 
96 (58.18) 79 (59.39) 95 (58.64) 63 (47.72) 
 
83(56.08) 
>2.5mmol/L n=, (%) 20 (12.12) 21 (15.78) 23 (14.19) 23 (17.42) 22(14.86) 
 
Serum Calcium x Phosphorus in mmol2/L2 n=, (%) 
No. of patients n=, (%) 
164 133 162 131 
 
148 
<4.4mmol²/L² n=, (%) 133 (81.09) 84.(63.15) 122(75.30) 83 (63.35) 
106 
(71.62) 
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>4.4mmol²/L² n=, (%) 31 (18.90) 49 (36.84) 40 (24.69) 48 (36.64) 42(28.37) 
 
No. of patients n=, (%) 163 (94.44) 168 (99.41 167 (98.81) 166 (98.22) 
166 
(98.22) 
Serum Phosphorus in mmol/L 




Serum Phosphorus in mmol/L 
Target Attained n=, (%) 61 (37.42) 60 (35.57) 72 (43.11) 64 (38.55) 
 
64 (38.55) 
No. of patients n=, (%) 165 133 162 132 148 
Serum Calcium in mmol/L  
Target not Attained n=, (%) 69 (41.81) 54 (40.60) 67(41.35) 69 (52.27) 
 
65 (43.91) 
Serum Calcium in mmol/L  
Target Attained n=, (%) 96 (58.18) 79 (59.39) 95 (58.64.) 63 (47.72) 
 
83 (56.08) 
No. of patients n=, (%) 164 (97.04) 133 (78.69) 162 (95.85) 131 (77.51) 148 87.57 
Serum Calcium x Phosphorus in 
mmol2/L2  




Serum Calcium x Phosphorus in 
mmol2/L2  




Records reflecting serum Phosphorus levels revealed that 102/166 (61.44%) failed to meet the 
required guidelines, while 64/166 (38.55%) of the records attained the required levels. Serum 
Calcium levels reflected that 65/148 (43.91%) did not meet the guidelines and 83/148 (56.08%) did. 
Calcium Phosphate Product was not attained by 42/148 (28.37%) of the records while 106/148 
(71.62%) reached the required guidelines for Bone disease management.  
4.7 Summary 
The estimated sample size was 176 records (return rate of 169/176, 96.0%). The typical patient 
with ESRD having HD was 60 years of age, male, classified as Coloured, married and had a diagnosis 
of diabetic nephropathy. Of the prescribed medicines for the four HD sessions, patients received: 
ESA 110/169 (65.08%), Iron Therapy 104/169 (61.53%), Phosphate Binders 57/169 (33.72%) and 
Vitamin D supplementation 54/169 (31/95%). For dialysis access, AVF and AVG were used the most 
frequently as recommended but 57/169 (33.72%) of the patient recordings indicated that dialysis 
access did not meet targets set in the guidelines. A mean of 47/169 (35.33%) of the recordings for 
dialysis adequacy (Single Pool Kt/V of 1.2 – 1.4 ) for the four HD sessions attained the target level 
stipulated in the guideline and 86/169 (64.66%) of the patient records indicated that target levels 
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for dialysis adequacy were not attained. For management of nutrition a mean of 130/168 (77.38%) 
records attained the guidelines for this parameter. For management of anaemia the mean target 
level for Hb of 10 – 12g/dl had been attained and 74/167 (44.31%) failed to meet the required 
guidelines for Hb; for Transferrin Saturation a mean of 108/161 (67.08%) recordings attained the 
prescribed target and 53/161 (32.91%) failed to reach the desired outcomes; and for ferritin levels 
34/163 (20.8%) reported levels below the desired target level, while, 77/163 (47.2%) represented 
levels above the desired target level. Collectively 111/163 (68.09%) of the records failed to attain 
target levels. Furthermore, 52/163 (31.09%) of the records attained the desired targets for Ferritin 
as required by the guidelines. For management of bone disease, records reflecting serum 
Phosphorus levels revealed that 102/166 (61.44%) failed to meet the required guidelines, while 
64/166 (38.55%) of the records attained the required levels; serum calcium levels reflected that 
65/148 (43.91%) did not meet the guidelines and 83/148 (56.08%) did; and calcium phosphate 
product was not attained by 42/148 (28.37%) of the records while 106/148 (71.62%) reached the 
required guidelines for this parameter. 
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CHAPTER FIVE DISCUSSION, IMPLICATIONS, 
RECOMMENDATIONS AND CONCLUSION 
5.1 Introduction 
Quality indicators for patients on haemodialysis (HD) as defined by international guidelines for 
dialysis access, dialysis adequacy, nutritional management of the dialysis patient, anaemia 
management and bone disease management have a solid scientific basis with clear clinical 
outcomes. Patients on HD are susceptible to many complications associated with this form of renal 
replacement therapy (RRT) and the guidelines aim to minimise these and to improve patients’ 
quality of life. The goals for nephrology in the next decade are: to reduce the burden of preventable 
causes of acute kidney injury in low-income countries and promote affordable renal replacement 
therapies; to make worldwide interventions available that help combat the burden of chronic 
kidney diseases with selective screening, prevention and treatment of curable diseases; to develop 
new drugs for kidney diseases; and to create new methods for diagnosis and treatments for 
inherited kidney disease (Remuzzi et al., 2013). 
Monitoring clinical outcomes for patients on HD is essential for good quality of life. The NKF-KDOQI 
(2002) has established guidelines that serve as clinical indicators with parameters to measure 
patient outcomes and serve as a blueprint for all renal units in South Africa and internationally for 
improving the management of kidney disease. At the start of the study it was not known what 
proportion of patients with (ESRD) on chronic haemodialysis (HD) in selected private dialysis units 
in the Western Cape Province reached target levels for each clinical indicator outlined in the 
guidelines. The aim of the present study was to design and validate a record review template for 
record review to describe target and actual outcomes for each clinical indicator to assess adherence 
to established guidelines. 
In the first three phases of the study a record review template was constructed and validated for 
content, ease of use (quality of instrument) and accuracy of transcription (inter-rater reliability). In 
phase 4 of the study the validated template was used for record review of patient data in selected 
private HD units in the Western Cape Province to assess adherence to established guidelines and 
the results were described in Chapter 4. The aim of the study was achieved. 
In this chapter the principal findings and implications for nursing education institutions, clinicians, 
healthcare management teams and further research are discussed, and recommendations made. 
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5.2 Principal findings 
5.2.1 Patients’ (n=169) demographic and clinical data 
Results showed that in general, the demographic and clinical characteristics of the study sample 
are different to those receiving treatment for HD units in the public healthcare sector. The median 
age of the 169 patients with ESRD and receiving HD was 60 years, ranging between 21 and 86 with 
most 99/169, (58.57%) patients between being between 53-70 years of age. According to the 2015 
South African Renal Registry Annual Report (SARS, 2015), the mean age for patients treated in 2015 
was 51.3% (± 15.0) years and the majority were male 59.3%. The population in the present study 
was older and more males were represented in the sample of patient records. The average age of 
patients undergoing dialysis in the United States of America (USA) has been increasing 
progressively over the last several decades and in 2000 the average age was approximately 62 years 
(Dimkovic et al., 2015; Power & Brown, 2013; Rao et al., 2016).  
South Africa’s population is currently estimated at more than 54 million, according to the 2015 
South African Renal Registry Annual Report. The majority of the country’s population (84%) are 
dependent on the public sector for the provision of health care and 16% have access to private 
health care. In South Africa rationing and selection criteria for renal replacement therapy results in 
younger patients 43.4 (±13.5) years of age being accepted into HD programmes in the public 
healthcare sector versus 55.0 (±14.3) years of age for the private sector (Davids et al., 2017). 
From an ethnicity perspective, Black persons constitute 80.5% of the South African population; 
Coloureds make up 8.8%; Whites 8.8% and Indians/Asians 2.5%. The present study was undertaken 
in private sector HD units in the Western Cape Province. An analysis of ethnicity of the study sample 
revealed that the majority of patients represented Coloureds 69/169 (40.8%) whereas Blacks and 
Whites respectively represented 22/169 (13%). These figures differ significantly from the 
distribution by ethnicity contained within the 2014 South African Renal Registry Annual Report for 
patients receiving HD, with black patients reported to make up 51.2%, Whites 22.1%, Coloureds 
14.5% and Indians/Asian 12.2% (Davids, Singh, Marias & Jacobs, 2014). The paucity of data on the 
provision of dialysis in developing countries is largely attributable to a deficiency of renal registries, 
thereby limiting the ability to compare our data to other similar settings.  
The majority 55/169 (32.54%) of the records in the present study reflected a diagnosis of diabetic 
nephropathy (32.5%) similar to results of 22% in Europe. The foremost causes of chronic kidney 
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disease (CKD) in both developed and many developing countries are attributable to chronic 
conditions such as diabetes and hypertension, whereas glomerulonephritis and unknown causes 
are more common in developing countries (Naicker, 2013). The most common causes of ESRD in 
the present study in descending order were Diabetes, Hypertension, Glomerulonephritis, Unknown 
Polycystic Kidney Disease and SLE. This list differs from the most commonly reported causes in ESRD 
in the 2012 South African Renal Registry Annual Report. In a 2013 publication, Naicker stated that 
hypertension affects about 25% of the adult population and is the cause of ESRD in approximately 
20% of patients on RRT in South Africa (Naicker, 2013). In the present study hypertension as the 
primary cause of CKD accounts for 24.9% of recordings.  
5.2.2 Results for medication 
Results for prescribed medications show that the majority of patients received Erythropoiesis 
Stimulating Agent (ESA) therapy and intravenous iron therapy. Very low levels of phosphate binders 
and calcium supplementation were reported. Calcium can be corrected by the type of dialysate 
used during the dialysis session but phosphate binders with low levels of calcium are important. 
Records reported elevated levels of serum phosphate and this correlates with the low prescription 
of phosphate binders. Anaemia management with prescription of ESA and intravenous iron 
replacement in haemodialysis patients poses several clinical challenges, including the maintenance 
of stable Hb levels within narrow target ranges, balancing iron and ESA dosage and optimizing 
response to ESA to achieve the lowest possible effective ESA dose (Yong & Kairaitis, 2010). 
5.2.3 Results for Quality Indicators 
The results of this study confirm that patients receiving HD are vulnerable to many complications. 
Guidelines have been implemented to improve care, yet use of access sites varies greatly across 
countries and VA complications remain a problem (Ethier et al., 2008). 
5.2.3.1 Results of Dialysis Access 
Dialysis access via arteriovenous fistula (AVF) and arteriovenous graft AVG combined showed that 
a target level of 112/169 (66.27%) had been attained and there were no missing data. Temporary 
catheters were used the least 5/169 (2.95%) and the use of permanent catheters remained 
constant between 52-55/169 (30.76-32.54%) for the duration of the study period.  
Local and international guidelines indicate that the AVF route is the vascular access of choice in 
haemodialysis patients (Yan et al., 2018). In terms of these guidelines, if it is not possible to 
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establish an AVF, the next access route of choice is an AV graft. Generally, access via a cuffed 
tunnelled venous catheter is not advocated as a permanent means of vascular access. In the 
present study 66% of the patients had vascular access via an AVF or AVG comparable to countries 
like Japan according to the Dialysis Outcomes and Practice Patterns Study (DOPPS) (Rayner et al., 
2004). Native arteriovenous fistula (AVF) was used by 67–91% of patients in Japan, Italy, Germany, 
France, Spain. The AVF use rose from 24% to 47% and the use of AVG’s decreased by 50% in the 
USA (Ethier et al., 2008). . 
Although 66% of the patients in the present study had vascular access via an AVF or AVG thereby 
complying with the recommended guidelines, surprisingly, this result was in contrast to the Dialysis 
Adequacy target that was not met in 51% of the records reviewed, as it would be expected that 
more patients would have reached the target guidelines because access parameters had met the 
guideline target. This could be due to 21% missing data. The dialysis adequacy outcome for the 
present study was 28% which is not optimal in terms of the KDOQI Guidelines (NKF-KDOQI, 2015). 
5.2.3.2 Results for Dialysis Adequacy  
Results for this quality indicator did not satisfy target levels. A mean of 47/169 (35.33%) of the 
recordings for dialysis adequacy (Single Pool Kt/V of 1.2 – 1.4) for the four HD sessions attained the 
target level stipulated in the guideline. The mean number of recordings for dialysis adequacy was 
133/169 (78.69%) with 36/169 (21.30%) missing data. Results below the target (<1.2) were found 
in 44/169 (33.08%) of the recordings and recordings above the target (>1.4) accounted for 42/169 
(31.57%) of the recordings. This means that 86/169 (64.66%) of the patient records indicated that 
target levels for dialysis adequacy were not attained. This is in contrast with the high percentage 
of AVF/AVG access sites. The dialyser size and blood flow per treatment will be useful in further 
investigations but were beyond the scope of this study. The result could be as a direct result of the 
missing data that accounted for 36 (21.3%) records. Similarly, in Palestine only 25 (39.1%) patients 
achieved the Kt/V goal, and in a study from Sri Lanka, it was shown that only 39 (28.2%)achieved 
the guideline target (Adas et al., 2014). 
In Europe (2004), the mean delivered dose of haemodialysis as measured by normalized urea 
clearance (Kt/V) varied from 1.28 to 1.50 (Goodkin, Mapes, & Held, 2001). Japan exhibits one of 
the lowest mortality rates in the world for HD patients, and receives dialysis doses below the 
current KDOQI guideline recommendations of spKt/V 1.2 or higher (Kimata et al., 2014). 
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5.2.3.3 Results for Nutritional Management  
A mean of 130/168 (77.38%) records attained the guidelines for management of nutrition while 
38/168 (22.61%) records failed to meet the prescribed guidelines for this parameter. According to 
Usvyat et al., (2013) serum albumin levels dropped between 0.33 (Asia) and 0.52 (North America) 
g/dl in the 2 years preceding death in female patients and these results were comparable in Europe 
and South and North America, and less pronounced in Asia.  The rate of serum albumin decline 
accelerated before death (Usvyat et al., 2013). Although there was no reported correlation with 
anaemia, a low serum albumin is thought to fairly accurately reflect an inflammatory state of 
moderate severity, and a low serum albumin is more likely to be associated with greater rates and 
worse levels of anaemia (Kliger et al., 2013). 
In End Stage Renal Disease (ESRD), serum plasma albumin is a predictor of patients’ future health 
outcomes for these patients. The multidisciplinary team must be knowledgeable about serum 
albumin and the ill-effects of hypoalbuminemia in the provision of quality care. Vigilance in 
maintaining albumin levels and nutritional goals is very important (Wyczesany & Steefel, 2015). 
Patients with ESRD have to adhere to and maintain lifestyle changes such as nutrition to improve 
health and well-being and a chance to ’self-manage’ care of their kidney disease (Palmer et al., 
2017). 
5.2.3.4 Results for Anaemia Management  
Suboptimal Hb levels were present in 44.31% of the patient recordings and therefore target levels 
for this quality indicator were not reached. For Transferrin Saturation a mean of 108/161 (67.08%) 
recordings attained the prescribed target and 53/161 (32.91%) failed to reach the desired 
outcomes. For ferritin levels 34/163 (20.8%) reported levels below the desired target level, while, 
77/163 (47.2%) represented levels above the desired target level. Collectively 111/163 (68.09%) of 
the records failed to attain target levels. Furthermore, 52/163 (31.09%) of the records attained the 
desired targets for Ferritin as required by the guidelines. In patients receiving HD it is more difficult 
to achieve Hb targets because of comorbidities, including numerous inflammatory diseases 
responsible for ESA resistance. 
Forty-nine percent of the study cohort reached the target Hb level 10g/d – 12g/dl. This may be due 
to the increase in prescription of erythropoietin and the optimization of the iron status as 
prescribed however, this is not in accordance with the recommendations set out in the guidelines 
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that  “at least 75% of a cohort of patients should have haemoglobin levels of 11g/dl and that no 
patient should have a haemoglobin level of less than 8g/dl (SARS, 2015).   
In terms of mortality, meta-analyses did not show any statistically significant difference between 
higher and lower Hb levels in haemodialysis patients (Zazzeroni, Pasquinelli, Nanni, Cremonini, & 
Rubbi, 2017). The target allows for relative flexibility in medical decision making and considers 
variability between patients’ comorbidities, prognosis, functional status, and responsiveness to ESA 
therapy. 
5.2.3.5 Results for management of Bone Disease  
Results for this quality indicator did not satisfy target levels as 60% of the records did not attain 
the target for Phosphorus; Calcium revealed that a 49% target had been reached for 148 records 
and the calcium Phosphate Product results achieved a 70.5% target level. 
5.3 Limitations and strengths of the study methods 
5.3.1 Limitations of the study methods 
Record Review of blood results of patients receiving HD to assess adherence to established 
guidelines for End Stage Renal Disease was limited by the small sample size that it yielded. While a 
randomized sample was intended and an appropriate sample size was calculated, due to lack of 
consent and other factors, all available records for patients who met the inclusion criteria were 
included, resulting in a convenience sample which limits external validity of the results. 
Convenience sampling has the potential for sampling bias (Higgins et al., 2011). Participants for the 
validation processes were selected by convenience sampling, which also poses a risk for selection 
bias (Higgins et al., 2011). The two participants in Phase 3 of the study who were requested to 
transcribe fictitious patient datasets onto the SPSS file in the presence of the researcher, may have 
felt under pressure to please the latter, thereby the potential for performance bias (Higgins, 2011). 
Furthermore, the study was conducted in the private sector thereby further reducing the 
generalisability of the study findings to other research sites.  
The design of the record review chart restricted any corrective measures that could be of benefit 
to further research as the chart was modelled on the quality indicators in established guidelines. 
The actual patient care measures therefore cannot be assessed from this data.  
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5.3.2 Strengths of the study methods 
Strength of this study were the standardised outcomes measures of adherence compared to the 
KDOQI guidelines. The KDOQI guidelines have been established since 1997, leading to 
standardisation of adherence outcome measures. Standardisation allows for future research across 
haemodialysis centres nationally and internationally (Matteson & Russel, 2010). 
5.4 Implications of the study and recommendations 
There are implications for nursing education institutions, healthcare institutions/management, 
research and, by implication for policy makers. Nephrology nurses should be familiar with current 
guidelines and work towards integrating standards of care into clinical practice (Dutka & Brickel, 
2010). 
Recommendations 
The benefit of clinical practice guidelines can only be useful if implemented into daily practice. 
The clear benefit will be better outcomes for patients and a reduction in the mortality and 
morbidity rates of patients in End Stage Renal Disease (ESRD) firstly by creating awareness of the 
importance and prioritization of access sites and dissemination of the results of this study 
amongst clinicians. Informed clinicians should feel more confident to assist patients to 
understand their pathology and the consequent lifestyle changes needed to improve adherence 
to their treatment plan and therefore an improved quality of life. 
Constant evaluation of patients’ blood results pre- and post-dialysis against quality indicators will 
alert clinicians to any deviation and to take corrective action immediately. Clinical Practice 
Guidelines (CPG) with its rigorous methodology based on scientifically sound systematic reviews, 
are effective for improving patient outcomes. As the focus on providing the best-quality health care 
increases, we can expect an increasing role of CPG adherence in the assessment of clinical care 
quality (Ryan, 2017). 
5.4.1 Nursing education institutions 
Curricula should include adequate content relating to kidney disease and prevention of avoidable 
conditions starting in undergraduate programmes. These factors need to be considered from a 
primary healthcare perspective given the fact that non-communicable lifestyle diseases are the 
major causes of ESRD evidenced by this study and supported in the reviewed literature. This should 
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be a collaborative effort between educators and clinicians including multidisciplinary team 
members and case studies need to inform teaching and learning in the classroom. Nephrology 
nursing students need to be made aware of their scope of practice and expected competencies. 
Nephrology nursing students should gain in-depth knowledge about the importance of clinical 
guidelines and should share this information with patients to encourage shared decision making in 
the treatment and care delivered (Ryan, 2017). This is particularly important because of the many 
co-morbidities experienced by patients with ESRD and therefore sharing information in clinical 
practice guidelines with patients and their families should improve adherence. Clinicians need 
regular structured educational sessions and clinical practice guidelines should be easily accessible 
to all clinicians caring for patients (Ryan, 2017). 
5.4.2 Health care institutions 
A question in the reviewed literature (Bennett & Simmonds, 2008) was: Is a Change in Adequacy 
Standards Necessary?. This might mean different times of the day and/or night for dialysis units to 
operate to accommodate more patients requiring HD. These suggestions carry financial and ethical 
costs. Results in the present study show the need for change in order to improve practice. However, 
this change can only occur when clinicians adhere to clinical practice guidelines to improve patient 
outcomes.  
Clinician adherence is of paramount importance to decrease morbidity and mortality rates, and to 
increase the quality of life of patients on dialysis. Awareness of the importance of the quality 
indicators must therefore be highlighted amongst clinicians. This will assist with the identification 
of associations that exist amongst the indicators for early detection and treatment of sub optimal 
outcomes. Nephrology practitioners need to be made more aware of their scope of practice as they 
function autonomously in the units due to the shortage of medical nephrologists in South Africa. 
The EuCliD® is a useful tool for identification of any variance from normal targets. The enhanced 
awareness, understanding, and implementation of the guidelines should ensure that patients 
receive immediate attention before complications occur. Data from the present study show that 
many patients presented with elevated serum phosphate levels, but few patients had phosphate 
binders prescribed. Knowledge of clinical practice guidelines could present a completely different 
result, as the blood results could be accessed and together with the multidisciplinary team an 
appropriate care plan could be developed for patients. 
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Interpretation of blood results form the basis of decision making in the management of patients 
with CKD from pre dialysis to transplant, irrespective of the type of renal replacement therapy. The 
quality indicators therefore inform individualised care based on the blood results. 
Knowledge of the requirements and recommendations for Vascular Access as a quality indicator 
should help nurses to be vigilant about access sites and to ask questions such as: is there 
recirculation, are there problems with cannulation and should the patient be referred to a vascular 
surgeon? Questions nurses can ask when target levels are not met for Haemodialysis Adequacy 
(Kt/V) relate to: access adequacy/appropriateness, dialysis prescription, being dialysed for the 
prescribed time, appropriate size of the dialyser, time pump speed, reasons for patients not turning 
up for dialysis. Nurses can refer patients to a nutritionist for nutritional management where 
indicated or to a social worker or psychologist if there are there specific issues that impact on the 
treatment plan. 
It is suggested that there is a lack of accountability on the part of patients to their treatment 
regimen and that education is the key to personal accountability (Cahill, 2007). Healthcare 
institutions should offer regular in-service education for renal practitioners on patient education 
and on changes to clinical guidelines and these practitioners should be empowered to contribute 
to change in practice by employing consensus research methods. 
5.4.3 Research 
Unanswered questions and future research 
• What educational strategies can healthcare institutions employ to encourage staff to 
adhere to established clinical guidelines for renal replacement therapy? 
• How can compliant patients who have ESRD be encouraged to participate in motivating 
other such patients to adhere to their treatment plan? 
• What ethical issues surrounding renal replacement therapy should be addressed? 
5.7 Conclusion 
This appears to be the only South African study that reports adherence levels to quality indicators 
for patients receiving HD: vascular access, haemodialysis adequacy, nutritional management, 
management of anaemia and prevention of bone disease in one study. Target levels for three of 
the five quality indicators were not met. These pertain to dialysis adequacy, management of bone 
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disease and of anaemia. Results have implications for the quality of life on patients on HD and renal 
personnel need to be informed about the importance of meeting target levels for all quality 
indicators. 
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Appendix 2: Full literature search strategy 












FINAL TOTAL FOR STUDY 
Set 1 (Population) 
Kidney Failure, Chronic [MeSH] 
OR End stage kidney disease OR end 
stage renal disease OR chronic kidney 
failure OR chronic renal failure OR ESRD 
AND 
Renal Replacement Therapy [MeSH]  
OR Renal dialysis OR hemodialysis OR 
haemodialysis OR renal replacement 
therapy 
Set 2 (Guidelines) 
Practice Guidelines as Topic [MeSH]  
OR Kidney Disease Outcomes Quality 
Initiative OR KDOQI OR KDIGO OR 
Kidney Disease Improving Global 
Outcomes OR Policy OR policies OR 
guideline OR guidelines OR 
recommendations OR consensus OR 
statement OR standard OR standards 
Set 3 (Compliance) 
Guideline Adherence [MeSH] 
OR Compliance OR Adherence OR 
Practice Patterns 
Set 4 
Treatment Outcome [MeSH]  
OR efficacy OR effectiveness OR 
outcome OR outcomes OR measure OR 
measures OR target OR indicators OR 
parameters OR adequacy 
Set 5 (measures) 
Anemia [MeSH]  
OR Anaemia OR anemia OR 
haemoglobin OR hemaglobin  
Serum Albumin [MeSH]  
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Chronic Kidney Disease-Mineral and 
Bone Disorder [MeSH] OR Bone mineral 
Arteriovenous Fistula [MeSH]  
OR Vascular access OR arteriovenous 
fistula OR arteriovenous grafts 
Dialysis Adequacy OR Dialysis Dose 
Set 6 (Personnel)  
Health Personnel [MeSH]  
OR Clinicians OR doctors OR health 
personnel OR medical personnel OR 
technologists OR nurses 
Set 7   Validation Studies (terms) 
Reproducibility of Results [MeSH] OR 
Validation Studies [Publication Type] 
instead of MeSH field choose publication 
type OR Validation OR validity OR 
validated OR reliability OR relevance OR 
evaluation 
Set 8 Record review 
Retrospective Studies [MeSH] OR Record 
review 
Set 9 Reliability 









































Set 1 AND Set 2 AND Set 3 AND Set 6 
Set 2 AND Set 3 AND Set 6 
Set 2 AND Set 3 and Set 5 
Set 1 AND Set 2 
Set 1 AND Set 2 AND Set 3 
Set 1 AND Set 2 AND Set 5 
Set 1 AND Set 2 AND Set 3 AND Set 6 
Set 1 AND Set 2 AND Set 7 
Set 1 AND Set 2 AND Set 5 AND Set 7 
Set 1 AND Set 2 AND Set 8 
Set 1 AND Set 2 AND Set 5 AND Set 8 
Set 1 AND Set 2 AND Set 9 















   
Set 1 (Population) 65728    
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Kidney Failure, Chronic [MeSH] 
OR 
End stage kidney disease OR end stage 
renal disease OR chronic kidney failure 
OR chronic renal failure OR ESRD 
AND 
Renal Replacement Therapy [MeSH] 
OR 
Renal dialysis OR hemodialysis OR 
haemodialysis OR renal replacement 
therapy 
Set 2 (Guidelines) 
Practice Guidelines as Topic [MeSH] 
OR 
Kidney Disease Outcomes Quality 
Initiative OR KDOQI OR KDIGO OR 
Kidney Disease Improving Global 
Outcomes OR  
Policy OR policies OR guideline OR 
guidelines OR recommendations OR 
consensus OR statement OR standard 
OR standards 
Set 3 (Compliance) 
Guideline Adherence [MeSH] 
OR 
Compliance OR Adherence OR Practice 
Patterns 
Set 4 
Treatment Outcome [MeSH] 
OR 
efficacy OR effectiveness OR outcome 
OR outcomes OR measure OR measures 
OR target OR indicators OR parameters 
OR adequacy 
Set 5 (measures) 
Anemia [MeSH] 
OR 
Anaemia OR anemia OR haemoglobin 
OR hemaglobin  
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Albumin OR protein levels 
Chronic Kidney Disease-Mineral and 
Bone Disorder [MeSH] 
OR 
Bone mineral 
Arteriovenous Fistula [MeSH] 
OR 
Vascular access OR arteriovenous fistula 
OR arteriovenous grafts 
Set 6 (Personnel) 
Health Personnel [MeSH] 
OR 
Clinicians OR doctors OR health 
personnel OR medical personnel OR 











Set 1 AND Set 2 AND Set 4 
Set 2 AND Set 4 AND Set 7 
Set 3 AND Set 4 and Set 5 
Set 2 AND Set 3 
Set 2 AND Set 3 AND Set 5 AND Set 6 
Set 1 AND Set 2 AND Set 6 AND Set 8 
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Appendix 3 – Information Sheet and Consent Form for Index of 





My name is Yolinda L van der Nest and I am a Master of Science (Nursing) degree student at the University of Cape 
Town. I am undertaking a study entitled RECORD REVIEW OF POST-HAEMODIALYSIS BLOOD RESULTS TO ASSESS 
ADHERENCE TO GUIDELINES FOR END STAGE RENAL DISEASE. 
Patients in End Stage Renal Disease on dialysis need to adhere to guidelines that will improve their quality of life. Renal 
patient morbidity and mortality can be decreased by improving clinical outcomes with effective management of 
Anaemia, Nutrition and Bone Disease and Adequacy of Dialysis and Vascular Access as set out in the KDQOI/KDIGO 
guidelines. Adherence to the guidelines ensures reduced morbidity and mortality and thereby improving quality of life 
in renal patients. 
In this study, I undertake to gain deeper insight into the extent in which, these aspects will be described and compared 
against the KDQOI/KDIGO guidelines and whether haemodialysis patients adhere to best practice guidelines. The study 
will measure patient outcomes retrospectively against pre-determined clinical outcome parameters.  
Why is this study being done? 
This study will add to the existing body of renal nursing knowledge in three ways by:  
1) providing data on haemodialysis best practice and recommendations from a local Western Cape perspective;   
2) creating knowledge about clinical outcomes for a sample of South African adult haemodialysis patients to determine 
whether a standardised protocol is fit for purpose for all patients in selected local private units (Saunders, 
MacLeod, Salyers, MacMillan, & Ogborn, 2013); and 
3) forming the basis for further study to ascertain whether care providers have the relevant knowledge, skill and 
attitude to maintain the gold standard for haemodialysis practice as set out in the guidelines. 
Does the study have ethics approval? 
Ethics approval (HREC REF: 305/2019) has been obtained from the UCT Faculty of Health Sciences’ Human Research 
Ethics Committee and is available upon request.  
Why am I being asked to take part? 
You have been invited to participate because you are a nephrology nurse/ medical doctor with expert knowledge in 
caring for patients on dialysis. The guidelines for dialysis form the basis of the care rendered to patients and application 
of these guidelines will improve patient outcomes. Your expert knowledge can provide valuable information on the 
validity of the Record Review Template (Appendix 1) designed for this study. Any information provided by you will 
remain confidential and anonymous. Your name will not be used at any stage during the study and a code number will 
be assigned instead. Only I will have access to the code number assigned to your name and this information will be 
stored on a password protected computer. 
What will happen if you decide to take part in the study? 
If you agree to participate in this study, you will be provided with the self-designed Record Review Template (Appendix 
1) and the checklist (Appendix 4) on which you will rate (1-4) the template. The data on the template are based on the 
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KDOQI/KDIGO guidelines and when I do the record review, I will compare the patient data to the KDOQI/KDIGO 
guidelines. There is also a section on the checklist for your rating of the face validity of the template such as layout, 
length, etc., A date, time and location will be agreed upon by yourself. Your rating will assist with any changes that will 
have to be made to the template before the actual study. 
It should take you about 30 minutes to complete the checklist. 
What are the risks and discomforts of this study? 
This study does not have any foreseeable adverse effects, risks or hazards for participants. The questions asked of you 
are intended to obtain assistance in validating the data extraction form (data review template, Appendix 1) that 
captures clinical variables from best practice renal guidelines to determine the level of guideline adherence from 
patient documentation.  
What if I decide not to take part? 
You have a choice to participate in or to exit the study at any time without penalty or obligation. 
Are there any benefits to you for being in this study? 
There may be no direct benefits to you for participating in this study other than an understanding of validating a data 
extraction form for review of patients receiving haemodialysis, which could improve future practice and improve 
patient outcomes. No financial benefits are payable for participating in the study. 
Who do I speak to (or contact) if I have any questions about the study? 
Researcher: Yolinda Louise van der Nest (3 Balfour Mansions, 7 Church Street Muizenberg 7945. 
Telephone Number: 079 492 9358 e-mail: Yolinda.vandernest@uct.ac.za 
Supervisor: Associate Professor Una Kyriacos, Division of Nursing & Midwifery, Department of Health & Rehabilitation 
Sciences, Faculty of Health Sciences, University of Cape Town, OBSERVATORY 7925. 
Telephone Number: 0761422676 e-mail: una.kyriacos@uct.ac.za 
HUMAN RESEARCH ETHICS COMMITTEE DETAILS: 
Professor Marc Blockman (Chairman) 
Faculty of Health Sciences Human Research Ethics Committee, Room E52-24, Groote Schuur Hospital Old Main Building, 
OBSERVATORY 7925,  
Telephone number: 021 406 6338 e-mail: marc.blockman@uct.ac.za  
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Appendix 3 continued) 
Participant consent form  
For expert opinion on the Record Review Template 
Researcher: Yolinda van der Nest R/N, Supervisor: Una Kyriacos PhD 
Initial 
1. I (the participant) confirm that I have read and understand 
the information sheet for the above study (dated 2018) 
and have had the opportunity to ask questions and have 
them answered to my satisfaction. 
 
 
2. I am aware that I can withdraw from the study at any time 
without penalty. 
 
3. I am aware that all my details on this consent form and the 
validation process are confidential.  
 
4. I am aware that there are no physical risks involved. 
Information offered by me is confidential and protected. 
There are no known or anticipated risks.  
 
5. I am aware that benefits to me include knowledge about 
validating a data extraction form for review of patients 
receiving haemodialysis and the benefits to the health 
care industry include the potential to improve future 
practice and patient outcomes. 
 
6. I consent to take part in the above study and have reached 








This study is being conducted by the University of Cape Town. Funding for this work is 
supported in part from my supervisor, Emeritus A/Prof Una Kyriacos from the National 
Research Foundation of South Africa, Grant No. 90295. 
Any opinion, finding and conclusion or recommendation expressed in this material is that 
of the author(s) and the NRF does not accept any liability in this regard. 
 
When complete: original copy to be kept with transcript documents with a second copy for 
the researcher. Please offer a third copy to the participant for own records.  
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Appendix 4 – Checklist for Content and Face Validity of the data 
review template 
 
RESEARCHER’S DETAILS:   SUPERVISOR’S DETAILS: 
Student: Master of Science in Nursing: 
Ms. Yolinda L van der Nest   Assoc/Prof. Una Kyriacos 
UNIVERSITY OF CAPE TOWN   UNIVERSITY OF CAPE TOWN 
Division of Nursing and Midwifery   Division of Nursing and Midwifery 
TEL: 021-4066173     TEL: 0761422676 
Yolinda.vandernest@uct.ac.za 
HUMAN RESEARCH ETHICS COMMITTEE DETAILS: 
Chairperson: Professor Mark Blockman 
Faculty of Health Sciences 
Human Research Ethics Committee 
Room E52-24 Groote Schuur Hospital Old Main Building 
OBSERVATORY 
7925 
TEL: 021-406 6626 
Title of Study: RECORD REVIEW OF POST-HAEMODIALYSIS BLOOD RESULTS TO ASSESS 
ADHERENCE TO GUIDELINES FOR END STAGE RENAL DISEASE 
Thank you for agreeing to evaluate the content and face validity of the self-designed 
Record Review Template (Appendix 1). Please e-mail or post the completed checklist to 
the researcher at the above address. 
The purpose of this checklist is to ensure uniform evaluation by all experts using a 
structured procedure. 
You, the expert, will establish  index of content validity (CVI) for each item on the 
template using a 4-point ordinal rating scale and this will be taken as the proportion of 
items that received a rating of 3 or 4 (Polit & Beck, 2004). 
If, in your opinion, there are omissions, these can be listed separately (Polit & Beck, 
2004). 
For evaluation of face validity, the checklist includes a rating scale for quantification of 
layout, format, quality of printing, the length of the questionnaire, the response scale of 
1-4, if visually easy to read and comprehend and if instructions at the beginning of the 
questionnaire are clear and easy to understand (Polit & Beck, 2004). 
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Index of Content Validity checklist 












Section A – Demographic Details 
A1 Gender 
A1.1 Male      
A1.2 Female      
A2 Age 
 Age      
A3 Ethnicity:  
A3.1 Asian      
A3.2 Black      
A3.3 Coloured      
A3.4 White      
A4 Marital Status 
A4.1 Single      
A4.2 Married      
A4.3 Separated      
A4.4 Divorced      
A5 Diagnosis 
A5.1 Hypertension      
A5.2 Diabetes      
A5.3 Glomerulonephritis      
A5.4 Systemic Lupus 
Erythematosus 
     
A5.5 Polycystic Kidney Disease      
A5.6 Other      
A5.7 Unknown      




















B1 Erythropoiesis Stimulating Agents 
B1.1 Eprex      
B1.2 Micera      
B1.3 Rocormen      
B1.4 Aranesp      
B1.5 Not prescribed      
B1.6 Treatment on hold      
B2 Iron Therapy 
B2.1 Venofer      
B2.2 Cosmofer      
B2.3 Other      
B2.4 Not prescribed      
B3 Phosphate Binders 
B3.1 Titralac      
B3.2 ENO tums      
B3.3 Phosphosorb      
B3.4 Not prescribed      
B4 Vitamin D supplements 
B4.1 One Alpha      
B4.2 Not prescribed      
       
Section C Quality Indicator Outcomes 
C1 Haemoglobin, g/dl 
C1.1 <10      
C1.2 10 – 12      
C1.3 >12.1      
C2 Transferrin Saturation, % 
C2.1 <20      
C2.2 >20      
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C3 Ferritin, ng/Dl 
C3.1 <200      
C3.2 200 – 500      
C3.3 >501      
C4 Dialysis Access 
C4.1 Temporary Catheter      
C4.2 Permanent Catheter      
C4.3 AVF      
C4.4 AVG      
C5 Single pool Kt/V 
C5.1 <1.2      
C5.2 1.2 – 1.4      
C5.3 >1.4      
C6 Serum Phosphorus, mmol/L 
C6.1 <0.8      
C6.2 0.8 – 1.4      
C6.3 >1.41      
C7 Serum Calcium, mmol/L 
C7.1 <2.15      
C7.2 2.15 – 2.5      
C7.3 >2.51      
C8 Serum Calcium x Phosphorus, mmol²/L² 
C8.1 >4.4      
C9 Serum Albumin, mmol/L 
C9.1 <35      
C9.2 >35      
Evaluation of FACE VALIDITY 
Please check one box for each statement relating to the questionnaire. 











Layout     
Format     
Quality of printing     
Length of the questionnaire     
If visually easy to read     
If visually easy to comprehend     
If instructions at the beginning of the 
questionnaire are clear and easy to 
understand 
    
Omissions: 
Comments: THANK YOU VERY MUCH 
References 
1. Lynn, M. R. Determination and quantification of content validity. Nursing Research 1986;35(6), 
November/December):382-85. 
2. Adapted with permission from: Kyriacos, U. 2011. The development, validation and testing of a vital signs 
monitoring tool for early identification of deterioration in adult surgical patients. PhD thesis. Cape Town: 
University of Cape Town.  
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Appendix 5 ‐ Information Sheet and Consent Form for reliability 





My name is Yolinda L van der Nest and I am a Master of Science (Nursing) degree student at the University of Cape 
Town. I am undertaking a study entitled RECORD REVIEW OF POST-HAEMODIALYSIS BLOOD RESULTS TO ASSESS 
ADHERENCE TO GUIDELINES FOR END STAGE RENAL DISEASE.  
Patients in End Stage Renal Disease on dialysis need to adhere to guidelines that will improve their quality of life. Renal 
patient morbidity and mortality can be decreased by improving clinical outcomes with effective management of 
Anaemia, Nutrition and Bone Disease and Adequacy of Dialysis and Vascular Access as set out in the KDQOI/KDIGO 
guidelines. Adherence to the guidelines ensures reduced morbidity and mortality and thereby improving quality of life 
in renal patients. 
In this study, I undertake to gain deeper insight into the extent in which, these aspects will be described and compared 
against the KDQOI/KDIGO guidelines and whether haemodialysis patients adhere to best practice guidelines. The study 
will measure patient outcomes retrospectively against pre-determined clinical outcome parameters.  
Why is this study being done? 
This study will add to the existing limited body of renal nursing knowledge in three ways by:  
1) providing data on haemodialysis best practice and recommendations from a local Western Cape perspective;   
2) creating knowledge about clinical outcomes for a sample of South African adult haemodialysis patients to determine 
whether a standardised protocol is fit for purpose for all patients in selected local private uniits (Saunders, 
MacLeod, Salyers, MacMillan, & Ogborn, 2013); and 
3) forming the basis for further study to ascertain whether care providers have the relevant knowledge, skills and 
attitude to maintain the gold standard for haemodialysis practice as set out in the guidelines if appropriate. 
Does the study have ethics approval? 
Ethics approval (HREC REF: 305/2019 ) has been obtained from the UCT Faculty of Health Sciences’ Human Research 
Ethics Committee and is available upon request.  
Why am I being asked to take part? 
You have been invited to participate because you are a nephrology nurse/ medical doctor with expert knowledge in 
caring for patients on dialysis. The guidelines for dialysis form the basis of the care rendered to patients and application 
of these guidelines will improve patient outcomes. Your expert knowledge can provide valuable information for 
reliability testing (percent accuracy of transcription) of the Record Review Template (Appendix 1) designed for this 
study. Any information provided by you will remain confidential and anonymous. Your name will not be used at any 
stage during the study and a code number will be assigned instead. Only I will have access to the code number assigned 
to your name and this information will be stored on a password protected computer. 
What will happen if you decide to take part in the study? 
If you agree to participate in this study, you will be provided with 1 EuCliD® form with 22 sets of fictitious data from 
fictitious patient records (Appendix 6) and 1 blank paper data extraction form (Appendix 1). The data extraction form 
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will be based on the KDOQI/KDIGO guidelines. You will be asked to transcribe the data from the EuCliD® form onto the 
data extraction form. You can do this in your own time but are requested to return the completed forms within 14 
days. What are the risks and discomforts of this study? 
This study does not have any foreseeable adverse effects, risks or hazards for participants. The questions asked are 
intended to provide us with valuable information on the level of guideline adherence as presented in patient 
documentation.  
What if I decide not to take part? 
You have a choice to participate in or to exit the study at any time without penalty or obligation. 
Are there any benefits to you for being in this study? 
There may be no direct benefits to you for participating in this study other than an understanding of validation by 
interrater reliability testing of a data extraction form which could improve future practice and improve patient 
outcomes. No financial benefits are payable for participating in the study. 
What will happen when the study is over? 
Following completion of this study, information gained from the experts will be analysed and improvements made to 
the Record Review Template that will be used for data collection. 
Who do I speak to (or contact) if I have any questions about the study? 
Researcher: Yolinda Louise van der Nest (MSc candidate, Division of Nursing & Midwifery, University of Cape Town) 3 
Balfour Mansions, 7 Church Street Muizenberg 7945 
Telephone Number: 079 492 9358 e-mail: Yolinda.vandernest@uct.ac.za 
Supervisor: Dr Una Kyriacos Division of Nursing & Midwifery Department of Health & Rehabilitation Sciences Faculty of 
Health Sciences University of Cape Town OBSERVATORY 7925 
Telephone Number: 0761422676 e-mail: una.kyriacos@uct.ac.za 
HUMAN RESEARCH ETHICS COMMITTEE DETAILS: 
Faculty of Health Sciences Human Research Ethics Committee Room E52-24 Groote Schuur Hospital Old Main Building 
OBSERVATORY 7925 Professor Marc Blockman (Chairman) 
Telephone number: 021 406 6338 e-mail: marc.blockman@uct.ac.za  
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(Appendix 5 continued) 
Participant consent form  
For expert opinion: Reliability testing 
Research team: Yolinda van der Nest R/N, Supervisor: Una Kyriacos PhD 
Initial 
1. I (the participant) confirm that I have read and understand 
the information sheet for the above study (dated 2018) 
and have had the opportunity to ask questions and have 
them answered to my satisfaction. 
 
 
2. I am aware that I can withdraw from the study at any time 
without penalty. 
 
3. I am aware that all my details on this consent form and the 
validation process are confidential.  
 
4. I am aware that there are no physical risks involved. 
Information offered by me is confidential and protected. 
There are no known or anticipated risks.  
 
5. I am aware that benefits to me include knowledge about 
interrater reliability testing. 
 
6. I consent to take part in the above study and have reached 




Print name of participant   Signature   Date 
 
 
Print name of researcher   Signature   Date 
 
This study is being conducted by the University of Cape Town. This work is based on the 
research supported in part by the National Research Foundation of South Africa for the 
Grant, Unique Grant No. 90295. 
Any opinion, finding and conclusion or recommendation expressed in this material is that 
of the author(s) and the NRF does not accept any liability in this regard. 
 
When complete: original copy to be kept with transcript documents with a second copy for 
the researcher. Please offer a third copy to the participant for own records.  
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Appendix 6: Example of 1 EuCliD® form populated with 4 fictitious 
datasets for Month 1, 2, 3,4 for 1 of 22 fictitious patients for 
transcription onto a blank SPSS Record Review Template 
(Appendix 1) to estimate accuracy (percent correctness) of 
transcriptions 
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 ACCESS  HAEMOGLOBIN  TRANSFERRIN 
SATURATION  
FERRITIN Kt/V 








































         g/dl                                 g/dl                   g/dl                   g/dl                  % % % % ng/dl    ng/dl  ng/dl   
ng/dl 
  
        
   1 
TC TC PC PC 7,6 9,7 8,6 8,7 12 28 34 34 614 712 1200 1200 1,12 1,16 1,11 1,3 
2 
AVF AVF AVF AVF 10,7 11,2 10,9 9,0 28 19 37 37 170 171 217 217 1,09 1,16 1,12 1,2 
3 







AVG 11,7 15,0 14,1 9,4 104 14 37 37 104 133 206 206 1,11 1,04 1,17 0,94 
5 
TC TC PC PC 9,6 10,3 9,6 11,3 28 19 16 16 100 188 550 550 0,7 0,8 1,1 1,6 
6 
PC PC PC PC 9,9 10,4 10,0 11,3 21 21 15 15 645 645 517 517 1,13 1,00 0,90 1,45 
7 
AVF TC PC PC 12,2 10,4 10,7 13,5 31 31 35 35 509 509 1058 1058 1,3 1,36 1,22 1,45 
8 
PC PC PC PC 9,8 10,0 9,8 10,4 27 52 65 65 620 542 614 895 1,06 1,11 0,94 0,99 
9 
PC PC PC PC 13,7 13,9 14,2 15,1 38 38 26 38 234 234 234 234 0,53 0,81 1,00 1,2 
10 
AVF AVF AVF PC 12,2 9,4 11,6 11,8 53 38 12 12 947 1188 1606 895 1,40 1,39 1,24 1,19 
11 
PC PC PC PC 8,8 12,9 11,0 11,3 50 18 45 45 499 464 348 670 1,11 0,86 1,21 1,20 
12 
PC PC PC AVF 10,0 11,2 10,8 10,2 36 32 20 20 661 681 514 514 0,95 1,31 1,39 1,22 
13 
AVF AVF AVF PC 10,9 10,5 10,7 11,5 86 70 20 20 1048 753 564 564 1,34 1,41 0,98 1,40 
14 
PC PC PC PC 10,6 11,1 11,2 9,6 31 23 30 30 411 475 737 679 1,17 0,97 1,20 1,29 
15 
AVF AVF AVF AVF 12,4 10,4 11,0 9,5 27 23 32 32 675 1164 1002 881 1,25 1,07 0,82 1,00 
16 
AVF AVF AVF AVF 8,8 9,9 10,2 12,1 13 29 52 52 345 369 1648 1648 1,22 1,12 1,27 1,24 
17 
AVF AVF AVF AVF 10,4 10,1 11,3 13,3 11 20 18 19 257 231 188 202 1,13 1,46 1,30 0,86 
18 
PC PC PC PC 10,9 12,1 12,9 10,1 26 26 28 28 608 551 565 565 1,08 1,13 1,18 1,15 
19 
PC PC PC PC 13,2 13,7 13,7 9,8 23 22 12 20 2176 710 178 627 1,11 0,75 0,87 1,34 
20 
TC TC PC PC 10,4 11,7 11,5 12,4 27 13 36 51 1615 1233 1421 2026 1,32 1,08 1,09 1,13 
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Appendix 7: Code guide 
A. Demographic Details  







18 – 35 
36-52  







































    (4) 
(5) 
(6) 






University of Cape Town – Van der Nest, Yolinda. (2020)  












































































B4d_Vit_D_Supplements_Month_4 Yes  (0) 
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No  (1) 
C. Quality Indicator Details  
C1a_Haemoglobin_Month_1 
< 10 g/dl 






< 10 g/dl 
10 – 12g/dl 





< 10 g/dl 






< 10 g/dl 






< 10 g/dl 






< 10 g/dl 






< 10 g/dl 






< 10 g/dl 






< 20 % 
> 20 % 
(0) 
(1) 
C2a_Transferrin_Saturation_Month_1_KDOQI_Guidelines < 20 % (0) 
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> 20 % (1) 
C2b_Transferrin_Saturation_Month_2 
< 20 % 




< 20 % 




< 20 % 




< 20 % 




< 20 % 




< 20 % 






































C3c_Ferritin_Month_3_KDOQI_Guidelines <200ng/dl (0) 
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0.8 – 1.4mmol/L 
(0) 
(1) 
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C8b_Serum_Calcium_Month_2 < 2.1mmol/L (0) 
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Appendix 8a: Research Committee Fresenius Medical Care 
3 Balfour Mansions 




5th March 2019 
To: The Research Committee Fresenius Medical Care 
REQUEST FOR APPROVAL TO CONDUCT RESEARCH IN SELECTED FRESENIUS MEDICAL CARE UNITS 
IN CAPE TOWN TO FULFIL REQUIREMENTS FOR A MASTER’S DEGREE IN NURSING SCIENCE: van 
der Nest Y. L. (VNSYOL001) 
My name is Yolinda L van der Nest and I am a Master of Science (Nursing) degree student at the 
University of Cape Town. The study has ethics approval from the Faculty of Health Sciences 
Human Research Ethics Committee (HREC REF:305/2019). 
Included, please find a copy of my research proposal. The aim of this study is to design and 
validate a record review template and to describe target and actual levels for each clinical 
indicator to assess adherence to established guidelines. This study will measure the patient 
outcomes retrospectively against the clinical outcome parameters.  
I hereby request permission to conduct my research within Fresenius Medical Care. I believe that 
the findings and recommendations thereof will form a platform for future studies that will involve 
transfer of knowledge to nursing staff to improve quality improvement initiatives. 
Authorisation is requested to conduct a research project RECORD REVIEW OF POST-
HAEMODIALYSIS BLOOD RESULTS TO ASSESS ADHERENCE TO GUIDELINES FOR END STAGE 
RENAL DISEASE in selected Fresenius Medical Care units in Cape Town 
 
Your approval will be greatly appreciated. 
 
Thank you in anticipation 
Y. L. van der Nest 
Student Number: VNSYOL001  
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APPENDIX 9: Example of permission requesting letter 
3 Balfour Mansions 
7 Church Street 
Muizenberg 
7945 
5th March 2019 
Fresenius Medical Care South Africa (Pty) Ltd 
Private Bag X10039 
Edenvale 
1610 
Dear Sir / Madam 
REQUEST FOR PERMISSION TO CONDUCT RESEARCH IN FRESENIUS MEDICAL CARE 
RESEARCH TOPIC: RECORD REVIEW OF POST-HAEMODIALYSIS BLOOD RESULTS TO ASSESS ADHERENCE 
TO GUIDELINES FOR END STAGE RENAL DISEASE 
My name is Yolinda L van der Nest and I am a Master of Science (Nursing) degree student at the University 
of Cape Town. Your written approval is requested to conduct research at the Fresenius Medical Care South 
Africa (Pty) Ltd.  
Approval has been granted by University of Cape Town Faculty of Health Sciences Human Research Ethics 
Committee. My ethical clearance number is: 
HREC REF: 305/2019.  
Included, please find a copy of my research proposal. The aim of this study is to design and validate a 
record review template and to describe target and actual levels for each clinical indicator to assess 
adherence to established guidelines.  
This study will measure the patient outcomes retrospectively against the clinical outcome parameters.  
If permission is granted, I will ensure that all information will be treated confidentially. Data sent to me 
from the Fresenius EuCliD database will be anonymized by using code numbers and therefore patient 
names will not be disclosed to me. Anonymity of dialysis centres will be ensured. As the employing body, I 
will ensure that you will receive a copy of the Executive Summary of the completed research. I will comply 
with legal requirements regarding the data that I will retrieve from the database. 
Your consideration of my request to conduct this study at your dialysis centres is greatly appreciated. 
Thank you 
Ms. Yolinda L van der Nest  
Student No.: VNSYOL001 
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Appendix 13: Researcher confidentiality and non-disclosure 
agreement 
CONFIDENTIALITY AND NON-DISCLOSURE AGREEMENT 
 
By 
Yolinda Louise van der Nest 
7002070060081 
3 Balfour Mansions 




FRESENIUS MEDICAL CARE SOUTH AFRICA (PTY) LTD 
(Registration number 1969/014163/07)  




1.1 The Disclosing Party has agreed to allow the Receiving Party to become privy to certain 
sensitive and Confidential Information of the Disclosing Party in order for the Receiving Party 
to carry out the Purpose. 
1.2 The Disclosing Party wishes to protect such Confidential Information in the manner set out 
in this Agreement. 
1.3 The Confidential Information represents substantial monetary, competitive, economic and 
strategic value to the Disclosing Party and could be have interest or benefit to its competitors.   
1.4 The Disclosing Party may suffer irreparable financial or other harm if the Confidential 
Information is divulged to other parties. 
1.5 The Disclosing Party wishes to ensure that the Confidential Information is held confidential 
and seeks to do so by means of this Agreement. 
1.6 The confidentiality undertakings contained herein are in addition to and not in lieu of any 
other confidentiality undertakings given by the Receiving Party to the Disclosing Party and 
shall survive termination of the pursuit by the Receiving Party of the Purpose. 
INTERPRETATION 
In this Agreement, unless inconsistent with or otherwise indicated by the context– 
“Agreement” means the agreement as set out herein and all the appendixes hereto; 
 “Confidential Information” means any information, documentation, record or report and all other 
information of the Disclosing Party, whether recorded orally, in writing, in print or electronic media, 
disclosed to or received by the Receiving Party pursuant to this Agreement including, but not limited 
to: 
the existence and contents of this Agreement;  
the Purpose and any information related to the Purpose;  
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patient’s information, including patients medical related information and personal information; 
information concerning any of the Disclosing Party’s subsidiaries or associated companies; and 
Personal Information which is disclosed by the Disclosing Party to the Receiving in terms of this 
Agreement. 
 “Parties” means the parties to this Agreement and “Party” means any one of them; and 
 “The Purpose” means the data, documentation, patient’s personal information and medical related 
information that the Disclosing Party will provide and/or make available to the Receiving Party 
through EuCliD. The Receiving Party shall strictly use the data or information for conducting his/her 
clinical studies or research with an academic institution and will use such data, information and/or 
documentation in a general manner without any reference or link to the Disclosing Party or the 
Disclosing Party’s patients. 
COMMENCEMENT AND DURATION 
This Agreement will be effective as at the date of signature of the last party signing and shall continue 
for an indefinite period. 
UNDERTAKINGS  
The Receiving Party hereby undertakes in favour of the Disclosing Party, in order to protect the 
proprietary interests of the Disclosing Party in respect of its Confidential Information, that it shall 
maintain the Disclosing Party’s Confidential Information in secrecy and strictest confidence and will 
exercise in relation thereto no lesser security measures and degree of care than those which the 
Receiving Party applies to its own confidential information, which the Receiving Party warrants as 
providing adequate protection against unauthorized disclosure, copying or use. 
EXCLUSIONS 
The obligations of the Receiving Party pursuant to the provisions of this Agreement shall not apply 
to any Confidential Information that is or becomes publicly known, otherwise than pursuant to a 
breach of this Agreement; or 
The Receiving Party will be entitled to disclose any Confidential Information if and to the extent that 
the Receiving Party is required or requested to do so by any law or by any court or regulatory agency 
or authority in any jurisdiction provided that, the Receiving Party will, if permitted by such law, court, 
regulatory agency or authority to do so, notify the Disclosing Party as soon as possible upon 
becoming aware of any such requirement. 
DOCUMENTATION AND RECORDS 
Documentation or records, whether written, electronic or otherwise, relating to or arising from the 
Confidential Information which comes into the possession of the Receiving Party as part of records 
or documentation that are supplied to it pursuant to this Agreement - 
shall be deemed to form part of the Confidential Information; and 
shall be surrendered to the Disclosing Party on demand.  
LIABILITY FOR DAMAGES 
To the extent that the Disclosing Party suffers any damage as a result of any disclosure to any 
unauthorised person of the Confidential Information by the Receiving Party -  
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the onus shall be on the Receiving Party to show that the disclosure was not in breach of the 
provisions of this Agreement; and 
the Receiving Party shall be liable for any damages, including direct, indirect, special and 
consequential damages, suffered by the Disclosing Party as a result of such disclosure, as 
determined by a court of competent jurisdiction. 
INDEMNITY 
The Receiving Party indemnifies the Disclosing Party and agrees to hold the Disclosing Party 
(including any of its Affiliates) harmless against any claims, penalties, fines, damages (whether direct 
or indirect, in contract or otherwise), losses, liabilities, costs (including costs on an attorney and client 
basis), expenses of any nature that may be imposed upon, incurred by, or awarded against the 
Disclosing Party by a third party in relation to a failure by the Receiving Party to comply with its 
obligations in terms of this Agreement.   
DISCLAIMER 
The Disclosing Party does not make any representation or give any warranties, express or implied 
or assume responsibility for the accuracy, reliability or completeness of any of the Confidential 
Information.  
RETURN OF CONFIDENTIAL INFORMATION  
The Receiving Party shall, on written demand by the Disclosing Party and in any event if the Purpose 
is no longer being pursued, cease the use of all Confidential Information furnished by the Disclosing 
Party pursuant to this Agreement, promptly return to the Disclosing Party all of the Confidential 
Information which is in physical form (including all copies) or destroy or expunge (to the extent 
reasonably practicable and legally permissible) any other records (including, without limitation, those 
in electronic, machine readable and hard copy form) as far as they contain Confidential Information. 
OWNERSHIP 
The Receiving Party hereby agrees and undertakes that any documentation of whatsoever nature 
or description relating to the Confidential Information which it has acquired or may acquire or which 
may come into its possession pursuant to this Agreement, shall remain the property of the Disclosing 
Party and shall be surrendered to the Disclosing Party forthwith on demand. 
ANNOUNCEMENTS 
The Receiving Party shall not make any public announcement or otherwise publish the existence of 




This Agreement constitutes the whole agreement between the Parties as to the subject matter hereof 
and no agreements, representations or warranties between the Parties regarding the subject matter 
hereof other than those set out in this Agreement are binding on the Parties. 
Variation 
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No addition to or variation, consensual cancellation or novation of this Agreement and no waiver of 
any right arising from this Agreement or its breach or termination shall be of any force or effect unless 
reduced to writing and signed by all the parties or their duly authorised representatives. 
Cession 
Neither Party shall be entitled to cede, assign or otherwise transfer any of its rights or obligations in 
terms of this Agreement without the prior written consent of the other Party. 
Severability 
In the event any one or more of the provisions of this Agreement shall for any reason be held to be 
invalid, illegal or unenforceable, the remaining provisions shall remain valid and enforceable. 
Furthermore, the unenforceable provision(s) shall be modified to carry out to the full extent possible 
the intent of the provision deemed unenforceable. 
 
IN WITNESS WHEREOF, the Parties hereto execute this agreement: 
THUS DONE AND SIGNED in Cape Town by Yolinda Louise van der Nest on this 
20th day of July 2019 in the presence of the undersigned  
Witness: 
Witness:  
1) ................................................   2)........................................... 
     Name:                                                             NAME:  
 
FRESENIUS MEDICAL CARE SOUTH AFRICA (PTY) LTD 
 
THUS, DONE AND SIGNED in ............................... by FRESENIUS MEDICAL CARE South Africa 
(PTY) LTD on this …….day of ………….20……. in the presence of the undersigned witness: 
Witness:  
1) ................................................   ..................................................... 
     Name:                                                             AUTHORISED REPRESENTATIVE 
            
       DESIGNATION: 
 
       NAME:  
       ..................................................... 
            AUTHORISED REPRESENTATIVE 
            
       DESIGNATION: 
 
       NAME:  
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Appendix 14: REporting of studies Conducted using Observational 
Routinely collected health Data (RECORD) guide 
The RECORD statement – checklist of items, extended from the STROBE statement, that should 
be reported in observational studies using routinely collected health data. 
 Item 
No. 
STROBE items Location in 
manuscript 
where items are 
reported 
RECORD items Location in manuscript 
where items are reported 
Title and abstract  
 1 (a) Indicate the 
study’s design 
with a commonly 
used term in the 
title or the 
abstract (b) 




summary of what 
was done and 
what was found 





Abstract Page iv 
RECORD 1.1: The type 
of data used should be 
specified in the title or 
abstract. When 
possible, the name of 
the databases used 
should be included. 
 
RECORD 1.2: If 
applicable, the 
geographic region and 
timeframe within which 
the study took place 
should be reported in 
the title or abstract. 
 
RECORD 1.3: If linkage 
between databases 
was conducted for the 
study, this should be 
clearly stated in the 
title or abstract. 
















2 Explain the 
scientific 
background and 
rationale for the 
investigation 
being reported 
  Page 16 
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  Page 19 
Methods 
Study Design 4 Present key 
elements of study 
design early in the 
paper 
  Page 39 







up, and data 
collection 
  Page 38 Introduction 
(3.1) 
Participants 6 (a) Cohort study - 
Give the eligibility 








- Give the 
eligibility criteria, 
and the sources 




Give the rationale 
for the choice of 
cases and controls 
Cross-sectional 
study - Give the 
eligibility criteria, 
 RECORD 6.1: The 
methods of study 
population selection 
(such as codes or 
algorithms used to 
identify subjects) 
should be listed in 
detail. If this is not 
possible, an 
explanation should be 
provided.  
 
RECORD 6.2: Any 
validation studies of 
the codes or algorithms 
used to select the 
population should be 
referenced. If 
validation was 
conducted for this 
study and not 
published elsewhere, 
detailed methods and 
Page 42 CVI  
Page 48 IRR (3.6.1) 
 












University of Cape Town – Van der Nest, Yolinda. (2020)  






and the sources 












- For matched 
studies, give 
matching criteria 
and the number of 
controls per case 
results should be 
provided. 
 
RECORD 6.3: If the 
study involved linkage 
of databases, consider 
use of a flow diagram 
or other graphical 
display to demonstrate 
the data linkage 
process, including the 
number of individuals 





Page 38 Diagram of the 
four research phases 










 RECORD 7.1: A 
complete list of codes 
and algorithms used to 
classify exposures, 
outcomes, 
confounders, and effect 
modifiers should be 
provided. If these 
cannot be reported, an 







8 For each variable 
of interest, give 
sources of data 







methods if there is 
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more than one 
group 
Bias 9 Describe any 
efforts to address 
potential sources 
of bias 
   
Study size 10 Explain how the 
study size was 
arrived at 
  Page 54 
Quantitative 
variables 
11 Explain how 
quantitative 
variables were 





chosen, and why 
  Page 73 
Statistical 
methods 




used to control for 
confounding 
(b) Describe any 




(c) Explain how 
missing data were 
addressed 
(d) Cohort study - 
If applicable, 
explain how loss 
to follow-up was 
addressed 
Case-control study 
- If applicable, 
explain how 
matching of cases 
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and controls was 
addressed 
Cross-sectional 












 ..  RECORD 12.1: Authors 
should describe the 
extent to which the 
investigators had 
access to the database 
population used to 
create the study 
population. 
 
RECORD 12.2: Authors 
should provide 
information on the 
data cleaning methods 
used in the study. 





Linkage  ..  RECORD 12.3: State 
whether the study 
included person-level, 
institutional-level, or 
other data linkage 
across two or more 
databases. The 
methods of linkage and 
methods of linkage 
quality evaluation 
should be provided. 
Institution level (Phase 2 
& 3) and person-level 
(Phase 4) Page 53 
Results 
Participants 13 (a) Report the 
numbers of 
individuals at each 
 RECORD 13.1: Describe 
in detail the selection 
of the persons included 
Diagram included 
explaining this Page 56 
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(c) Consider use of 
a flow diagram 
in the study (i.e., study 
population selection) 
including filtering based 
on data quality, data 
availability and linkage. 
The selection of 
included persons can 
be described in the text 
and/or by means of the 
study flow diagram. 
Descriptive 
data 










(b) Indicate the 
number of 
participants with 
missing data for 
each variable of 
interest 
(c) Cohort study - 
summarise follow-
up time (e.g., 
average and total 
amount) 
  Table 3. 5: Results 
(number and percent for 
ratings 1-4) for CVI of the 
record review template 
(n=5 experts) 
Page 44 
Table 3. 6: Results for face 
validity of the record 
review template from the 
checklist (n=5 
participants)Page 47 
Table 3.9: Differences in 
inter-rater reliability (IRR) 
results for 16 items 
between two raters for 
accuracy of transcription 
Page 50 -52 
Outcome 
data 
15 Cohort study - 
Report numbers 
of outcome events 
or summary 
  As outlined in section 
3.9.2 and summarized in 
Table 4.1, the estimated 
sample size was 176 
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- Report numbers 











records and the return 
rate were 169 (96.02 %) 
Main results 16 (a) Give 
unadjusted 











adjusted for and 












relative risk into 
absolute risk for a 
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17 Report other 
analyses done—





   
Discussion 
Key results 18 Summarise key 
results with 
reference to study 
objectives 
  Page 88 
Limitations 19 Discuss limitations 
of the study, 
taking into 
account sources of 




magnitude of any 
potential bias 
 RECORD 19.1: Discuss 
the implications of 
using data that were 
not created or 







data, and changing 
eligibility over time, as 
they pertain to the 













studies, and other 
relevant evidence 
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21 Discuss the 
generalisability 
(external validity) 
of the study 
results 
   
Other Information 
Funding 22 Give the source of 
funding and the 
role of the funders 
for the present 
study and, if 
applicable, for the 
original study on 
which the present 
article is based 







 ..  RECORD 22.1: Authors 
should provide 
information on how to 
access any 
supplemental 
information such as the 
study protocol, raw 




*Reference: Benchimol EI, Smeeth L, Guttmann A, Harron K, Moher D, Petersen I, Sørensen HT, 
von Elm E, Langan SM, the RECORD Working Committee.  The REporting of studies Conducted 
using Observational Routinely-collected health Data (RECORD) Statement.  PLoS Medicine 2015; in 
press. 
 
*Checklist is protected under Creative Commons Attribution (CC BY) license. 
 
